Predictors for Cancer Treatment

ABSTRACT

The present invention provides methods of predicting a response to a cancer treatment by determining CD68 level or PSMB1 (P11A) polymorphism in a biological sample and the presence or quantity of a second biomarker in the patient. The invention also provides kits and methods for treating cancer.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to provisional application Ser. No.61/522,596, filed Aug. 11, 2011 and provisional application Ser. No.61/560,555, filed Nov. 16, 2011, both of which are incorporated hereinby reference in their entirety.

FIELD OF THE INVENTION

The invention is related to treatment of cancer patients.

BACKGROUND OF THE INVENTION

While advances in development of successful cancer therapies progress,only a subset of patients respond to any particular therapy. With thenarrow therapeutic index and the toxic potential of many availablecancer therapies, such differential responses potentially contribute topatients undergoing unnecessary, ineffective and even potentiallyharmful therapy regimens.

One way to optimize therapy to treat individual patients is to determinewhether the patient one or more predictors that correlate with aparticular outcome in response to therapy. See, e.g., WO2004/053066;WO2006/133420; WO2008/021183; and WO2009/148528. The ability to predictdrug sensitivity in patients is particularly challenging because drugresponses reflect both the properties intrinsic to the target cells andalso a host's metabolic properties.

There is a need to identify further predictive markers to identifyparticular cancer patients who are expected to have a favorable outcomewhen administered particular cancer therapies.

SUMMARY OF THE INVENTION

The invention provides a method for identifying whether a patient has anincreased chance for a favorable outcome in response to a cancertreatment, comprising: determining the presence, absence or quantity ofone or more predictors in the patient, wherein the presence, absence orquantity of the predictor correlates with at least one favorableoutcome.

The presence of predictors may be determined by obtaining a biologicalsample from said patient. The cancer treatment may compriseadministration of a proteasome inhibitor, such as bortezomib. Thepredictors may be one or more of low CD68, PSMB1 (P11A), PSMB5 (R24C),P65, time since last cancer treatment, one prior treatment, low FLIPIscore, age (65 or younger), and low tumor burden.

Also provided are diagnostic kits for identifying patients likely tohave a positive outcome in response to a cancer treatment.

The invention also provides methods for treating cancer patients bydetermining the presence, absence or quantity of one or more predictorsin the patient, and selecting a method of treatment dependent on whetherthe patient is likely to respond to the treatment.

Also provided are uses for proteasome inhibitors for the treatment ofcancer, wherein the patients are characterized by one or more of: lowCD68, PSMB1 (P11A), PSMB5 (R24C), P65, time since last cancer treatment,one prior treatment, low FLIPI score, age, and low tumor burden.

DESCRIPTION OF THE FIGURES

FIGS. 1-8 show decision trees for determining whether a particularpatient will have an increased chance for favorable outcome in responseto treatment. “Selected” means that the patient will have an increasedchance for favorable outcome in response to treatment.

DETAILED DESCRIPTION OF THE INVENTION

The present invention describes predictors that serve as useful toolsfor the prognosis and planning for the treatment of cancer. Thepredictors are predictive of whether there will be a favorable outcomein response to a particular treatment, for example, treatment with aproteasome inhibitor.

Without limitation, the present invention provides (a) methods for apredicting response to a treatment in a cancer patient by determiningpresence or quantity of one or more predictors, (b) kits useful indetermination of the presence or quantity of the one or more predictors,(c) methods for treating cancer by selecting patients based on presenceor quantity of one or more predictors and (d) treating cancer inpatients with one or more predictors.

In certain embodiments, a method is provided for predicting response toa cancer treatment (for example, treatment with a proteasome inhibitorsuch as bortezomib) in a cancer patient comprising determining thepresence or quantity of a predictor in a patient or a biological samplefrom the patient; and wherein the presence or quantity of the predictoris correlated with at least one positive outcome. Certain embodimentscomprise determining the presence or quantity of a second predictor inthe patient or a biological sample from the patient, wherein thepresence or quantity of the second predictor is correlated with at leastone positive outcome.

The present invention involves the identification of predictors alsoreferred to herein as “variants”, “markers” “biomarkers” and/or“factors”, that correlate with an increased probability of favorableresponse to a cancer treatment. The association of patient response to acancer treatment with these predictors can increase of higher confidencein the safety and/or efficacy with the particular treatment. Thepredictors may be a gene, protein, patient characteristic, or aspect ofthe patient history.

Predictors according to this invention which correlate with at least onefavorable outcome include low CD68, PSMB1 (P11A) polymorphism, PSMB5(R24C) polymorphism, P65, age (under 65), one prior treatment, lowFollicular Lymphoma International Prognostic Index (FLIPI) score, timesince last anti-cancer treatment and low tumor burden. Preferably, thepatient has low CD68 or PSMB1 (P11A) and the presence of at least oneother predictor. In one embodiment, the patient has low CD68 and PSMB1(P11A) polymorphism. Predictor pairs according to this invention whichcorrelate with at least one favorable outcome include those shown inTables 6 and 7.

By “low CD68” is meant that the subject or biological sample from thepatient shows less CD68 quantity than the average patient or biologicalsamples from an average patient who has the same disease. In certainembodiments, low CD68 means that 25% or less of the cells in abiological sample express CD68; 50% or less of the cells in a biologicalsample express CD68; 25% or less of the follicular cells in a biologicalsample express CD68; 50% or less of the follicular cells in a biologicalsample express CD68; 25% or less of the perifollicular cells in abiological sample express CD68; or 50% or less of the perifollicularcells in a biological sample express CD68.

By “low FLIPI” score is meant a score of 0 or 1 factor on the FollicularLymphoma International Prognostic Index (FLIPI score). To determineFLIPI score, one point is assigned to each of: age greater than 60years, Stage III or IV disease, greater than 4 lymph node groupsinvolved, serum hemoglobin less than 12 g/dL and elevated serum LDH.

As used herein, the terms “comprising”, “containing”, “having” and“including” are used in their open, non-limiting sense.

“Quantity” may mean the value, intensity, concentration, amount, degree,or expression level. For example, quantity of a gene may be the numberof times a gene or portion thereof is present in a subject's genome orin the cells of the subject. Quantity may also mean the number of cellsin a biological sample expressing a marker, or the overall expressionlevel or intensity of the marker in a biological sample. Quantity mayalso refer to the number of types or lines of therapy the patient towhich the patient may previously been exposed. The quantity may be incomparison to an absolute number, in comparison to a reference samplefrom a healthy patient, in comparison to an average number from healthypatients, or in comparison to an average number from patients withsimilar disease.

The cancer treatment may include administration of a single drug ortreatment, or a combination treatment comprising administration of morethan one drug or treatment. The cancer treatment may be administrationof chemotherapy, radiotherapy, or immunotherapy; or the cancer treatmentmay be a bone marrow transplant.

In certain embodiments, the cancer treatment comprises administering aproteasome inhibitor to a patient. A proteasome inhibitor is anysubstance which inhibits enzymatic activity of the 20S or 26S proteasomein vitro or in vivo. In some embodiments, the proteasome inhibitor is apeptidyl boronic acid. Peptidyl boronic acids include bortezomib.Proteasome inhibitors include those compounds disclosed in U.S. Pat.Nos. 5,756,764; 5,693,617; 6,831,099; 6,096,778; 6,075,150; 6,018,020;7,119,080; 6,747,150; 6,617,317; 6,548,668; 6,465,433; 6,297,217;6,083,903; 6,066,730; 5,780,454; 7,422,830; 7,109,323; 6,958,319;6,713,446; and 6,699,835. The proteasome inhibitor may be bortezomib.

In certain embodiments, the cancer treatment comprises treatment withanti-cancer agents, including but not limited to, acemannan,aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine,amifostine, aminoglutethimide, amsacrine, anagrelide, anastrozole,ancestim, asparaginase, bevacizumab, bexarotene, broxuridine,capecitabine, celmoleukin, cetrorelix, cetuximab, cladribine,clofarabine, clotrimazole, daclizumab, dexrazoxane, dilazep, docosanol,doxifluridine, bromocriptine, carmustine, cyclophosphamide, cytarabine,diclofenac, edelfosine, edrecolomab, eflornithine, emitefur, exemestane,exisulind, fadrozole, filgrastim, finasteride, fludarabine phosphate,formestane, fotemustine, gallium nitrate, gemcitabine, glycopine,heptaplatin, hydroxyurea, ibandronic acid, imiquimod, iobenguane,irinotecan, irsogladine, lanreotide, leflunomide, lenograstim, lentinansulfate, letrozole, liarozole, lobaplatin, lonidamine, masoprocol,melarsoprol, melphalan, mercaptopurine, methotrexate, metoclopramide,mifepristone, miltefosine, mirimostim, mitoguazone, mitolactol,mitomycin, mitoxantrone, molgramostim, nafarelin, nartograstim,nedaplatin, nilutamide, noscapine, oprelvekin, osaterone, oxaliplatin,pamidronic acid, pegaspargase, pentosan polysulfate sodium, pentostatin,picibanil, pirarubicin, porfimer sodium, prednisone, raloxifene,raltitrexed, rasburicase, rituximab, romurtide, sargramostim, sizofuran,sobuzoxane, sonermin, steroids, suramin, tasonermin, tazarotene,tegafur, temoporfin, temozolomide, teniposide, tetrachlorodecaoxide,thalidomide, thymalfasin, thyrotropin alfa, topotecan, toremifene,trastuzumab, treosulfan, tretinoin, trilostane, trimetrexate, ubenimex,valrubicin, verteporfin, vincristine, vinblastine, vindesine, andvinorelbine. In a preferred embodiment, the cancer treatment comprisesrituximab. In other preferred embodiments, the cancer treatmentcomprises melphalin or prednisone, or a combination of melphalin andprednisone.

In certain embodiments, the cancer treatment is a combination treatment.The combination treatment may comprise treatment with a proteasomeinhibitor and another cancer treatment or anti-cancer agent. In certainembodiments, the other anti-cancer agent is a monoclonal antibody, e.g.,rituximab. In other embodiments, the other anti-cancer agent ismelphalin, prednisone, or a combination of melphalin and prednisone.

The favorable outcome may be an overall response rate, overall survivalrate, overall complete response rate, duration of response, longer timeto next therapy, treatment free interval, positive response totreatment, a longer time-to-progression, longer term survival and/orlonger progression-free survival. The favorable outcome may bedose-dependent or dose-independent. The favorable outcome may favorablebe in comparison to no treatment, or in comparison to another cancertreatment or cancer treatment(s).

“Cancer” or “tumor” is intended to include any neoplastic growth in apatient, including an initial tumor and any metastases. The cancer canbe of the hematological or solid tumor type. Hematologic cancers includesuch as myelomas e.g., multiple myeloma), leukemias (e.g., Waldenstrom'ssyndrome, acute myelogenous leukemia, chronic lymphocytic leukemia,granulocytic leukemia, monocytic leukemia, lymphocytic leukemia), andlymphomas (e.g., follicular lymphoma, mantle cell lymphoma, diffuselarge B cell lymphoma, malignant lymphoma, plasmocytoma, reticulum cellsarcoma, Hodgkin's disease, non-Hodgkin's lymphoma or follicular B-cellnon-Hodgkin's lymphoma). Solid tumors can originate in organs, andinclude cancers such as brain, skin, lung, breast, prostate, ovary,colon, kidney, and liver. The cancer may be at the primary site, ametastasis, refractory (e.g. refractory to one or more lines oftreatment) and/or recurring. In certain embodiments, the cancer isfollicular B-cell non-Hodgkin's lymphoma or multiple myeloma.

When the predictor is present within the patient's body, the presence,absence or quantity of the predictor may be assessed by obtaining abiological sample from a patient and determining whether said biologicalsample contains the predictor or in what amounts the biological samplecontains the predictor. A “biological sample” as used herein refers to asample containing or consisting of tissues, cells, biological fluids andisolates thereof, isolated from a subject, as well as tissues, cells andfluids present within a subject. Examples of biological samples include,for example, sputum, blood, blood cells (e.g., white blood cells),amniotic fluid, plasma, serum, semen, saliva, bone marrow, tissue orfine-needle biopsy samples, urine, peritoneal fluid, pleural fluid, andcell cultures. Biological samples may also include sections of tissuessuch as frozen sections taken for histological purposes. In certainembodiments, the biological sample may be or include tumor cells.Biological samples from a hematological tumor may include bone marrowand/or peripheral blood.

Detection of predictor in a biological sample may be performed by anyconventional method for detecting the type of predictor, e.g., directmeasurement, immunohistochemistry, immunoblotting, immunoflourescense,immunoabsorbence, immunoprecipitations, protein array, flourescence insitu hybridization, FACS analysis, hybridization, in situ hybridization,Northern blots, Southern blots, Western blots, ELISA, radioimmunoassay,gene array/chip, PCR, RT-PCR, or cytogenetic analysis.

When the predictor is based on a particular genotype or polymorphism,the biological sample may be analyzed by genotyping. The term “genotype”refers to the alleles present in DNA from a subject or patient, where anallele can be defined by the particular nucleotide(s) present in anucleic acid sequence at a particular site(s). Often a genotype is thenucleotide(s) present at a single polymorphic site known to vary in thehuman population. “Genotyping” refers to the process of determining thegenotype of an individual by the use of biological assays. Currentmethods of doing this include PCR, DNA sequencing, antisenseoligonucleotide probes, and hybridization to DNA microarrays or beads.

A “single nucleotide polymorphism” (SNP, pronounced snip) is a DNAsequence variation occurring when a single nucleotide—A, T, C, or G—inthe genome (or other shared sequence) differs between members of aspecies (or between paired chromosomes in an individual). For example,two sequenced DNA fragments from different individuals, AAGCCTA toAAGCTTA, contain a difference in a single nucleotide. In this case it issaid that there are two alleles: C and T. Almost all common SNPs haveonly two alleles.

The detection of the presence or absence of at least one genotypevariance involves contacting a nucleic acid sequence corresponding toone of the genes identified herein or a product of such a gene with aprobe. The probe is able to distinguish a particular form of the gene orgene product or the presence or a particular variance or variances,e.g., by differential binding or hybridization.

When the predictor is the presence or quantity (including the expressionlevel) of a particular gene or protein, the presence or quantity(including the expression level) may be determined byimmunohistochemistry of a biological sample.

In certain embodiments, a kit is provided for identifying patients whoare candidates for a cancer treatment comprising a first reagent fordetecting the presence or quantity of one of the predictors of theinvention in a biological sample and a second reagent for detecting thepresence or quantity of a second predictor of the invention in abiological sample, and instructions for employing the predictors toidentify patients who are candidates for the treatment. In certainembodiments, the first reagent detects CD68 quantity and the secondreagent detects PSMB1 (P11A) polymorphism or PSMB5 (R24C) polymorphism.The reagents may be antibodies (for example, when testing CD68) or theymay be probes or arrays of probes (for example, when detecting genepolymorphism)

In certain embodiments, a method for treating a patient for cancercomprising: determining the presence or quantity of a first predictor inpatient or a biological sample from said patient; and determining thepresence or quantity of a second predictor in said patient or abiological sample from said patient; and selecting a method of treatmentdependent on whether said patient is likely to respond to saidtreatment.

The invention also provides uses of proteasome inhibitors for thetreatment of cancer in a patient, where the patient is characterized bythe presence, absence, or quantity of at least one predictor correlatedwith at least one positive outcome in response to the proteasomeinhibitor.

All publications cited herein are hereby incorporated by reference.Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood to one of ordinary skill inthe art to which this invention pertains.

Example 1

Non-Hodgkin lymphoma (NHL) encompasses several unique malignant lymphoiddisease entities that vary in clinical behavior, morphologic appearance,immunologic, and molecular phenotype. Follicular lymphoma (FL), the mostcommon indolent NHL, exhibits similar variability with some patientsexhibiting very slow disease course while others progress and die withinonly 5 year (Dave 2004). A randomized, open-label, active-controlled,multicenter, multinational, prospective study to compare the efficacyand safety of the combination of bortezomib and rituximab (Vc-R) tosingle-agent rituximab in subjects who have relapsed or refractory,rituximab-naive or -sensitive follicular B-cell NHL was performed.

Subjects were centrally randomized to Treatment Groups A (Vc-R) or B(rituximab) in a 1:1 ratio taking into account the followingstratification factors:

-   -   Follicular Lymphoma International Prognostic Index (FLIPI) score        (low [0 or 1 factor], intermediate [2 factors], high [≧3        factors]);    -   Prior rituximab therapy (yes, no);    -   Time since last dose of anti-lymphoma therapy (≦1 year, >1        year);    -   Region (United States/Canada, European Union, Rest of World).

Tumor samples for DNA and protein analysis and a blood sample for DNAanalysis were collected.

Protein candidates selected were NF-κB (RELA/p65), PSMA5, p27, and CD68.These proteins are attenuated by bortezomib treatment (NF-κB (RELA/p65);PSMA5, p27), regulated by the ubiquitin proteasome pathway (p27), orassociated with poor prognosis in lymphoma (CD68). Elevated expressionlevels of NF-κB (RELA/p65) were associated with longertime-to-progression (TTP) in mantle cell lymphoma (MCL) and in multiplemyeloma (Goy 2010, Mulligan 2007, and Keats 2007). Low level expressionof PSMA5 was associated with longer TTP in MCL (Goy 2010). Survivalanalysis in the MCL study also showed that high levels of p27 correlatedwith better overall survival (OS) (Goy 2010). CD68 was also prespecifiedand has recently been reported to be a prognostic marker for pooroutcome in lymphoma and is also associated with response to rituximab.Candidate genes selected for somatic mutation analysis were Bcl-2 andNotch-1. Other candidates were considered, but were not included becausethe frequency of the known mutations was less then 10% in the lymphomasetting. Additionally, small amounts of DNA were recovered fromcollected samples, so the analyses were limited to these two candidates.Bcl-2 has mutation frequencies of 23% in B-cell lymphoma and 50% infollicular lymphoma (Arif 2009) and Notch-1 has a mutation frequency of24%. Bcl-2 is an important anti-apoptotic protein frequently overexpressed in aggressive lymphomas and previous reports have suggestedthat bortezomib overcomes Bcl-2-mediated protection (Fischer 2005, Yin2005, Yeung 2006, Mitsiades 2002 and Wojcik 2002). Notch-1 has beenshown to increase the residence time of NF-κB (RELA/p65) in the nucleus(Shin 2006). This acts in direct opposition to bortezomib, whichprevents NF-κB from reaching the nucleus by inhibiting proteasomaldegradation of I-kappa-B proteins, whose role is to retain NF-κB in thecytoplasm. Notch 1-mediated increased residence time of NF-κB in thenucleus activates the transcription of the cell cycle regulators, eg,cyclins D1 and D2, which may contribute to the up-regulation of genesinvolved in immune and inflammatory processes (Karin 2002). Mutationsfound in functional sequences of these two genes were hypothesized tocontribute to inter-individual responses to treatment with bortezomib.

Drug target candidate genes were included for both bortezomib (PSMB1, 2,5, 6, 8, 9) and rituximab (FCGR2A, FCGR3A). The chemical structure ofbortezomib interacts with PSMB subunits 1, 2, and 5 and there isdocumented evidence of polymorphisms in these subunits as well as inPSMB6, 7, and 8. Polymorphisms within the subunits may affect theability of the drug to bind effectively or may prevent autocatalyticprocessing of pro-sequences that could lead to variability in levels ofproteasomes and/or response to bortezomib in individual patients. Forrituximab, the presence of single nucleotide polymorphisms (SNPs)corresponding to phenotypic expression of valine (V) or phenylalanine(F) at amino acid 158 of FCGR3A and of histidine (H) or arginine (A) atamino acid 131 of FCG2A greatly influences the affinity of IgG for theFcγ receptor (Binstadt 2003, Wu 1997). Expression of the high-affinity Vallele at 158 results in tighter binding of FCG3A to IgG1 and IgG3,whereas the low-affinity F allele is associated with decreased bindingof FCG3A to IgG. Similarly, the high-affinity H allele at 131 results ingreater affinity of FCGR2A for IgG2, whereas the low-affinity A allelecorrelates with decreased binding. Correlation of these low-affinitypolymorphisms has been associated with worse clinical response andprogression-free survival (PFS) after rituximab therapy in studies ofNHL (Cartron 2002). Therefore, we examined whether subjects with thesepolymorphisms were responsive to treatment with Vc-R as this may be analternative therapy for patients with limited treatment options.

The exploratory objectives in this study were to identify patientpopulations who were more or less likely to respond to Vc-R or rituximabalone by:

-   -   Performing association analyses of CD68, NF-κB (RELA/p65),        PSMA5, and p27 protein expression levels with selected clinical        study endpoints    -   Performing association analyses of Notch-1 and Bcl-2 somatic        mutations (single and in combination) with selected clinical        study endpoints    -   Performing association analyses of FCGR2A and FCGR3A        polymorphisms (SNPs) with selected clinical study endpoints    -   PSMB1, PSMB2, PSMB5, PSMB6, PSMB8, and PSMB9 polymorphisms        (SNPs) with selected clinical study endpoints    -   Performing combinations of biomarkers with selected clinical        study endpoints.

Multiple testing corrections were done using the false discovery rate(FDR) method for pair-wise comparisons and by forward selection whenmultiple biomarker combinations were compared. In practical terms, theFDR is the expected proportion of false positives; for example, if 1000observations were predicted to be different, and the FDR for theseobservations was 0.10, then 100 of these observations would be expectedto be false positives. Over-fitting is controlled by cross validationand independent validation within the analysis.

Genes with sufficient variation include:

FCGR2A (H166R, Q62R, Q62X) FCGR3A (V212F) PSMB1 (P11A) PSMB5 (R24C)PSMB8 (G8R) PSMB9 (R60H, V321)

PSMA (positive nuclear and cytoplasmic staining)CD68 (overall positive, positive follicular, positive peri-follicular)P27 (nuclei positive, intensity score)RELA/p65 (positive nuclear and cytoplasmic staining, intensity score).

The intent-to-treat (ITT) population was defined as all subjects whowere randomized. Subjects in this population were analyzed according tothe treatment to which they were randomized. Biomarker evaluations weredone on this population when biomarker data was generated for theclinical study endpoints.

Protein marker expression levels (CD68, NF-κB (P65), PSMA5, P27) weredetermined by immunohistochemistry (IHC). The expression levelcut-points for single-marker analyses were:

CD68:

% positive follicular (0-25, 26-50, 51-75, >75),% positive peri-follicular (0-25, 26-50, 51-75, >75),overall % positive (0-25, 26-50, 51-75, >75)

NF-κB (p65):

% positive cytoplasmic signal (<90%, >91% cutoffs),% positive nuclear signal (0, <5%, >5%)Nuclear staining intensity (<1+, >2+)

PSMA5:

% positive cytoplasmic signal (0-20, 30-50, 60-70, 80-90)% positive nuclear signal (0-20, 30-50, 60-70, 80-90)Cytoplasmic staining intensity (<2+, 3+)Nuclear positive vs. all other

P27:

% positive nuclear staining (0-20, 30-50, 60-70, 80-100)Nuclear signal intensity (<1+, >2+)

Cut-points selected for pair-wise comparisons were chosen to reduce thetotal number of comparisons that would be done. The selected cut-pointsare found in Table 1:

TABLE 1 Cut-Points for Protein Markers Included in the Pair-WiseComparisons Protein Marker Cutoff 20S (PSMA5) % nuclear staining ≦20vs. >20 20S (PSMA5) % positive cytoplasmic signal ≦90 vs. >90 20Sintensity cytoplasmic signal ≦2+ vs. >2 CD68 overall positive ≦50vs. >50 CD68 positive follicular ≦50 vs. >50 CD68 positiveperifollicular ≦50 vs. >50 P27 % nuclei positive ≦70 vs. >70 P27 signalintensity ≦1+ vs. >1 P65 (NF-κB) % nuclear staining 0 vs. >0 P65 (NF-κB)% positive cytoplasmic signal ≦90% vs. >90% P65 (NF-κB) intensitycytoplasmic signal ≦1+ vs. >1

Germline SNP data for PSMB subunits and FCGR2A and FCGR3A genes weregenerated by standard polymerase chain reaction (PCR) methodologies.Alleles detected in these assays are found in Table 2:

TABLE 2 Alleles for PSMB Subunits and FCGR2A and FCGR3A Genes FCGR2AFCGR3A PSMB1 PSMB2 PSMB5 PSMB6 PSMB8 PSMB9 H166R D118N A171S E49X L206MA234D G8R G9E (aka H131R) P273L D183G 1208N G187V R24C P107A R141C R60HQ62R E63V P11A L159F — — V182M V32I Q62X H194Y P193L — — — — — V217IL102R — — — — — — — L281F — — — — — — — R270X — — — — — — — S231A — — —— — — — S72R — — — — — — — V142I — — — — — — — V212F — — — — — — (akaV158F)

The following clinical endpoints were included in the analysis withineach treatment group and an overall comparison was made with thebiomarker-related endpoints: Progression-free survival, defined as theinterval between the date of randomization and the date of progressivedisease (PD) or death, whichever is first reported in the ITTpopulation; overall survival; overall response rate (complete response[CR]+CR unconfirmed [CRu]+partial response [PR]); overall CR rate(CR+CRu); duration of response; time to next anti-lymphoma therapy; andtreatment free interval.

Subjects from who met all of the following criteria were included in theanalysis: subjects in the ITT population; subjects with evaluablebiomarker data determined by IHC- or PCR-based methodologies; andsubjects with clinical data for at least one of the clinical endpointslisted above.

The primary biomarker analysis was aimed at identification ofdifferentially expressed proteins, mutations, or genotypes that wereassociated with clinical study endpoints. Covariates included in theanalysis were: FLIPI score (low [0 or 1 factor], intermediate [2factors], high [≧3 factors]); prior rituximab therapy (yes, no); timesince last dose of anti-lymphoma therapy (≦1 year, >1 year); region(United States/Canada, European Union, Rest of World), age, sex, race,Ann Arbor stage (I, II, III, IV), Number of prior lines of therapy (1, 2and more), and high tumor burden (yes, no).

For single-marker association analyses and pair-wise comparisons, a logrank test and Cox proportional hazard model was utilized for assessmentsof PFS, TTP, and OS between the treatment groups. Kaplan-Meier curveswere utilized to estimate the distribution differences between groups inthe time-to-event analyses. Comparison of the response rates between thetreatment groups was conducted using the Fishers exact test.Single-marker association analyses were stratified by the covariates.

For pair-wise comparison analysis, biomarker pairs were formed bycombinations of two markers. A log rank test was utilized forassessments of PFS, TTP, and OS between the treatment groups in thesubpopulation defined by biomarker pairs. Kaplan-Meier curves wereutilized to estimate the distribution differences between groups in thetime-to-event analyses. Comparison of the response rates between thetreatment groups was conducted using the Fishers exact test. Methods ofAnalysis for the multiple biomarker comparison models can be found insection 4.6.

For each analysis, demographic and baseline characteristic variableswere to be summarized for the biomarker population as follows.Descriptive statistics (mean, standard deviation, median, and range)were calculated for baseline demographic data (including: age (year),age category (>65 years and ≦65 years), sex (male, female), race (White,Asian/Pacific Islander, and Black/Other), FLIPI score (low [0 or 1factor], intermediate [2 factors], high [≧3 factors]); prior rituximabtherapy (yes, no); time since last dose of anti-lymphoma therapy (≦1year, >1 year); Ann Arbor stage (I, II, III, IV), number of prior linesof therapy (1, 2 and more), high tumor burden (yes, no), and region(United States/Canada, European Union, Rest of World) and were comparedwith summary statistics from the clinical trial data sets.

The stratified log rank test and Cox proportional hazard model wasutilized for assessments of PFS between the treatment groups. TheKaplan-Meier method was to be used to estimate the distribution ofoverall PFS for each treatment group in the biomarker population, andoverall; stratified by expression level, SNP, or mutation (or covariategroups as noted above). The hazard ratio and 95% confidence interval wasbased on a stratified Cox's proportion hazard model with treatment asthe explanatory variable. Analyses were done for the population overalland by treatment group, and each of these analyses were also stratifiedby the following factors if sufficient sample size existed:

FLIPI score (low [0 or 1 factor], intermediate [2 factors], high [≧3factors])Prior rituximab therapy (yes, no)Time since last dose of anti-lymphoma therapy (≦1 year, >1 year)Region (United States/Canada, European Union (Belgium, Czech Republic,Finland, France, Germany, Great Britain, Greece, Hungary, Italy, Poland,Portugal, Slovakia, Spain, and Sweden), Rest of World (Argentina,Australia, Brazil, India, Israel, Mexico, China, Korea, Romania, Russia,South Africa, Thailand, and Ukraine))

Age (<65, >65) Sex Race

Ann Arbor stage (I, II, III, IV)Number of prior lines of therapy (1, 2 and more)High tumor burden (yes, no)

Overall Survival was measured from the date of randomization to the dateof the subject's death. If the subject was alive or the vital status wasunknown, it was censored at the date that the subject was last known tobe alive. Similar to PFS and TTP, the Cox proportional hazard model wasused to evaluate the association between biomarker endpoints and OS.Kaplan-Meier survival curves were presented. Analyses were done for thepopulation overall and by treatment group, and each of these analyseswas stratified by the covariates used for PFS.

Comparison of the response rates between the treatment groups wasconducted using the Fishers Exact Test. Duration of response, time toresponse, and time to clinical relapse were analyzed descriptively,where appropriate, and the biomarker subset was compared (ifappropriate, determined as per the initial analysis) to the overallclinical cohort, by treatment group and overall. An exploratory estimateof the response rates in each treatment group was presented with 2-sided95% confidence intervals. The number and percentage of subjects fallinginto each response category was descriptively tabulated.

Analyses were done for the population overall and by treatment group.Each of these analyses were stratified by the same covariates utilizedfor PFS assessment.

Further analyses were planned because of the number of pair-wisecomparisons that were significant prior to FDR corrections and becausethese pairs selected unique individuals with longer PFS and a trend forlonger survival. These analyses sought to identify a single biomarkerclassifier that selected for a large PFS benefit and an OS benefit (ortrend) with a high population frequency. The dataset was utilizedwhereby discovery and confirmation test sets within the same populationwere defined. The study was conducted as follows:

Subjects with no missing biomarker values (n=354) were assigned in aratio of 7:3 into a discovery and confirmation set using simplerandomization. The balance demographic factors and clinical covariateslisted previously were confirmed using either the t-test or Mann-Whitneytest. The discovery set (67%) was used for identification of biomarkerswith significant association with PFS; subjects included had no missingbiomarker data. The confirmation set (33%) was used for independentvalidation. Subjects with missing data were included in the confirmationdataset provided that significant biomarker data identified in thediscovery phase was available. Additionally, evaluable sample from Chinawere also included in the confirmation set.

As in the initial analyses, if all subjects have the same proteinexpression level for a particular biomarker, that biomarker was removedfrom the analysis. If all subjects had the same mutation, no mutation,or 1 mutation level represented 90% of the samples, then either thatmutation or that gene was removed from the analysis.

In the discovery phase of biomarker combination analysis, all subjectsthat had missing values for any biomarker specified in Section 2 wereexcluded. Samples with missing data were included in the confirmationset provided that the missing data was not part of the associateddataset. Samples with missing biomarker data were considered“unevaluable” and were excluded from the confirmation set, all othersamples not used in the discovery set were included in the confirmationset.

Biomarker outliers were not removed from the analysis.

Demographic and baseline covariates were to be compared using the t-testor Mann-Whitney test to ensure that there were no statisticallysignificant differences between the discovery and confirmation sets.Demographic and baseline characteristics were to be summarized for thediscovery and confirmation sets and overall. Subjects excluded in thefinal analysis were not to be evaluated in this data comparison.Descriptive statistics (mean, standard deviation, median, and range)were to be calculated for the baseline demographic data and comparisonbetween the demographic and test set were to be made to ensure therewere no significant differences between them.

Covariates included in the analysis were: FLIPI score (low [0 or 1factor], intermediate [2 factors], [≧3 high factors]); prior rituximabtherapy (yes, no); time since last dose of anti-lymphoma therapy (≦1year, >1 year), age, Ann Arbor stage (I, II, III, IV), Number of priorlines of therapy (1, 2 and more), high tumor burden (yes, no), region(United States/Canada, European Union, Rest of World), sex, and race.

All markers and covariates were to be treated as categorical variablesin the analysis. Protein biomarkers were to be dichotomized. Thecut-points for protein markers were to be optimized based on enrichmentof responders vs. non-responders and reasonable population size.Specifically, for each biomarker, number of responders andnon-responders (based on overall response) and their percentages in theevaluable population were to be determined using every potentialcut-point listed in the Table 3. Summary tables with potentialcut-points, number of responders, number of non-responders, and theirpercentages were to be generated for each biomarker.

TABLE 3 Response by Cut-Point (Evaluable Population) Protein MarkerCutoff 20S (PSMA5) % nuclear staining 20%, 50%, 70%, 90% 20S (PSMA5) %positive cytoplasmic signal 20%, 50%, 70%, 90% 20S intensity cytoplasmicsignal 0, 1, 2 CD68 overall positive 25, 50, 75, 90 CD68 positivefollicular 25, 50, 75, 90 CD68 positive perifollicular 25, 50, 75, 90P27 % nuclei positive 20%, 50%, 70%, 90% P27 signal intensity 0, 1, 2P65 (NF-κB) % nuclear staining 0, 1, 5, 10, 20 P65 (NF-κB) % positivecytoplasmic signal 20%, 50%, 70%, 90% P65 (NF-κB) intensity cytoplasmicsignal 0, 1, 2

All genotypes were to be considered separately in the analysis (eg, C/C,C/T, T/T):

FCGR2A (H166R, Q62R, Q62X) FCGR3A (V212F) PSMB1 (P11A) PSMB5 (R24C)PSMB8 (G8R) PSMB9 (R60H, V32I).

Evaluation and Ranking of Single-Marker Associations with PFS (Discoveryset)The initial step of the analysis was selection and ranking of markersthat were to be used in subsequent multiple comparison analysis. Allprotein, SNPs with greater than 10% genotype variability, and clinicalcovariates listed were to be included as categorical variables. Theevaluation was to include the following steps:Biomarkers (including clinical covariates) that showed improvement ofPFS from prior single-marker association analysis (p<0.2) were reported.Only analyses that were done using IRC review were used.Each biomarker and clinical covariate was evaluated by Cox regression toassess the importance of biomarkers with respect to PFS. The P-valuesand weights/odds ratios of all markers in the Cox model were reported.To evaluate correlation among biomarkers, a pairwise correlation matrixwas generated using Spearman correlation method. Biomarkers that showedhigh correlation (p<0.05 and correlation coefficient >0.7) werehighlighted. Markers that had high correlation were re-analyzed in a Coxregression model with their interaction terms.

An interim summary of this analysis was generated for selecting markersthat were used in multiple comparison analysis. The markers that wereselected were based on the following criteria:

Relatively lower P-values in Cox regression for marker effect on PFS.PFS benefit in Vc-R arm compared to R arm that were based on interactionwith treatment in Cox regression or single marker logrank tests.If multiple markers are highly correlated and have high ranks from Coxregression, representative marker(s) that have the highest rank from Coxregression with interaction terms were used. Subpopulations of samplesshowing a large PFS benefit in Vc-R arm compared to the R arm were to beidentified by an exhaustive search of “AND” combination of biomarkers.Specifically, subpopulations of patients were formed from “AND”combinations of any two or three biomarkers selected in section 4.6.1.The difference of PFS for the patient subsets defined by the markers wasevaluated using the log-rank test with PFS as response variable and5-fold cross-validation as described below.

The discovery set was randomly split into 5 subsets with 20% of subjectsin each subset. An 80% subset was formed by combining 4 of the 5subsets. Using the 80% subset, subpopulations of patients were formedfrom “AND” combinations of biomarkers. If the number of samples (N) ineither Vc-R or R is <5 for the subpopulation, the subpopulation wasskipped. For subpopulations with N≧5 in both arms, the difference in PFSfor the patient subsets defined by the two markers was evaluated usingthe log-rank test. A looser P-value cutoff was applied because of theexploratory nature of this analysis. The PFS benefit was subsequentlytested on the remaining 20% subset.

The remaining 4 cross validation sets were tested similarly (P valuecutoff was not applied due to small sample size). Specifically, adifferent 20% subset from above and a new 80% subset formed withremaining subjects was used to repeat logrank tests until all 5 20%subsets were tested. The proportion of iterations with large PFS benefitin both 90% subset and 10% subset were reported.

Biomarker combinations were merged and evaluated again for PFS benefitand statistical significance with cross validation. For subpopulationsformed from merging of marker combinations, if the size of thesubpopulation is ≦10% of the discovery set, no statistical test will beperformed. Exhaustive merging of marker pairs and assessment of PFSbenefit was performed. Only marker combinations or merging of markercombinations that were significant were reported to save computationaltime. Results were saved after each iteration.

For top ranked marker combinations, decision rules for defining selectedpatient subpopulations were established using Classification andRegression Tree. Association of the selected patient subpopulations forother clinical endpoints was also evaluated. Performance of PFS and OSin the confirmation set was evaluated by testing the association ofbiomarkers identified in the discovery set using the decision rulesdefined. The PFS of both biomarker positive and negative subgroups wasreported for both study arms in the confirmation set. P-value cutoff wasnot applicable due to a small sample size, but was still reported.

Samples included in the independent confirmation set may have missingvalues for biomarkers not found to associate with PFS, however, subjectswho could not be classified due to missing values of the selectedbiomarkers were regarded as “unevaluable” and were excluded.

Initial analyses focused on single-marker associations stratified bycovariates. Significant associations were found in the single markerassociation analysis including CD68, PSMB1 (P11A), P65 and PSMB5 (R24C).Subsequent pair-wise analysis identified a biomarker pair withsignificantly longer PFS and a trend for an OS benefit. Because therewere no data sets available for independent confirmation of thisfinding, dataset was split into the Discovery and Confirmation setsdescribed above. As part of that analysis, multiple biomarkercombinations were compared and other significant combinations wereidentified. The association deemed to be most clinically appropriatefrom all analyses was the PSMB P11A heterozygote in combination withCD68 Low (0-50%) expression. Sub-populations of clinical interest aresubjects with high tumor burden, prior rituximab and one or two priorlines of therapy.

Pair-wise combinations of markers were conducted using the stratifiedlog rank test for each potential pair to determine differences in PFSbetween the Vc-R and rituximab only treatment groups. One-hundred andtwo biomarker pairs had a log rank p<0.05. Of these, 97 pairs had a >1%population frequency. Fourteen pairs also showed a PFS improvement of ≧6months. In this analysis, 1,140 pair-wise comparisons were made(covariates were paired with each individual marker to supplement theanalyses). Following FDR correction, 1 pair was significant (FDR=0.051).This biomarker pair identified 33% of the biomarker evaluable populationthat had a 7.5 month PFS advantage when treated with Vc-R compared withrituximab alone (Table 4) and a trend for better OS (p=0.055, HR: 0.426[0.174, 1.046] This pair is composed of PSMB1 P11A (C/G heterozygote)and CD68 Low expression defined as 0-50 positively stained cells.Following, this pair will be referred to as the biomarker positivesubgroup. The biomarker negative subgroup does not have this biomarkerpair and has a different PSMB1 genotype and CD68 expression level.

TABLE 4 Comparison of Biomarker Positive Population With BiomarkerNegative Population for PFS and OS Biomarker Positive Biomarker NegativeTotal (N = 118) (N = 238) (N = 356) Vc-R Rituximab Vc-R Rituximab Vc-RRituximab PFS N 57 61 118 120 175 181 Median (months) 16.6 9.1 12.5 12.513.6 11.3 95% CI (0.26-0.639) (0.759-1.425) (0.621-1.032) p-value 0.00010.8097 0.0855 HR 0.407  1.04  0.801  OS N 57 61 118 120 175 181 Median(months) NA NA NA NA NA NA 95% CI (0.174-1.046) (0.617-1.658)(0.527-1.239) p-value 0.0550 0.9645 0.3270 HR 0.426  1.011  0.808 Biomarker positive = PSMB P11A heterozygote and CD68 “Low” biomarkerpair, Biomarker negative = all subjects without this pair, Vc-R =Bortezomib + Rituximab, PFS = progression free survival, OS = overallsurvival, CI = confidence interval, HR = hazard ratio

Importantly, biomarker positive subgroup (PSMB1 P11A heterozygote andCD68 Low expression) also had a significantly better overall responserate 73.7% for those treated with Vc-R compared to 47.5% with R alone(p=0.0077), and a longer time to next treatment (p=0.0013) and durationof treatment free interval (p=0.0017).

Similar AE profiles were observed in the biomarker positive andbiomarker negative populations. Similar treatment exposure was observedin the biomarker positive and biomarker negative populations. Subjectstreated with rituximab in the biomarker positive population had a mediandose of 2941 mg/m² compared to 2940 mg/m² in the biomarker negativepopulation. Subjects treated with Vc-R in the biomarker positivepopulation had a median dose of 31.1 mg/m² compared to 30 mg/m² in thebiomarker negative population. Total number of doses, duration ofexposure, dose intensity, relative dose intensity and maximum number ofcycles received also showed very similar differences.

Subjects treated with Bortezomib+rituximab maintained longer PFS whenbiomarker positive and stratified by any FLIPI score, by tumor burden,by Ann Arbor score, by age, by region, by sex, and by race. In patientswith higher risk and poor prognosis, e.g. high tumor burden, medium orhigh FLIPI, older than 65, or with prior rituximab treatment, greaterPFS improvement were observed in patients when biomarker positivecomparing to when biomarker negative. Longer PFS was maintainedregardless of time from last treatment or number of previous treatmentsby prior rituximab or by number of rituximab treatments less than orequal to 2.

Subjects treated with Bortezomib+rituximab maintained longer overallsurvival when biomarker positive and stratified by FLIPI score, by tumorburden, by Ann Arbor score, by age, by region, by sex, and by race.Subjects treated with Velcade+rituximab maintained longer PFS whenpositive for CD68 low (0-50) and stratified by any FLIPI score, by tumorburden, by Ann Arbor score, by age, by region, by sex, and by race. WhenCD68 high, they did better on rituximab alone as expected. Subjectstreated with Velcade+rituximab maintained longer PFS when positive forPSMB P11A heterozygote and stratified by any FLIPI score, by tumorburden, by Ann Arbor score, by age, by region, by sex, and by race. WhenCD68 high, they did better on rituximab alone as expected.

A trend for a longer OS was found for biomarker positive subjects(p=0.055, HR 0.426. When the biomarker contributions are examinedindividually, this trend is less distinguishable. For subjects that arePSMB1 P11A C/G heterogygotes, the significance is p=0.2525 and HR=0.673while subjects that are CD68 positive (0-50), the significance isp=0.0714 and HR=0.615.

Subjects treated with Velcade+rituximab had a trend for better OS whenpositive for CD68 low (0-50) and stratified by any FLIPI score, by tumorburden, by Ann Arbor score, by age, by region, by sex, and by race.Subjects treated with Velcade+rituximab had a trend for better OS whenpositive for PSMB1 P11A heterozygote and stratified by any FLIPI score,by tumor burden, by Ann Arbor score, by age, by region, by sex, and byrace.

Following cross validation, the pair previously described (CD68 Low andPSMB P11A) was found to be significant in the smaller discovery cohort(p=0.0003, 14.2 months for Vc-R vs 8.5 months for R, HR=0.4 (0.24,0.67)). There was still a trend for longer OS in the biomarker positivepopulation (p=0.1291), HR=0.47(0.17, 1.27). Although the number ofsubjects in the confirmation cohorts is small, the positive trend inboth PFS and OS was found to be maintained. In confirmation cohort 1(n=106), subjects treated with Vc-R had approximately 18.2 mo PFS whilethose treated with R alone had 9.5 months PFS (p=0.0817, HR=0.44). Inconfirmation cohort 2 (n=426), subjects treated with Vc-R had 13.9months median PFS while those treated with R had 9.5 months median PFS(p=0.0878, HR=0.49). The trend in OS was also maintained

It was of interest to determine the individual contributions of eachbiomarker to the PFS benefit found in subjects with both biomarkers(PSMB1 P11A heterozygote and CD68 Low). Within the biomarker positivepopulation, subjects with PSMB1 P11A (C/G) had 16.6 months median PFSwhen treated with Vc-R compared to 9.5 months median PFS when treatedwith R alone, showing a 7.1 month PFS advantage when the combination wasused. This benefit was not seen in biomarker negative subjects withVc-R. Consistent with prior publication on CD68 and rituxan, this studyshows that subjects with higher CD68 expression do better on rituximabalone (16.2 months median PFS) than those with lower CD68 expression(9.3 months median PFS). However, these subjects with low CD68 (0-50)had significantly longer PFS (14 months median) when treated with thecombination compared to similar patients treated with R alone (9.3months median); this is a 4.7 month PFS advantage (HR=0.64 (95% CI:0.475-0.864).

These results suggest that patient subgroups can be identified prior totherapy that have significantly longer PFS and a trend for better OSwhen treated with combination Vc-R compared to R alone. One biomarkerpair that maintains significance after multiple comparison corrections(FDR=0.051) includes a proteasomal subunit SNP [PSMB1 P11A heterozygote]and CD68 with low (0-50) expression. Three hundred fifty six subjectswere evaluable for both of these biomarkers within this study.Additionally, this biomarker pair had a high population frequency withapproximately one third of the evaluable subjects having both of thesebiomarkers. Subjects with this biomarker pair had a longer PFS intervalwhen treated with Vc-R (16.6 months) compared to rituximab alone (9.1months) demonstrating a PFS benefit of approximately 7.5 months with thecombination. This group also appears to have an OS benefit with Vc-Rthat clearly trends toward significance (HR: 0.426 (0.174-1.046)P=0.0550), a higher ORR (73.7% on Vc-R vs 47.5% on rituximab alone,p=0.0077), a longer time to next treatment interval (33.1 mo on Vc-R vs14.8 mo on rituximab alone, p=0.0013) and a longer duration of treatmentfree interval (27.8 mo vs 10.1 mo, p=0.0017).

Importantly, the CD68/PSMB P11A biomarker positive cohort wasrepresentative of the overall trial population with regard todemographics and clinical characteristics. Of note, approximately halfof this cohort was represented by subjects with high risk disease andpoor prognostic features. In patients with higher tumor burden (˜54%),medium or high FLIPI (˜76%), older age (>65) (˜25%), with priorRituximab treatment (˜46%), or with two (˜26%) or more than two (˜30%)lines of prior therapy the PFS benefit of the CD68/PSMB P11A biomarkerpositive cohort appears to be maintained. These patients are generallyregarded as “high risk” with limited treatment options and thesepreliminary findings suggest that biomarker positive subjects with highrisk features may benefit from Vc-R.

Polymorphisms in PSMB1 and PSMB5 were found to have significantassociations with clinical endpoints as single markers. The combinationof PSMB1 [P11A] with CD68 was found to be synergistic and present in ahigh proportion of the study cohort. PSMB1 P11A is a polymorphism foundin the leader sequence of the proteasome PSMB1 gene (Chen 1996). Theleader sequence is responsible for appropriate subunit assembly and ithas been reported that alterations of charged amino acids reduces theefficiency of subunit assembly (Schmidt 1999). Once assembledautocatalysis allows removes the leader sequence. The second biomarkerin the pair is CD68 expressing tumor infiltrating macrophages. Previousreports have shown that high levels of CD68 associate with betterresponse to rituximab (Taskinen 2007).

Importantly, this study has shown that subjects with low levels of CD68expression have longer PFS and better overall response to Vc-R comparedto R alone especially when present with PSMB1 P11A heterozygote asdiscussed above. Following cross validation, the pair previouslydescribed (CD68 Low and PSMB P11A) was found to be significant in thesmaller discovery cohort (p=0.0003, 14.2 months for Vc-R vs 8.5 monthsfor rituximab alone, HR=0.4 (0.24, 0.67)). There was still a trend forlonger OS in the biomarker positive population (p=0.1291), HR=0.47(0.17,1.27). Although the number of subjects in the confirmation cohorts wassmall, the positive trend in both PFS and OS was found to be maintained.In confirmation cohort 1 (which excludes subjects from China; n=106),subjects treated with Vc-R had approximately 18.2 mo PFS while thosetreated with R alone had 9.5 months PFS (p=0.0817, HR=0.44). Inconfirmation cohort 2 (which includes China subjects and subjects withmissing data; n=126), subjects treated with Vc-R had 13.9 months medianPFS while those treated with R had 9.5 months median PFS (p=0.0878,HR=0.49). The trend in OS was also maintained.

Example 2

Single predictors which correlated with a positive response are shown inTable 5.

TABLE 5 Single predictors. PFS Marker Vc + R vs. R N Logrank % N inMarker A Subtype median days Vc + R vs. R P-value ITT CD68 OVERALL  0-2511.5 mo vs 10.6 mo 40 vs 44 0.422 12.4 POSITIVE 0.9 mo PFS improvementCD68 OVERALL 26-50 12.1 mo vs 9.3 mo 114 vs 108 0.0588 32.9 POSITIVE 2.8mo PFS improvement CD68 POSITIVE  0-25 14.1 mo vs 9.3 mo 50 vs 60 0.093416.3 FOLLICULAR 4.8 mo PFS improvement CD68 POSITIVE 26-50 13.4 mo vs9.1 mo 84 vs 91 0.0289 25.9 FOLLICULAR 4.3 mo PFS improvement P65INTENSITY <=1+ 11.6 mo vs 9.3 mo 41 vs 43 0.2455 12.4 CYTOPLASMIC 2.3 moPFS improvement SIGNAL PSMB1/P11A C/G 14 mo vs 9.3 mo 115 vs 127 0.021835.9 4.7 mo improvement PSMB5/R24C C/T 17.6 mo vs 9.3 mo 41 vs 41 0.401612.1 8.3 mo improvement

Example 3

Predictor pairs which correlated with a positive response are shown inTables 6 and 7.

TABLE 6 Significant marker pairs. PFS Vc − R vs. R N Logrank Marker AMarker B median month Vc − R vs. R P-value FDR PSMB5/R24C P65 INTENSITY27 mo vs. 10.4 mo 5 vs. 7 0.0439 0.489 C/T CYTOPLASMIC SIG- 16.6 moimprovement NAL <=1+ PSMB1/P11A 20S % POSITIVE 18.9 mo vs. 9.5 mo 50 vs50 0.0145 0.447 C/G CYTOPLASMIC SIG- 9.4 improvement NAL: >90 PSMB1/P11ACD68 POSITIVE 16.6 mo vs. 9.1 mo 57 vs 61 0.0001 0.051 C/G FOLLICULAR:0-50 7.5 mo improvement PSMB1/P11A CD68 POSITIVE 16.6 mo vs. 9.2 mo 24vs 28 0.0365 0.471 C/G PERIFOLLICULAR: >50 7.4 improvement PSMB9/R60HP65 % NUCLEAR 16.2 mo vs. 9.5 mo 35 vs 28 0.0303 0.455 G/G STAINING: >06.7 improvement PSMB5/R24C CD68 POSITIVE 13.7 mo vs. 7.2 mo 18 vs 210.0220 0.447 C/T FOLLICULAR: 0-50 6.5 mo improvement HI Tumor BD CD68OVERALL 22.8 mo vs. 16 mo 64 vs 68 0.0177 0.447 NO POSITIVE: 0-50 6.8 moimprovement HI Tumor BD CD68 POSITIVE 20.5 mo vs. 13.8 mo 64 vs 660.0310 0.455 NO FOLLICULAR: 0-50 6.7 mo improvement Prior RX: 1 CD68POSITIVE 18.2 mo vs. 9.3 mo 63 vs 69 0.0129 0.447 FOLLICULAR: 0-50 8.9mo improvement PSMB1/P11A Time since last 18.2 mo vs. 10.7 mo 72 vs 740.0198 0.447 C/G Rx: >1 year 7.5 mo improvement Prior Ritutux CD68POSITIVE 15.9 mo vs. 9.2 mo 73 vs 86 0.0066 0.437 NO FOLLICULAR: 0-506.7 mo improvement PSMB1/P11A Age group: <=65 15.3 mo vs. 9.2 mo 86 vs96 0.0071 0.437 C/G 6.1 mo improvement Sex 20S % NUCLEAR 13.7 mo vs. 7.7mo 63 vs 48 0.0050 0.437 MALE STAINING: >20 6 mo improvement Race Group20S % NUCLEAR 11.4 mo vs. 3.8 mo 11 vs 7 0.0320 0.455 OTHERSTAINING: >20 7.6 mo improvement PSMB1/P11A PSMB5/R24C 13.7 mo vs. 7.8mo 7 vs. 7 0.0221 0.4468 C/G C/T 5.9 mo improvement

TABLE 7 Significant marker pairs PFS Vc − R vs. R Logrank Combinationmedian month P-value P65 Cytoplasmic signal >90% & 23.6 vs. 10.6 mo (13mo) 0.0132 1 prior treatment* 16 vs. 8.9 mo (7.1 mo) n.s. CD68 PosFollic (0-50) & 14.2 vs 8.5 mo (5.7 mo) 0.0025 P11A[C/G]** 14.4 vs 9.2mo (5.2 mo) n.s.

-   Arif A (2009), Jamal S, Mushtaq S, Ahmed S, Mubarik A. Frequency of    bcl-2 gene rearrangement in B-Cell Non-Hodgkin's lymphoma. Asian    Pacific J Cancer Prey 2009; 10(2): 237-240.-   Binstadt B A (2003), Geha R S, Bonilla F A. IgG Fc receptor    polymorphisms in human disease: Implications for intravenous    immunoglobulin therapy. J Allergy Clin Immunol 2003; 111(4):    697-703.-   Cartron G (2002), Dacheux L, Salles G, Solal-Celigny P, Bardos P,    Colombat P, Watier H. Therapeutic activity of humanized anti-CD20    monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa    gene. Blood 2002; 99(3): 754-758.-   Chen P (1996), Hochstrasser M. Autocatalytic subunit processing    couples active site formation in the 20S proteasome to completion of    assembly. Cell 1996; 86: 961-972.-   Chen S (2010), Blank J L, Peters T, Liu X J, Rappoli D M, Pickard M    D, Menon S, Driscoll D L, Lingaraj T, Burkhardt A L, Chen W, Garcia    K, Sappal D S, Gray J, Hales P, Leroy P J, Ringeling J, Rabino C,    Spelman J J, Morganstem J P, Lightcap E S. Genome-wide siRNA screen    for modulators of cell death induced by proteasome inhibitor    bortezomib. Cancer Res 2010; 70(11): 4318-4326.-   Clinical Study Protocol 26866138-LYM3001. A randomized, open-label,    multicenter study of VELCADE with rituximab or rituximab alone in    subjects with relapsed or refractory, rituximab naïve or sensitive    follicular B-cell non-Hodgkin's lymphoma. Document No.    EDMS-PSDB-4649082:4.0; Johnson & Johnson Pharmaceutical Research &    Development (19 May 2006).-   Clinical Study Report 26866138-LYM3001. A randomized, open-label,    multicenter study of VELCADE with rituximab or rituximab alone in    subjects with relapsed or refractory, rituximab naïve or sensitive    follicular B-cell non-Hodgkin's lymphoma. Document No.    EDMS-ERI-16225335:1.0; Johnson & Johnson Pharmaceutical Research &    Development (9 Feb. 2011).-   Dave S S (2004), Wright G, Tan B, Rosenwald A, Gascoyne R D, Chan W    C, Fisher R I, Braziel R M, Rimsza L M, Grogan T M, Miller T P,    Leblanc M, Greiner T C, Weisenburger D D, Lynch J C, Vose J,    Armitage J O, Smeland E B, Kvaloy S, Holte H, Delabie J, Connors J    M, Lansdorp P M, Ouyang Q, Lister T A, Davies A J, Norton A J,    Muller-Hermelink H K, Ott G, Campo E, Montserrat E, Wilson W H,    Jaffe E S, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N,    Chiorazzi M, Staudt L M. Prediction of survival in follicular    lymphoma based on molecular features of tumor-infiltrating immune    cells. NEJM 2004; 351(21): 2159-2169.-   Fischer U (2005), Schulze-Osthoff K. New approaches and therapeutics    targeting apoptosis in disease. Pharmacol Rev 2005; 57(2): 187-215.-   Goy A (2010), Bernstein S, McDonald A, Pickard M, Shi H, Fleming M,    Bryant B, Trepicchio W, Fisher R, Boral A, Mulligan G. Potential    biomarkers of bortezomib activity in mantle cell lymphoma from the    phase 2 PINNACLE trial. Leukemia & Lymphoma 2010; 51(7): 1269-1277.-   Karin M (2002), Cao Y, Florian G R, Li Z W. NF-kB in cancer: From    innocent bystander to major culprit. Nature Rev Cancer 2002; 2(4):    301-310.-   Keats J J (2007), Fonseca R, Chesi M, Schop R, Baker A, Chng Wj, Van    Wier S, Tiedemann R, Shi C X, Sebag M, Braggio E, Henry T, Zhu Y X,    Fogle H, Price-Troska T, Altmann G, Mancini C, Brents L A, Kumar S,    Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M,    Valdez R, Trent J, Stewart A K, Carpten J, Bergsagel P L.    Promiscuous mutations activate the noncanonical NF-kappaB pathway in    multiple myeloma. Cancer Cell 2007; 12(2): 131-144.-   Mitsiades N (2002), Mitsiades C S, Poulaki V, Chauhan D, Fanourakis    G, Gu X, Bailey C, Joseph M, Libermann T A, Treon S P, Munshi N C,    Richardson P G, Hideshima T, Anderson K C. Molecular sequelae of    proteasome inhibition in human multiple myeloma cells. Proc Natl    Acad Sci USA 2002; 99(22): 14374-14379.-   Mulligan G (2007), Mitsiades C, Bryant B, Zhan F, Chng W J, Roels S,    Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio W L, Broyl A,    Sonnveld P, Shaghnessy J D, Bergsagel P L, Schenkein D, Esseltine D    L, Boral A, Anderson K C. Gene expression profiling and correlation    with clinical outcome in clinical trials of the proteasome inhibitor    bortezomib. Blood 2007; 109(8): 3177-3188.-   Schmidt M (1999), Zantopf D, Kraft R, Kostka S, Preissner R,    Kloetzel P M. Sequence information within proteasomal prosequences    mediates efficient integration of β-subunits into the 20S proteasome    complex. J Mol Biol 1999; 288(1): 117-128.-   Shin H M (2006), Minter L M, Cho O H, Gottipati S, Fauq A H, Golde T    E, Sonenshein G E, Osborne B A. Notchl augments NF-kappaB activity    by facilitating its nuclear retention. EMBO 2006; 25(1): 129-138.-   Taskinen M (2007), Karjalainen-Lindsberg M L, Nyman H, Eerola L M,    Leppa S. A high tumor-associated macrophage content predicts    favorable outcome in follicular lymphoma patients treated with    rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.    Clin Cancer Res 2007; 13(19): 5784-5789.-   Wojcik C (2002). Regulation of apoptosis by the ubiquitin and    proteasome pathway. J Cell Mol Med 2002; 6(1): 25-48.-   Wu J (1997), Edberg J C, Redecha P B, Bansal V, Guyre P M, Coleman    K, Salmon J E, Kimberly R P. A novel polymorphism of FcgammaRIIIa    (CD16) alters receptor function and predisposes to autoimmune    disease. J Clin Invest 1997; 100(5): 1059-1070.-   Yeung B H (2006), Huang D C, Sinicrope F A. PS-341 (bortezomib)    induces lysosomal cathepsin b release and a caspase-2 dependent    mitochondrial permeabilization and apoptosis in human pancreatic    cancer cells. J Biol Chem 2006; 281(17): 11923-11932.-   Yin D (2005), Zhou H, Kumagai T, Liu G, Ong J M, Black K L, Koeffler    H P. Proteasome inhibitor PS-341 causes cell growth arrest and    apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005;    24(3): 344-354.

Example 4

Appendix 2 presents an overall summary of the single-marker associationswith clinical endpoint other than PFS and stratified by clinicalcovariates from the previous examples.

Appendix 3 outlines the data for all significant pair-wise combinationsfrom the previous examples. Note: Selected=Biomarker positive, NotSelected=Biomarker negative.

Example 5

The VISTA study was an open-label, randomized study ofVELCADE/Melphalan/Prednisone versus Melphalan/Prednisone in subjectswith previously untreated multiple myeloma. San Miguel, N. Engl. J. Med.2008 Aug. 28; 359(9):906-17. The primary efficacy objective of thisstudy was to determine whether the addition of VELCADE (Bortezomib forInjection) to standard melphalan/prednisone (MP) therapy improves thetime to disease progression (TTP) in subjects with previously untreatedmultiple myeloma.

The exploratory objectives in biomarker analysis from the VISTA studywere to identify patient populations that are more or less likely torespond to VELCADE/Melphalan/Prednisone versus Melphalan/Prednisonealone by:

-   -   Confirming the finding (from lymphoma studies) of a single        marker association of PSMB1 P11A and PSMB5 R24C with PFS and OS.    -   Association with other clinical endpoints including: time to        progression (TTP), complete response (CR), Overall response        rate, time to response and duration of response.

Association of PSMB1 P11A and PSMB5 R24C individually or in combinationwith TTP, PFS, and OS were estimated using the log rank test betweentreatment groups for biomarker positive and negative populations. Theoverall biomarker population by treatment arm had similar associationsmade. Medians of TTP, PFS, and OS, difference in median TTP, PFS, and OSbetween treatment groups, log rank P-value, hazard ratio and its 95%confidence intervals and frequencies of events were reported.Kaplan-Meier plots were presented for each biomarker. When positiveassociations were found for TTP, OS or PFS, then the other clinicalendpoints were tested with similar methods and output. For ORR, Fishersexact test was used. The number and percentage of subjects falling intoeach response category were descriptively tabulated.

Table 8 shows the progression free survival benefit of 5.3 months withVELCADE-MP vs. MP alone in patients with PSMB1 P1 1A (C/G) marker.

Biomarker Positive Biomarker Negative Total Statistic Vmp mp Vmp mp Vmpmp Event/Total 39/82 61/89 47/87 68/94 86/169 129/183 (%) (47.6) (68.5)(54.0) (72.3) (50.9) (70.5) Median 20.3 mo 15 mo 17.7 mo 11.2 mo 19 mo12.6 mo (95% CI) (556,873) (253,511) (459,610) (254,436) (533,662)(279,463) HR 0.44 0.62 0.54 (Vmp vs (0.29,0.67) (0.43,0.90) (0.41,0.71)mp) HR p- <.0001 0.0117 <.0001 Value (Vmp vs mp)Table 9 shows the overall survival benefit of 6 months with VELCADE-MPvs. MP alone in patients with PSMB1 P1 1A (C/G) marker.

Biomarker Positive Biomarker Negative Total Statistic Vmp mp Vmp mp Vmpmp Event/Total 47/82 65/89 42/87 55/94 89/169 120/183 (%) (57.3) (73.0)(48.3) (58.5) (52.7) (65.6) Median 52 39 58 46 56 42 (95% CI)(1322,1845) (893,1412) (1318,—) (965,1745) (1372,1845) (1014,1470) HR0.63 0.81 0.72 Vmp vs (0.44,0.92) (0.54,1.22) (0.55,0.95) mp) HR p-0.0167 0.3153 0.0179 Value (Vmp vs mp)

APPENDIX 2 Table 2.1: Overall survival (OS) by Protein Expression and byCovariate, IRC Review (Significant [p ≦ 0.05], Frequency of ≧10% orHigher) Marker: HR R R Vc-R Vc-R Subgroup Marker: Level Subgroup (95%CI) HR (log scale) Evt/N Median Evt/N Median N Total 20S % POSITIVECYTOPLASMIC SIGNAL: 0-20 2 Prior Lines of Therapy 8.28 (0.85, 80.83)

 1/10 — 3/4   809 122 20S % POSITIVE CYTOPLASMIC SIGNAL: 95-100 2 PriorLines of Therapy 0.42 (0.17, 1.00)

14/35 1205 9/40 — 122 CD68 OVERALL POSITIVE: 26-50 2 Prior Lines ofTherapy 0.33 (0.12, 0.87)

13/26 1205 7/30 — 111 CD68 POSITIVE PERIFOLLICULAR: 26-50 2 Prior Linesof Therapy 0.30 (0.09, 1.04)

 7/16 1205 5/27 —  98 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% 2 PriorLines of Therapy 0.42 (0.19, 0.97)

19/52 — 9/44 — 125 P65 INTENSITY CYTOPLASMIC SIGNAL: ≧2+ 2 Prior Linesof Therapy 0.35 (0.14, 0.88)

19/55 — 7/43 — 125 CD68 OVERALL POSITIVE: 26-50 No High Tumor Burden0.21 (0.06, 0.72)

14/54 — 3/46 — 204 CD68 POSITIVE PERIFOLLICULAR: 26-50 No High TumorBurden 0.11 (0.01, 0.82)

10/41 — 1/33 — 182 P27 %NUCLEI POSITIVE: 0-20 No High Tumor Burden 3.91(0.98, 15.69)

 3/29 — 6/17 — 215 20S INTENSITY CYTOPLASMIC SIGNAL: ≦2+ IntermediateFLIPI Score 5.43 (1.17, 25.14)

 2/48 — 9/41 — 168 P65 INTENSITY CYTOPLASMIC SIGNAL: ≦1+ IntermediateFLIPI Score 6.84 (0.80, 58.74)

 1/17 — 5/13 — 170 CD68 POSITIVE FOLLICULAR: 0-25 No Prior RituximabTherapy 0.21 (0.05, 0.97)

11/36 — 3/25 1343 210 CD68 POSITIVE FOLLICULAR: 0-25 ≦65 years old 0.29(0.10, 0.83)

14/46 — 5/41 — 292 20S INTENSITY CYTOPLASMIC SIGNAL: ≧3+ Male 0.30(0.12, 0.77)

10/27 — 8/62 — 204 CD68 POSITIVE PERIFOLLICULAR: 26-50 Male 0.29 (0.10,0.83)

11/30 — 5/39 — 169 P27 % NUCLEI POSITIVE: 60-70 Male 0.09 (0.01, 0.93)

 4/12 — 1/14 — 202 CD68 OVERALL POSITIVE: 51-75 Ann Arbor Stage III 6.24(1.25, 31.02)

 2/21 — 6/13 1078 144 20S % POSITIVE CYTOPLASMIC SIGNAL: 0-20 Ann ArborStage IV 7.22 (0.80, 65.02)

 1/15 — 4/11 1103 236 20S % POSITIVE CYTOPLASMIC SIGNAL: 95-100 AnnArbor Stage IV 0.50 (0.27, 0.91)

25/56 1205 19/75  1343 236

APPENDIX 2 Table 2.2: OS by Germline Genetic Variant nd by Covariate,IRC Review (Significant [p ≦ 0.05], Frequency of ≧10% or Higher) HR R RVc-R Vc-R Marker: Subgroup Marker: Level Subgroup (95% CI) HR (logscale) Evt/N Median Evt/N Median N Total PSMB9/R60H: A/A 3 Prior Linesof Therapy 6.92 (0.79, 60.79)

1/6  — 5/7  846  85 PSMB5/R24C: C/T Intermediate FLIPI Score 0.10 (0.01,0.97)

4/10 971 1/16 — 186 PSMB5/R24C: C/T Ann Arbor Stage IV 0.22 (0.07, 0.66)

9/15 717 5/28 — 270

APPENDIX 2 Table 2.3: OS by Somatic Mutation and by Covariate, IRCReview (Significant [p ≦ 0.05], Frequency of ≦10% or Higher) Marker: HRR R Vc-R Vc-R Subgroup Marker: Level Subgroup (95% CI) HR (log scale)Evt/N Median Evt/N Median N Total NOTCH/X28DE L: MND 2 Prior Lines ofTherapy 0.44 (0.20, 0.97)

20/56 — 10/48 — 109 NOTCH/P2513L: MD No High Tumor Burden 0.14 (0.02,1.15)

 7/26 —  1/21 — 163 BCL2/P59L: MD High Tumor Burden 0.17 (0.04, 0.65)

5/6 282  4/14 — 172 BCL2/P59L: MD High FLIPI Score 0.21 (0.05, 0.86)

6/6 282 4/7 843 125 BCL2/P59L: MD No Prior Rituximab Therapy 0.12 (0.03,0.48)

5/5 174  4/13 — 178 BCL2/P59L: MD Rest of World 0.22 (0.06,0.84

4/5 174  5/12 — 152 NOTCH/P2513L: MD >65 years old 0.30 (0.09, 1.03)

 8/13 795  4/13 —  92 BCL2/P59L: MD Female 0.26 (0.07, 0.92)

6/8 536  4/14 — 180 BCL2/R106H: MD Male 0.25 (0.07, 0.84)

 8/10 318  4/12 — 169 NOTCH/Q2460X : MD Male 0.11 (0.02, 0.70)

3/3 595  5/12 — 142 NOTCH/X28DE L: MND Male 0.57 (0.32, 1.00)

26/75 — 22/97 — 180 BCL2/P59L: MD Ann Arbor Stage IV 0.12 (0.03, 0.50)

5/5 174  4/12 — 149

APPENDIX 2 Table 2.4: Time to Progression (TTP), by Protein Expressionand by Covariate, IRC Review (Significant [p ≦ 0.05], Frequency of ≧10%or Higher) Marker: HR R R Vc-R Vc-R Subgroup Marker: Level Subgroup (95%CI) HR (log scale) Evt/N Median Evt/N Median N Total CD68 POSITIVEFOLLICULAR: 26-50 No Subgroup 0.66 (0.45, 0.96)

65/91 277 48/84 414 387 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% NoSubgroup 0.75 (0.59, 0.96)

139/204 334 116/186 414 470 CD68 POSITIVE FOLLICULAR: 26-50 1 Prior Lineof Therapy 0.51 (0.27, 0.94)

26/39 349 18/40 881 176 CD68 POSITIVE PERIFOLLICULAR: >75 1 Prior Lineof Therapy 0.24 (0.09, 0.65)

13/18 275  7/16 716 174 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% 1 PriorLine of Therapy 0.67 (0.45, 0.98)

56/89 349 48/88 506 203 20S % NUCLEAR STAINING: 30-50 2 Prior Lines ofTherapy 0 41 (0.18, 0.95)

11/13 239 13/22 431 122 CD68 OVERALL POSITIVE: 0-25 2 Prior Lines ofTherapy 0.22 (0.05, 0.90)

6/8 142 4/7 771 111 CD68 POSITIVE PERIFOLLICULAR: 0-25 2 Prior Lines ofTherapy 0.13 (0.03, 0.64)

7/8  70 4/7 771 98 CD68 POSITIVE FOLLICULAR: 51-75 3 Prior Lines ofTherapy 9.40 (1.13, 78.09)

1/4 — 8/8 276 60 P27 SIGNAL INTENSITY: ≧2+ 4 Prior Lines of Therapy 3.02(1.09, 8.34)

 9/15 348  8/10 144 32 CD68 OVERALL POSITIVE: 26-50 No High Tumor Burden0.50 (0.29, 0.86)

37/54 357 22/46 881 204 CD68 POSITIVE FOLLICULAR: 26-50 No High TumorBurden 0.50 (0.27, 0.93)

29/44 351 17/39 881 182 CD68 OVERALL POSITIVE: 26-50 High FLIPI Score0.58 (0.36, 0.94)

36/45 277 35/52 366 181 CD68 POSITIVE FOLLICULAR: 26-50 High FLIPI Score0.57 (0.33, 0.97)

31/37 205 25/36 347 156 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% HighFLIPI Score 0.65 (0.45, 0.94)

61/83 239 53/77 358 193 P65 INTENSITY CYTOPLASMIC SIGNAL: ≧2+ High FLIPIScore 0.67 (0.46, 0.98)

60/80 275 51/76 358 193 P27 % NUCLEI POSITIVE: 60-70 Intermediate FLIPIScore 3.34 (1.20, 9.30)

 6/13 513 10/11 215 165 P65 % POSITIVE CYTOPLASMIC SIGNAL: 90%Intermediate FLIPI Score 2.77 (1.00, 7.64)

 5/16 567 15/19 351 170 P65 % NUCLEAR STAINING: 0 No Prior RituximabTherapy 0.69 (0.49, 0.97)

 77/102 322 55/92 426 255 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% NoPrior Rituximab Therapy 0.68 (0.49, 0.95)

 80/112 345  61/105 463 255 CD68 OVERALL POSITIVE: 0-25 ≦1 year sincelast anti-lymphoma treatment 2.66 (1.02, 6.96)

11/18 424 11/13 202 173 CD68 POSITIVE FOLLICULAR: 0-25 >1 year sincelast anti-lymphoma treatment 0.49 (0.26, 0.91)

23/34 357 20/33 519 235 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% >1 yearsince last anti-lymphoma treatment 0.69 (0.49, 0.96)

 77/117 357  61/112 519 288 CD68 OVERALL POSITIVE: 26-50 Rest of World0.63 (0.40, 1.00)

40/51 277 34/52 367 198 CD68 OVERALL POSITIVE: 26-50 ≦65 years old 0.65(0.44, 0.95)

57/77 278 50/84 414 329 CD68 POSITIVE FOLLICULAR: 26-50 ≦65 years old0.55 (0.36, 0.86)

52/67 270 34/62 406 292 CD68 POSITIVE PERIFOLLICULAR: >75 ≦65 years old0.46 (0.22, 0.98)

17/23 275 12/23 506 289 P27 SIGNAL INTENSITY: ≧2+ ≦65 years old 0.73(0.55, 0.97)

104/153 281  91/149 406 344 P65 % NUCLEAR STAINING: 0 ≦65 years old 0.72(0.53, 0.98)

 97/138 287  71/118 414 349 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% ≦65years old 0.66 (0.50, 0.89)

108/154 278  83/142 422 349 P65 INTENSITY CYTOPLASMIC SIGNAL: ≧2+ ≦65years old 0.74 (0.55, 0.98)

105/152 287  85/139 406 349 20S % POSITIVE CYTOPLASMIC SIGNAL: 0-20 >65years old 0.14 (0 .02, 1.21)

5/6 278 4/7 738 118 CD68 POSITIVE FOLLICULAR: 51-75 Female 2.38 (1.11,5.13)

14/26 708 13/14 324 217 20S % NUCLEAR STAINING: 60-70 Male 0.37 (0.17,0.84)

13/16 212 15/20 358 204 20S INTENSITY CYTOPLASMIC SIGNAL: ≧3+ Male 0.58(0.34, 1.00)

20/27 280 39/62 422 204 CD68 POSITIVE PERIFOLLICULAR: 26-50 Male 0.48(0.27, 0.86)

22/30 239 26/39 429 169 P27 SIGNAL INTENSITY: ≧2+ Male 0.70 (0.48, 1.00)

52/72 280  69/101 360 202 P65 % NUCLEAR STAINING: 0 Male 0.67 (0.46,0.98)

56/74 280 56/84 358 207 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% Male0.61 (0.42, 0.87)

54/72 271 65/97 414 207 CD68 POSITIVE PERIFOLLICULAR: 26-50 Other 0.14(0.01, 1.31)

4/4 128 4/5 346 22 CD68 POSITIVE FOLLICULAR: 26-50 White 0.59 (0.39,0.89)

53/77 334 39/73 463 335 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% White0.72 (0.55, 0.94)

119/179 345  99/162 426 406 P65 INTENSITY CYTOPLASMIC SIGNAL: ≦1+ AnnArbor Stage III 0.26 (0.08, 0.90)

 7/11 204  7/11 464 151 20S % POSITIVE CYTOPLASMIC SIGNAL: 95-100 AnnArbor Stage IV 0.66 (0.43, 1.00)

43/56 278 47/75 414 236 CD68 OVERALL POSITIVE: 26-50 Ann Arbor Stage IV0.65 (0.42, 0.99)

44/56 277 45/68 366 222 P27 % NUCLEI POSITIVE: 30-50 Ann Arbor Stage IV0.43 (0.20, 0.92)

15/19 278 13/23 485 237 P27 SIGNAL INTENSITY: ≧2+ Ann Arbor Stage IV0.70 (0.50, 0.99)

64/85 283  73/113 358 237 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% AnnArbor Stage IV 0.65 (0.46, 0.91)

67/87 275  66/104 366 240

APPENDIX 2 Table 2.5: TTP by Germline Genetic Variant and by Covariate,IRC review (Significant [p ≦ 0.05], Frequency of ≧10% or Higher) Marker:HR R R Vc-R Vc-R Subgroup Marker: Level Subgroup (95% CI) HR (log scale)Evt/N Median Evt/N Median N Total PSMB1/P11A: C/G No Subgroup 0.70(0.51, 0.96)

 82/127 288  74/115 426 542 PSMB9/V32I: C/C No Subgroup 0.80 (0.65,0.99)

177/266 345 157/254 417 542 PSMB5/R24C: C/T 2 Prior Lines of Therapy0.32 (0.11, 0.95)

 8/10 280  6/12 534 142 PSMB1/A171S: G/G High Tumor Burden 0.74 (0.57,0.97)

110/147 273 107/149 344 296 PSMB1/I208N: T/T High Tumor Burden 0.74(0.57, 0.97)

110/147 273 107/149 344 296 PSMB1/P11A: C/G High Tumor Burden 0.66(0.44, 0.99)

52/72 253 44/65 358 296 PSMB1/P193L: C/C High Tumor Burden 0.74 (0.57,0.97)

110/147 273 107/149 344 296 PSMB2/E49X: G/G High Tumor Burden 0.74(0.57, 0.97)

110/147 273 107/149 344 296 PSMB2/G187V: G/G High Tumor Burden 0.74(0.57, 0.97)

110/147 273 107/149 344 296 PSMB2/L159F: C/C High Tumor Burden 0.74(0.57, 0.97)

110/147 273 107/149 344 296 PSMB5/L206M: C/C High Tumor Burden 0.74(0.57, 0.97)

110/147 273 107/149 344 296 PSMB5/R24C: C/T High Tumor Burden 0.39(0.19, 0.77)

17/21 275 18/24 352 296 PSMB6/A234D: C/C High Tumor Burden 0.74 (0.57,0.97)

110/147 273 107/149 344 296 PSMB8/G8R: G/G High Tumor Burden 0.73 (0.56,0.96)

104/140 271 105/145 344 296 PSMB8/R141C: C/C High Tumor Burden 0.74(0.57, 0.97)

110/147 273 107/149 344 296 PSMB8/V182M: G/G High Tumor Burden 0.74(0.57, 0.97)

110/147 273 107/149 344 296 PSMB9/G9E: G/G High Tumor Burden 0.74 (0.56,0.96)

110/145 271 107/148 344 296 PSMB9/V32I: C/C High Tumor Burden 0.73(0.56, 0.96)

108/142 273 101/142 331 296 PSMB1/A171S: G/G High FLIPI Score 0.68(0.49, 0.92)

 84/112 273  75/110 350 222 PSMB1/I208N: T/T High FLIPI Score 0.68(0.49, 0.92)

 84/112 273  75/110 350 222 PSMB1/P193L: C/C High FLIPI Score 0.68(0.49, 0.92)

 84/112 273 75/110 350 222 PSMB2/E49X: G/G High FLIPI Score 0.68 (0.49,0.92)

 84/112 273  75/110 350 222 PSMB2/G187V: G/G High FLIPI Score 0.68(0.49, 0.92)

 84/112 273  75/110 350 222 PSMB2/L159F: C/C High FLIPI Score 0.68(0.49, 0.92)

 84/112 273  75/110 350 222 PSMB5/L206M: C/C High FLIPI Score 0.68(0.49, 0.92)

 84/112 273  75/110 350 222 PSMB6/A234D: C/C High FLIPI Score 0.68(0.49, 0.92)

 84/112 273  75/110 350 222 PSMB6/P107A: C/C High FLIPI Score 0.68(0.49, 0.93)

 81/107 275  74/108 350 222 PSMB8/G8R: G/G High FLIPI Score 0.69 (0.50,0.95)

 77/105 273  73/107 350 222 PSMB8/R141C: C/C High FLIPI Score 0.68(0.49, 0.92)

 84/112 273  75/110 350 222 PSMB8/V182M: G/G High FLIPI Score 0.68(0.49, 0.92)

 84/112 273  75/110 350 222 PSMB9/G9E: G/G High FLIPI Score 0.69 (0.50,0.94)

 84/111 273  75/109 348 222 PSMB9/V32I: C/C High FLIPI Score 0.65 (0.47,0.89)

 80/105 239  71/105 348 222 PSMB1/P11A: C/G No Prior Rituximab Therapy0.64 (0.43, 0.98)

49/68 330 43/70 464 287 PSMB9/V32I: C/C No Prior Rituximab Therapy 0.73(0.55, 0.99)

 98/138 351  79/136 483 287 PSMB1/A171S: G/G >1 year since lastanti-lymphoma treatment 0.71 (0.54, 0.94)

104/165 381  91/166 529 331 PSMB1/I208N: T/T >1 year since lastanti-lymphoma treatment 0.71 (0.54, 0.94)

104/165 381  91/166 529 331 PSMB1/P11A: C/G >1 year since lastanti-lymphoma treatment 0.60 (0.39, 0.91)

47/74 338 42/72 576 331 PSMB1/P193L: C/C >1 year since lastanti-lymphoma treatment 0.71 (0.54, 0.94)

104/165 381  91/166 529 331 PSMB2/E49X: G/G >1 year since lastanti-lymphoma treatment 0.71 (0.54, 0.94)

104/165 381  91/166 529 331 PSMB2/G187V: G/G >1 year since lastanti-lymphoma treatment 0.71 (0.54, 0.94)

104/165 381  91/166 529 331 PSMB2/L159F: C/C >1 year since lastanti-lymphoma treatment 0.71 (0.54, 0.94)

104/165 381  91/166 529 331 PSMB5/L206M: C/C >1 year since lastanti-lymphoma treatment 0.71 (0.54, 0.94)

104/165 381  91/166 529 331 PSMB6/A234D: C/C >1 year since lastanti-lymphoma treatment 0.71 (0.54, 0.94)

104/165 381  91/166 529 331 PSMB6/P107A: C/C >1 year since lastanti-lymphoma treatment 0.71 (0.53, 0.94)

103/159 381  90/162 519 331 PSMB8/G8R: G/G >1 year since lastanti-lymphoma treatment 0.73 (0.55, 0.98)

 96/155 414  86/159 519 331 PSMB8/R141C: C/C >1 year since lastanti-lymphoma treatment 0.71 (0.54, 0.94)

104/165 381  91/166 529 331 PSMB8/V182M: G/G >1 year since lastanti-lymphoma treatment 0.71 (0.54, 0.94)

104/165 381  91/166 529 331 PSMB9/G9E: G/G >1 year since lastanti-lymphoma treatment 0.70 (0.53, 0.93)

104/163 381  91/165 519 331 PSMB9/V32I: C/C >1 year since lastanti-lymphoma treatment 0.69 (0.51, 0.92)

102/160 379  86/158 529 331 PSMB1/A171S: G/G ≦65 years old 0.71 (0.55,0.91)

131/198 326 115/194 435 392 PSMB1/I208N: T/T ≦65 years old 0.71 (0.55,0.91)

131/198 326 115/194 435 392 PSMB1/P11A: C/G ≦65 years old 0.58 (0.40,0.85)

62/96 288 50/86 506 392 PSMB1/P193L: C/C ≦65 years old 0.71 (0.55, 0.91)

131/198 326 115/194 435 392 PSMB2/E49X: G/G ≦65 years old 0.71 (0.55,0.91)

131/198 326 115/194 435 392 PSMB2/G187V: G/G ≦65 years old 0.71 (0.55,0.91)

131/198 326 115/194 435 392 PSMB2/L159F: C/C ≦65 years old 0.71 (0.55,0.91)

131/198 326 115/194 435 392 PSMB5/L206M: C/C ≦65 years old 0.71 (0.55,0.91)

131/198 326 115/194 435 392 PSMB5/R24C: C/C ≦65 years old 0.71 (0.55,0.93)

115/170 334 103/167 429 392 PSMB6/A234D: C/C ≦65 years old 0.71 (0.55,0.91)

131/198 326 115/194 435 392 PSMB6/P107A: C/C ≦65 years old 0.71 (0.55,0.92)

126/189 330 113/190 435 392 PSMB8/G8R: G/G ≦65 years old 0.72 (0.56,0.93)

124/189 330 111/186 422 392 PSMB8/R141C: C/C ≦65 years old 0.71 (0.55,0.91)

131/198 326 115/194 435 392 PSMB8/V182M: G/G ≦65 years old 0.71 (0.55,0.91)

131/198 326 115/194 435 392 PSMB9/G9E: G/G ≦65 years old 0.70 (0.55,0.90)

131/196 326 115/193 431 392 PSMB9/R60H: G/G ≦65 years old 0.69 (0.50,0.96)

 79/119 330  68/113 487 392 PSMB9/V32I: C/C ≦65 years old 0.69 (0.53,0.89)

129/192 326 108/186 435 392 PSMB9/R60H: A/G Male 0.54 (0.31, 0.94)

22/28 273 34/48 351 241 PSMB1/A171S: G/G Ann Arbor Stage IV 0.72 (0.54,0.95)

 95/127 278  93/143 360 270 PSMB1/I208N: T/T Ann Arbor Stage IV 0.72(0.54, 0.95)

 95/127 278  93/143 360 270 PSMB1/P11A: C/G Ann Arbor Stage IV 0.64(0.42, 0.96)

46/59 235 48/68 351 270 PSMB1/P193L: C/C Ann Arbor Stage IV 0.72 (0.54,0.95)

 95/127 278  93/143 360 270 PSMB2/E49X: G/G Ann Arbor Stage IV 0.72(0.54, 0.95)

 95/127 278  93/143 360 270 PSMB2/G187V: G/G Ann Arbor Stage IV 0.72(0.54, 0.95)

 95/127 278  93/143 360 270 PSMB2/L159F: C/C Ann Arbor Stage IV 0.72(0.54, 0.95)

 95/127 278  93/143 360 270 PSMB5/L206M: C/C Ann Arbor Stage IV 0.72(0.54, 0.95)

 95/127 278  93/143 360 270 PSMB6/A234D: C/C Ann Arbor Stage IV 0.72(0.54, 0.95)

 95/127 278  93/143 360 270 PSMB6/P107A: C/C Ann Arbor Stage IV 0.74(0.55, 0.99)

 92/124 279  92/140 358 270 PSMB8/G8R: G/G Ann Arbor Stage IV 0.73(0.54, 0.98)

 88/120 279  88/138 352 270 PSMB8/R141C: C/C Ann Arbor Stage IV 0.72(0.54, 0.95)

 95/127 278  93/143 360 270 PSMB8/V182M: G/G Ann Arbor Stage IV 0.72(0.54, 0.95)

 95/127 278  93/143 360 270 PSMB9/G9E: G/G Ann Arbor Stage IV 0.71(0.53, 0.94)

 95/126 278  93/142 358 270 PSMB9/V32I: C/C Ann Arbor Stage IV 0.69(0.51, 0.93)

 93/123 277  89/138 363 270

APPENDIX 2 Table 2.6: TTP by somatic mutation and by covariate, IRCreview (Significant [p ≦ 0.05], Frequency of ≦10% and Higher) Marker:Level Subgroup HR (95% CI) HR (log scale) R Evt/N R Median Vc-R Evt/NVc-R Median Marker: Subgroup N Total BCL2/A43G: MND No Subgroup 0.73(0.55, 0.95)

110/161 334  96/154 435 315 BCL2/C.-11C>T: MND No Subgroup 0.77 (0.60,1.00)

130/192 334 113/179 422 390 BCL2/E29K: MND No Subgroup 0.71 (0.53, 0.95)

102/150 326  87/139 435 318 BCL2/P46S: MND No Subgroup 0.73 (0.55, 0.97)

100/147 287  92/147 429 310 BCL2/P59S: MND No Subgroup 0.73 (0.55, 0.97)

100/145 288  94/147 429 309 BCL2/Q52P: MND No Subgroup 0.73 (0.55, 0.96)

105/153 288  97/154 429 307 BCL2/R106H: MND No Subgroup 0.72 (0.55,0.95)

112/162 338  94/151 422 372 NOTCH/X28DEL: MND No Subgroup 0.78 (0.61,1.00)

133/194 334 120/189 414 400 NOTCH/X28INS: MND No Subgroup 0.75(0.59,0.96)

138/198 334 123/195 414 401 BCL2/A43G: MND 1 Prior Line of Therapy 0.62(0.40, 0.97)

45/72 349 35/67 624 139 BCL2/P59L: MD 1 Prior Line of Therapy 0.14(0.02, 0.83)

3/3 398  6/11 553 139 NOTCH/X28INS: MND 1 Prior Line of Therapy 0.65(0.44, 0.97)

53/84 365 47/88 553 178 BCL2/P46L: MD 2 Prior Lines of Therapy 0.14(0.02, 1.28)

5/5 226 2/4 —  83 BCL2/R106H: MND 6 or More Prior Lines of Therapy 0.11(0.01, 1.04)

4/4  50 4/5 305  11 NOTCH/G_A1702P: MND 6 or More Prior Lines of Therapy0.13 (0.01, 1.19)

5/6  70 4/5 305  11 NOTCH/I1681N: MND Prior Lines of Therapy 0.13 (0.01,1.19)

5/6  70 4/5 305  11 NOTCH/L1679P: MND Prior Lines of Therapy 0.13 (0.01,1.19)

5/6  70 4/5 305  11 NOTCH/L1679Q: MND 6 or More Prior Lines of Therapy0.13 (0.01, 1.19)

5/6  70 4/5 305  11 NOTCH/P2515FS4: MND 6 or More Prior Lines of Therapy0.13 (0.01, 1.19)

5/6  70 4/5 305  11 NOTCH/X26DEL: MND 6 or More Prior Lines of Therapy0.14 (0.01, 1.31)

4/5 130 4/5 305  10 NOTCH/X26INS: MND 6 or More Prior Lines of Therapy0.14 (0.01, 1.31)

4/5 130 4/5 305  10 NOTCH/X28DEL: MND 6 or More Prior Lines of Therapy0.13 (0.01, 1.25)

4/5  70 4/5 305  11 NOTCH/X28INS: MND 6 or More Prior Lines of Therapy0.12 (0.01, 1.10)

5/6  70 4/5 305  11 NOTCH/X26DEL: MND No High Tumor Burden 0.65 (0.43,1.00)

56/87 422 36/71 630 163 NOTCH/X28INS: MND No High Tumor Burden 0.62(0.42, 0.93)

62/98 422 41/82 630 184 BCL2/A43G: MND High Tumor Burden 0.65 (0.46,0.92)

63/83 241 64/90 352 173 BCL2/E29K: MND High Tumor Burden 0.63 (0.43,0.90)

59/79 239 57/82 358 174 BCL2/P46L: MND High Tumor Burden 0.61 (0.42,0.90)

50/67 241 59/83 352 173 BCL2/P46S: MND High Tumor Burden 0.61 (0.42,0.88)

55/73 239 63/89 348 170 BCL2/P59L: MD High Tumor Burden 0.21 (0.05,0.86)

4/6 137 11/14 506 172 BCL2/P59L: MND High Tumor Burden 0.64 (0.44, 0.94)

54/72 241 56/80 344 172 BCL2/P59S: MND High Tumor Burden 0.60 (0.42,0.87)

56/73 241 62/87 358 170 BCL2/Q52P: MND High Tumor Burden 0.60 (0.42,0.85)

58/76 239 65/92 352 168 BCL2/R106H: MND High Tumor Burden 0.66 (0.46,0.93)

63/83 241 64/93 352 209 NOTCH/F1593S: MND High Tumor Burden 0.68 (0.48,0.98)

57/77 253 64/91 358 168 NOTCH/G_A1702P: MND High Tumor Burden 0.68(0.49, 0.95)

68/90 241 69/96 348 187 NOTCH/I1681N: MND High Tumor Burden 0.69 (0.49,0.96)

68/90 241 70/97 348 187 NOTCH/L1575P: MND High Tumor Burden 0.69 (0.48,0.99)

56/76 253 64/91 358 168 NOTCH/L1586P: MND High Tumor Burden 0.68 (0.48,0.98)

57/77 253 64/91 358 168 NOTCH/L1586Q: MND High Tumor Burden 0.68 (0.48,0.96)

58/78 241 67/94 352 172 NOTCH/L1594P: MND High Tumor Burden 0.68 (0.48,0.98)

57/77 253 64/91 358 168 NOTCH/L1597H: MND High Tumor Burden 0.68 (0.48,0.96)

58/78 241 67/94 352 172 NOTCH/L1597_S1598I NSG: MND High Tumor Burden0.68 (0.48, 0.98)

57/77 253 64/91 358 168 NOTCH/L1601P: MND High Tumor Burden 0.67 (0.47,0.96)

57/77 253 63/90 358 168 NOTCH/L1679P: MND High Tumor Burden 0.69 (0.49,0.96)

68/90 241 70/97 348 187 NOTCH/L1679Q: MND High Tumor Burden 0.69 (0.49,0.96)

68/90 241 70/97 348 187 NOTCH/L2458V: MND High Tumor Burden 0.70 (0.49,0.99)

61/83 253 68/95 352 178 NOTCH/P2513L: MND High Tumor Burden 0.66 (0.45,0.96)

57/76 253 51/71 358 198 NOTCH/P2515FS4: MND High Tumor Burden 0.69(0.49, 0.96)

68/90 241 70/98 352 189 NOTCH/Q2441X: MND High Tumor Burden 0.70 (0.49,0.99)

61/83 253 68/95 352 178 NOTCH/Q2460X: MND High Tumor Burden 0.69 (0.48,1.00)

57/79 270 60/87 360 181 NOTCH/R1599>QS: MND High Tumor Burden 0.68(0.48, 0.98)

57/77 253 64/91 358 168 NOTCH/R1599P: MND High Tumor Burden 0.68 (0.48,0.96)

58/78 241 67/94 352 172 NOTCH/V1579DEL: MND High Tumor Burden 0.68(0.48, 0.98)

57/77 253 64/91 358 168 NOTCH/V1579E: MND High Tumor Burden 0.68 (0.48,0.96)

58/78 241 67/94 352 172 NOTCH/V1579G: MND High Tumor Burden 0.68 (0.48,0.98)

57/77 253 64/91 358 168 NOTCH/X28INS: MND High Tumor Burden 0.73 (0.53,0.99)

 76/100 253  82/113 324 217 BCL2/A43G: MND High FLIPI Score 0.63 (0.41,0.95)

47/66 239 43/61 358 127 BCL2/E29K: MND High FLIPI Score 0.64 (0.41,0.99)

43/62 239 39/55 366 128 BCL2/P46L: MND High FLIPI Score 0.60 (0.38,0.95)

37/53 210 40/55 352 124 BCL2/P59L: MND High FLIPI Score 0.64 (0.41,1.00)

40/57 239 39/55 358 125 BCL2/P59S: MND High FLIPI Score 0.63 (0.41,0.97)

42/59 224 41/57 352 123 BCL2/Q52P: MND High FLIPI Score 0.62 (0.41,0.95)

44/61 224 43/60 352 121 BCL2/R106H: MND High FLIPI Score 0.60 (0.39,0.92)

50/68 239 38/57 366 151 NOTCH/G_A1702P: MND High FLIPI Score 0.67 (0.45,0.99)

52/72 212 49/67 346 139 NOTCH/I1681N: MND High FLIPI Score 0.67 (0.45,0.99)

52/72 212 49/67 346 139 NOTCH/L1679P: MND High FLIPI Score 0.67 (0.45,0.99)

52/72 212 49/67 346 139 NOTCH/L1679Q: MND High FLIPI Score 0.67 (0.45,0.99)

52/72 212 49/67 346 139 NOTCH/P2515FS4: MND High FLIPI Score 0.66 (0.45,0.99)

52/72 239 47/67 358 141 NOTCH/X28DEL: MND High FLIPI Score 0.66 (0.45,0.96)

60/81 239 50/73 352 159 NOTCH/X28INS: MND High FLIPI Score 0.61 (0.42,0.89)

61/81 239 52/76 352 160 BCL2/R106H: MD Intermediate FLIPI Score 3.47(1.07, 11.29)

 4/10 924 10/11 281 130 BCL2/P46S: MND Low FLIPI Score 0.51 (0.27, 1.00)

24/38 349 14/38 —  83 BCL2/Q52P: MND Low FLIPI Score (0.28, 1.00)

26/41 349 15/40 508  81 NOTCH/G_A1702P: MND Low FLIPI Score 0.52 (0.28,0.97)

28/43 381 15/41 —  84 NOTCH/I1681N: MND Low FLIPI Score 0.52 (0.28,0.97)

28/43 381 15/41 —  84 NOTCH/L1679P: MND Low FLIPI Score 0.52 (0.28,0.97)

28/43 381 15/41 —  84 NOTCH/L1679Q: MND Low FLIPI Score 0.52 (0.28,0.97)

28/43 381 15/41 —  84 NOTCH/X28INS: MND Low FLIPI Score 0.56 (0.32,1.00)

30/48 349 19/48 771  98 BCL2/A43G: MND No Prior Rituximab Therapy 0.69(0.48, 0.99)

69/98 345 52/85 485 183 BCL2/E29K: MND No Prior Rituximab Therapy 0.65(0.45, 0.96)

65/93 345 46/76 508 186 BCL2/P46S: MND No Prior Rituximab Therapy 0.66(0.45, 0.97)

60/87 287 48/79 508 175 BCL2/Q52P: MND No Prior Rituximab Therapy 0.68(0.47, 0.99)

63/91 287 51/83 485 174 BCL2/R106H: MND No Prior Rituximab Therapy 0.67(0.46, 0.98)

66/95 351 46/79 483 213 NOTCH/X28INS: MND No Prior Rituximab Therapy0.71 (0.51, 1.00)

 79/112 357  64/107 463 226 BCL2/P46L: MD >1 year since lastanti-lymphoma treatment 0.20 (0.05, 0.72)

10/10 408  4/10 637 180 NOTCH/X28IN8: MND >1 year since lastanti-lymphoma treatment 0.72 (0.51, 1.00)

 75/113 379  67/119 506 237 BCL2/E29K: MND Rest of World 0.65 (0.43,0.98)

55/75 241 41/63 415 154 BCL2/R106H: MND Rest of World 0.66 (0.44, 0.97)

60/83 275 42/69 422 184 NOTCH/X28INS: MND Rest of World 0.68 (0.48,0.96)

72/97 275 59/92 406 194 BCL2/A43G: MND ≦65 years old 0.63 (0.46, 0.87)

 89/124 277  67/115 483 239 BCL2/C.-11C>T: MND ≦65 years old 0.69 (0.52,0.93)

102/147 278  81/135 429 296 BCL2/E29K: MND ≦65 years old 0.60 (0.43,0.84)

 83/117 275  59/103 485 241 BCL2/P46L: MD ≦65 years old 0.40 (0.16,0.99)

13/14 226  8/15 485 238 BCL2/P46L: MND ≦65 years old 0.66 (0.47, 0.93)

 74/105 277  62/104 429 238 BCL2/P46S: MND ≦65 years old 0.62 (0.45,0.87)

 80/111 275  66/113 456 236 BCL2/P59L: MND ≦65 years old 0.64 (0.45,0.89)

 80/112 277  59/103 431 237 BCL2/P59S: MND ≦65 years old 0.63 (0.45,0.87)

 81/110 275  69/114 435 235 BCL2/Q52P: MND ≦65 years old 0.63 (0.46,0.86)

 85/117 275  69/117 435 234 BCL2/R106H: MND ≦65 years old 0.60 (0.44,0.83)

 89/124 275  64/112 483 281 NOTCH/F1593S: MND ≦65 years old 0.69 (0.50,0.95)

 84/117 277  66/110 429 227 NOTCH/G_A1702P: MND ≦65 years old 0.66(0.48, 0.89)

 96/133 277  72/121 429 255 NOTCH/I1681N: MND ≦65 years old 0.66 (0.49,0.90)

 96/133 277  73/122 422 255 NOTCH/L1575P: MND ≦65 years old 0.70 (0.50,0.96)

 83/116 277  66/110 429 227 NOTCH/L1586P: MND ≦65 years old 0.69 (0.50,0.95)

 84/117 277  66/110 429 227 NOTCH/L1586Q: MND ≦65 years old 0.69 (0.50,0.95)

 86/120 277  69/114 422 234 NOTCH/L1594P: MND ≦65 years old 0.69 (0.50,0.95)

 84/117 277  66/110 429 227 NOTCH/L1597H: MND ≦65 years old 0.69 (0.50,0.95)

 86/120 277  69/114 422 234 NOTCH/L1597_S1598I NSG: MND ≦65 years old0.69 (0.50, 0.95)

 84/117 277  66/110 429 227 NOTCH/L1601P: MND ≦65 years old 0.68 (0.49,0.94)

 84/117 277  65/109 431 227 NOTCH/L1679P: MND ≦65 years old 0.66 (0.49,0.90)

 96/133 277  73/122 422 255 NOTCH/L1679Q: MND ≦65 years old 0.66 (0.49,0.90)

 96/133 277  73/122 422 255 NOTCH/L2458V: MND ≦65 years old 0.67 (0.49,0.92)

 86/120 275  71/117 422 237 NOTCH/P2513L: MND ≦65 years old 0.59 (0.41,0.84)

 77/107 275 51/90 429 269 NOTCH/P2515FS4: MND ≦65 years old 0.67 (0.49,0.90)

 96/134 278  74/123 431 259 NOTCH/Q2441X: MND ≦65 years old 0.67 (0.49,0.92)

 86/120 275  71/115 422 237 NOTCH/Q2460X: MND ≦65 years old 0.64 (0.45,0.90)

 78/110 275  60/104 422 239 NOTCH/R1599>QS: MND ≦65 years old 0.69(0.50, 0.95)

 84/117 277  66/110 429 227 NOTCH/R1599P: MND ≦65 years old 0.69 (0.50,0.95)

 86/120 277  69/114 422 234 NOTCH/V1579DEL: MND ≦65 years old 0.69(0.50, 0.95)

 84/117 277  66/110 429 227 NOTCH/V1579E: MND ≦65 years old 0.69 (0.50,0.95)

 86/120 277  69/114 422 234 NOTCH/V1579G: MND ≦65 years old 0.69 (0.50,0.95)

 84/117 277  66/110 429 227 NOTCH/X26DEL: MND ≦65 years old 0.70 (0.52,0.94)

 96/137 281  78/132 431 273 NOTCH/X26INS: MND ≦65 years old 0.68 (0.51,0.92)

 97/138 281  78/133 435 273 NOTCH/X28DEL: MND ≦65 years old 0.66 (0.50,0.89)

106/149 278  83/140 422 298 NOTCH/X28INS: MND ≦65 years old 0.64 (0.48,0.85)

109/149 277  85/143 429 298 NOTCH/P2513L: MND ≦65 years old 1.96 (1.03,3.75)

16/33 616 24/33 414  92 BCL2/P59L: MD Female 0.28 (0.08, 0.95)

6/8 398  9/14 512 180 BCL2/P59S: MND Female 0.66 (0.44, 0.97)

66/97 348 42/73 512 178 BCL2/Q52P: MND Female 0.68 (0.46, 1.00)

 67/100 348 43/76 553 176 BCL2/R106H: MND Female 0.65 (0.44, 0.98)

65/96 357 38/70 506 203 BCL2/A43G: MND Male 0.60 (0.40, 0.91)

43/59 273 51/76 414 135 BCL2/E29K: MND Male 0.60 (0.39, 0.93)

40/55 271 46/68 414 138 BCL2/P46S: MND Male 0.64 (0.42, 0.98)

37/52 241 52/75 360 133 BCL2/Q52P: MND Male 0.64 (0.42, 0.97)

38/53 271 54/78 360 131 NOTCH/G_A1702P: MND Male 0.66 (0.44, 0.98)

44/63 241 56/81 360 145 NOTCH/I1681N: MND Male 0.67 (0.45, 1.00)

44/63 241 57/82 360 145 NOTCH/L1679P: MND Male 0.67 (0.45, 1.00)

44/63 241 57/82 360 145 NOTCH/L1679Q: MND Male 0.67 (0.45, 1.00)

44/63 241 57/82 360 145 NOTCH/L2458V: MND Male 0.63 (0.42, 0.95)

42/59 241 56/80 360 139 NOTCH/P2513L: MND Male 0.58 (0.38, 0.91)

39/54 239 42/63 414 155 NOTCH/P2515FS4: MND Male 0.65 (0.43, 0.96)

44/62 273 57/84 406 148 NOTCH/Q2441X: MND Male 0.64 (0.42, 0.95)

42/59 241 56/79 360 139 NOTCH/Q2460X: MND Male 0.61 (0.40, 0.94)

41/57 241 47/70 414 142 NOTCH/X28DEL: MND Male 0.69 (0.48, 1.00)

54/75 275 65/97 352 180 NOTCH/X28INS: MND Male 0.68 (0.47, 0.97)

57/78 275  67/100 358 181 BCL2/A43G: MND White 0.72 (0.54, 0.97)

 93/140 345  84/139 483 279 BCL2/E29K: MND White 0.70 (0.51, 0.96)

 85/129 345  77/127 506 282 BCL2/P46L: MD White 0.38 (0.16, 0.88)

18/21 346  8/16 512 279 BCL2/P46S: MND White 0.69 (0.51, 0.94)

 87/130 334  79/131 463 275 BCL2/P59L: MND White 0.73 (0.53, 0.99)

 85/129 334  74/123 431 278 BCL2/P59S: MND White 0.69 (0.51, 0.94)

 87/128 334  80/130 463 274 BCL2/Q52P: MND White 0.69 (0.51, 0.93)

 91/135 334  83/137 463 272 NOTCH/P2515FS4: MND White 0.75 (0.57, 1.00)

102/154 348  91/148 431 304 NOTCH/X28INS: MND White 0.75 (0.57, 0.97)

119/174 345 107/171 422 352 NOTCH/P2513L: MD Ann Arbor Stage III 0.40(0.17, 0.95)

13/15 345 12/14 414 116 BCL2/A43G: MND Ann Arbor Stage IV 0.61 (0.41,0.89)

57/71 275 52/83 414 154 BCL2/C.-11C>T: MND Ann Arbor Stage IV 0.66(0.47, 0.94)

66/84 277  64/100 358 193 BCL2/E29K: MND Ann Arbor Stage IV 0.58 (0.39,0.87)

53/67 275 44/73 415 154 BCL2/P46L: MND Ann Arbor Stage IV 0.59 (0.38,0.91)

40/52 253 47/74 360 148 BCL2/P46S: MND Ann Arbor Stage IV 0.62 (0.42,0.93)

48/61 253 53/81 358 147 BCL2/P59L: MND Ann Arbor Stage IV 0.63 (0.42,0.96)

46/59 273 45/73 352 149 BCL2/P59S: MND Ann Arbor Stage IV 0.64 (0.43,0.97)

45/58 273 51/79 360 147 BCL2/Q52P: MND Ann Arbor Stage IV 0.60 (0.41,0.90)

49/62 273 53/83 360 145 BCL2/R106H: MND Ann Arbor Stage IV 0.57 (0.39,0.84)

57/72 274 51/83 414 186 NOTCH/F1593S: MND Ann Arbor Stage IV 0.64 (0.43,0.95)

50/64 253 52/79 360 143 NOTCH/G_A1702P: MND Ann Arbor Stage IV 0.61(0.42, 0.88)

59/75 273 57/87 360 163 NOTCH/I1681N: MND Ann Arbor Stage IV 0.62 (0.43,0.89)

59/75 273 58/88 358 163 NOTCH/L1575P: MND Ann Arbor Stage IV 0.64 (0.43,0.95)

50/64 253 52/79 360 143 NOTCH/L1586P: MND Ann Arbor Stage IV 0.64 (0.43,0.95)

50/64 253 52/79 360 143 NOTCH/L1586Q: MND Ann Arbor Stage IV 0.64 (0.44,0.94)

52/67 273 55/83 360 150 NOTCH/L1594P: MND Ann Arbor Stage IV 0.64 (0.43,0.95)

50/64 253 52/79 360 143 NOTCH/L1597H: MND Ann Arbor Stage IV 0.64 (0.44,0.94)

52/67 273 55/83 360 150 NOTCH/L1597_S1598I NSG: MND Ann Arbor Stage IV0.64 (0.43, 0.95)

50/64 253 52/79 360 143 NOTCH/L1601P: MND Ann Arbor Stage IV 0.64 (0.43,0.95)

50/64 253 52/79 360 143 NOTCH/L1679P: MND Ann Arbor Stage IV 0.62 (0.43,0.89)

59/75 273 58/88 358 163 NOTCH/L1679Q: MND Ann Arbor Stage IV 0.62 (0.43,0.89)

59/75 273 58/88 358 163 NOTCH/L2458V: MND Ann Arbor Stage IV 0.62 (0.42,0.90)

53/68 273 56/86 360 154 NOTCH/P2513L: MND Ann Arbor Stage IV 0.55 (0.36,0.84)

48/61 273 41/69 414 176 NOTCH/P2515FS4: MND Ann Arbor Stage IV 0.61(0.42, 0.88)

58/74 273 58/91 366 167 NOTCH/Q2441X: MND Ann Arbor Stage IV 0.61 (0.42,0.90)

53/68 273 56/85 360 154 NOTCH/Q2460X: MND Ann Arbor Stage IV 0.57 (0.38,0.86)

49/64 273 49/79 414 156 NOTCH/R1599>QS: MND Ann Arbor Stage IV 0.64(0.43, 0.95)

50/64 253 52/79 360 143 NOTCH/R1599P: MND Ann Arbor Stage IV 0.64 (0.44,0.94)

52/67 273 55/83 360 150 NOTCH/V1579DEL: MND Ann Arbor Stage IV 0.64(0.43, 0.95)

50/64 253 52/79 360 143 NOTCH/V1579E: MND Ann Arbor Stage IV 0.64 (0.44,0.94)

52/67 273 55/83 360 150 NOTCH/V1579G: MND Ann Arbor Stage IV 0.64 (0.43,0.95)

50/64 253 52/79 360 143 NOTCH/X26DEL: MND Ann Arbor Stage IV 0.65 (0.45,0.92)

61/76 275  66/101 360 180 NOTCH/X26INS: MND Ann Arbor Stage IV 0.64(0.45, 0.91)

62/79 275  66/101 360 180 NOTCH/X28DEL: MND Ann Arbor Stage IV 0.64(0.46, 0.91)

67/85 275  65/103 358 195 NOTCH/X28INS: MND Ann Arbor Stage IV 0.60(0.42, 0.84)

70/87 274  66/105 358 196

APPENDIX 2 Table 2.7: Duration of response by protein expression and bycovariate, IRC review. * (All reported groups are significant (p ≦ 0.05)and with a frequency ≧10%) Marker: HR HR R R Vc-R Vc-R Subgroup Marker:Level Subgroup (95% CI) (log scale) Evt/N Median Evt/N Median N TotalCD68 OVERALL POSITIVE: 0-25 High FLIPI Score 3.66 (1.10, 12.16)

 7/11 423 7/8 202 91 P27 % NUCLEI POSITIVE: 60-70 High FLIPI Score 0.14(0.03, 0.74)

7/9 337 3/6 1162 96 20S INTENSITY CYTOPLASMIC SIGNAL: ≦2+ IntermediateFLIPI Score 2.39 (1.08, 5.26)

 9/25 554 20/26 264 99 20S INTENSITY CYTOPLASMIC SIGNAL: ≧3+Intermediate FLIPI Score 0.38 (0.17, 0.84)

17/25 352 10/23 813 99 20S INTENSITY CYTOPLASMIC SIGNAL: ≧3+ No PriorRituximab Therapy 0.53 (0.29, 0.97)

22/32 427 20/43 638 155 20S % NUCLEAR STAINING: 30-50 Prior RituximabTherapy 2.39 (0.97, 5.86)

 9/13 356 13/14 245 97 CD68 OVERALL POSITIVE: 0-25 ≦1 year since lastanti- lymphoma treatment 9.97 (1.13, 88.13)

5/7 354 5/5 145 79 20S INTENSITY CYTOPLASMIC SIGNAL: ≧3+ ≦65 years old0.55 (0.31, 0.98)

28/39 417 20/44 654 177 CD68 POSITIVE FOLLICULAR: 0-25 Female 0.38(0.15, 1.01)

12/20 354  8/15 648 131 CD68 OVERALL POSITIVE: 51-75 Male 0.27 (0.07,1.03)

5/7 279  6/12 784 98 CD68 OVERALL POSITIVE: >75 Male 0.10 (0.01, 1.02)

3/3 284 2/7 — 98 CD68 POSITIVE PERIFOLLICULAR: >75 Male 0.11 (0.01,1.11)

3/3 284 2/7 — 86 P27 % NUCLEI POSITIVE: 60-70 Male 0.29 (0.08, 1.08)

5/6 281 7/9 502 99 P65 INTENSITY CYTOPLASMIC SIGNAL: ≦1+ Ann Arbor StageIII 0.16 (0.02, 1.19)

2/4 173 5/8 474 87

APPENDIX 2 Table 2.8: Duration of Response by Germline Genetic Variantand by Covariate, IRC Review. (All Reported Groups are Significant (p ≦1.05) and at a Frequency ≧10%) Marker: HR HR R R Vc-R Vc-R SubgroupMarker: Level Subgroup (95% CI) (log scale) Evt/N Median Evt/N Median NTotal PSMB9/R60H: A/G Male 0.42 (0.19, 0.94)

10/11 211 19/28 351 120 PSMB5/R24C: C/C Ann Arbor Stage II 3.29 (1.07,10.09)

 4/18 — 13/20 438  43

APPENDIX 2 Table 2.9: Duration of Response by Somatic Mutation and byCovariate, IRC Review. (All Reported Groups are Significant (P ≦ 0.05)and at a Frequency ≧10%) Marker: Marker: HR HR R R Vc-R Vc-R SubgroupLevel Subgroup (95% CI) (log scale) Evt/N Median Evt/N Median N TotalBCL2/ P59L: MD No Subgroup 0.15 (0.03, 0.71)

4/5 343  9/15 488 177 BCL2/ P59L: MD 1 Prior Line of Therapy 0.11 (0.01,1.21)

2/2 345  5/10 488 82 BCL2/ P59L: MD Prior Rituximab Therapy 0.14 (0.01,1.33)

3/3 330 4/5 372 68 BCL2/ P46L: MD >1 year since last anti- lymphomatreatment 0.26 (0.06, 1.09)

5/5 356 4/8 502 115 BCL2/ P59L: MD >1 year since last anti- lymphomatreatment 0.13 (0.02, 0.82)

3/4 330  6/10 502 116 BCL2/ E29K: MND ≦65 years old 0.61 (0.37, 1.00)

32/49 353 32/66 648 128 NOTCH/ X28INS: MND ≦65 years old 0.66 (0.43,1.00)

44/64 369 45/84 490 152 NOTCH/ P2513L: MND >65 years old 2.28 (1.02,5.09)

10/23 948 18/22 356 62 BCL2/ P59L: MD White 0.10 (0.02, 0.57)

4/5 343  8/14 488 163 BCL2/ A43G: MND Ann Arbor Stage IV 0.57 (0.33,1.00)

23/28 353 29/50 488 78 BCL2/ E29K: MND Ann Arbor Stage IV 0.51 (0.28,0.93)

21/26 344 23/43 490 78 BCL2/ R106H: MND Ann Arbor Stage IV 0.54 (0.30,0.96)

21/26 352 27/48 423 90 NOTCH/ X28INS: MND Ann Arbor Stage IV 0.58 (0.35,0.98)

26/31 353 35/58 423 91

APPENDIX 2 Table 2.10: Time to Next Anti-Lymphoma Therapy by ProteinExpression and by Covariate, IRC Review. (All Reported Groups areSignificant (p ≦ 0.05) and at a Frequency ≧10%) Marker: HR HR R R Vc-RVc-R Subgroup Marker: Level Subgroup (95% CI) (log scale) Evt/N MedianEvt/N Median N Total CD68 OVERALL POSITIVE: 0-25 No Subgroup 0.41 (0.23,0.73)

30/44 409 19/41 1047 442 CD68 POSITIVE FOLLICULAR: 0-25 No Subgroup 0.54(0.33, 0.88)

40/60 462 29/51 834 387 CD68 POSITIVE PERIFOLLICULAR: 0-25 No Subgroup0.48 (0.27, 0.87)

26/39 374 20/41 1103 384 P27 SIGNAL TENSITY: ≧2+ No Subgroup 0.77 (0.60,0.99)

127/199 533 114/196 700 463 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% NoSubgroup 0.75 (0.58, 0.96)

129/204 505 108/186 726 470 CD68 POSITIVE PERIFOLLICULAR: >75 1 PriorLine of Therapy 0.43 (0.19, 0.97)

15/18 437 10/16 744 174 P27 % NUCLEI POSITIVE: 0-20 1 Prior Line ofTherapy 0.38 (0.15, 0.97)

19/26 434  6/16 1047 204 P65 % NUCLEAR STAINING: 0 1 Prior Line ofTherapy 0.63 (0.41, 0.95)

54/79 546 39/73 841 203 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% 1 PriorLine of Therapy 0.61 (0.42, 0.90)

59/89 550 47/88 841 203 P65 INTENSITY CYTOPLASMIC SIGNAL: ≧2+ 1 PriorLine of Therapy 0.64 (0.43, 0.95)

54/85 568 47/91 841 203 CD68 OVERALL POSITIVE: 0-25 2 Prior Lines ofTherapy 0.20 (0.04, 1.04)

6/8 204 2/7 1005 111 CD68 POSITIVE PERIFOLLICULAR: 0-25 2 Prior Lines ofTherapy 0.09 (0.01, 0.81)

6/8 171 1/7 — 98 P65 % NUCLEAR STAINING: ≦5% 2 Prior Lines of Therapy0.31 (0.10, 0.92)

7/9 225  7/12 705 125 P27 % NUCLEI POSITIVE: 60-70 3 Prior Lines ofTherapy 8.15 (0.93, 71.30)

1/6 — 5/5 227 74 P27 SIGNAL INTENSITY: ≧2+ 5 Prior Lines of Therapy 0.20(0.04, 1.02)

5/6 228 3/8 939 16 P65 % NUCLEAR STAINING: ≦5% 5 Prior Lines of Therapy0.13 (0.01, 1.34)

3/3 235 2/4 1235 16 CD68 OVERALL POSITIVE: 0-25 No High Tumor Burden0.23 (0.07, 0.79)

 8/14 552  5/19 1235 204 CD68 OVERALL POSITIVE: 51-75 No High TumorBurden 2.27 (0.98, 5.28)

10/25 — 12/18 511 204 CD68 POSITIVE FOLLICULAR: 0-25 No High TumorBurden 0.38 (0.17, 0.87)

14/22 573 12/25 939 182 CD68 POSITIVE PERIFOLLICULAR: 0-25 No High TumorBurden 0.22 (0.06, 0.74)

 8/13 501  5/16 1235 182 P27 % NUCLEI POSITIVE: 0-20 High Tumor Burden0.54 (0.30, 0.98)

23/27 220 23/31 503 248 P27 % NUCLEI POSITIVE: 30-50 High Tumor Burden0.45 (0.22, 0.93)

17/22 421 13/25 599 248 P27 SIGNAL INTENSITY: ≦1+ High Tumor Burden 0.42(0.19, 0.93)

16/18 220 11/17 975 248 CD68 OVERALL POSITIVE: 0-25 Intermediate FLIPIScore 0.27 (0.08, 0.96)

 7/11 485  5/15 1235 159 CD68 POSITIVE FOLLICULAR: 0-25 IntermediateFLIPI Score 0.44 (0.19, 1.01)

14/20 421 11/20 939 141 CD68 POSITIVE PERIFOLLICULAR: 0-25 IntermediateFLIPI Score 0.27 (0.08, 0.95)

 7/13 501  5/17 1235 139 CD68 OVERALL POSITIVE: 0-25 Low FLIPI Score0.32 (0.10, 0.99)

 8/10 422  5/11 1075 102 CD68 OVERALL POSITIVE: 0-25 No Prior RituximabTherapy 0.36 (0.14, 0.93)

12/19 533  7/21 1103 241 CD68 POSITIVE FOLLICULAR: 0-25 No PriorRituximab Therapy 0.40 (0.19, 0.84)

23/36 485 10/25 1103 210 CD68 POSITIVE PERIFOLLICULAR: 0-25 No PriorRituximab Therapy 0.33 (0.11, 0.95)

12/18 533  5/15 — 208 20S % NUCLEAR STAINING: 60-70 Prior RituximabTherapy 0.39 (0.15, 1.00)

17/21 343  6/12 1075 212 CD68 OVERALL POSITIVE: 0-25 Prior RituximabTherapy 0.41 (0.19, 0.89)

18/25 235 12/20 834 201 P27 SIGNAL INTENSITY: ≧2+ Prior RituximabTherapy 0.64 (0.44, 0.94)

60/88 421 48/85 718 210 P65 % NUCLEAR STAINING: ≦5% Prior RituximabTherapy 0.29 (0.14, 0.64)

16/21 232 13/27 975 215 CD68 OVERALL POSITIVE: 0-25 >1 year since lastanti- lymphoma treatment 0.26 (0.11, 0.60)

17/26 409  9/28 1235 269 CD68 POSITIVE FOLLICULAR: 0-25 >1 year sincelast anti- lymphoma treatment 0.48 (0.25, 0.93)

22/34 550 16/33 1005 235 CD68 POSITIVE PERIFOLLICULAR: 0-25 >1 yearsince last anti- lymphoma treatment 0.40 (0.18, 0.88)

15/24 533 11/27 1235 234 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% >1 yearsince last anti- lymphoma treatment 0.68 (0.48, 0.98)

 69/117 593  54/112 983 288 20S INTENSITY CYTOPLASMIC SIGNAL: ≧3+European Union 0.58 (0.34, 0.97)

34/52 533 25/52 1075 214 CD68 OVERALL POSITIVE: 0-25 European Union 0.40(0.18, 0.90)

14/22 374 11/25 1103 211 CD68 POSITIVE PERIFOLLICULAR: >75 EuropeanUnion 0.35 (0.13, 0.96)

13/17 675  7/14 1185 185 P27 % NUCLEI POSITIVE: 80-100 European Union0.59 (0.35, 1.00)

29/41 655 27/51 939 214 P27 SIGNAL INTENSITY: ≧2+ European Union 0.67(0.46, 0.99)

57/89 649 49/91 939 214 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% EuropeanUnion 0.67 (0.46, 0.99)

57/92 552 48/87 975 216 P65 INTENSITY CYTOPLASMIC SIGNAL: ≦1+ EuropeanUnion 0.45 (0.19, 1.02)

13/18 409 11/21 1005 216 CD68 OVERALL POSITIVE: 0-25 ≦65 years old 0.38(0.20, 0.73)

24/34 374 15/32 1005 329 CD68 POSITIVE FOLLICULAR: 0-25 ≦65 years old0.45 (0.26, 0.77)

33/46 332 24/41 764 292 CD68 POSITIVE PERIFOLLICULAR: 0-25 ≦65 years old0.48 (0.24, 0.98)

20/31 332 13/29 1075 289 CD68 POSITIVE PERIFOLLICULAR: >75 ≦65 years old0.45 (0.22, 0.91)

19/23 437 13/23 726 289 P27 % NUCLEI POSITIVE: 0-20 ≦65 years old 0.52(0.29, 0.96)

26/34 327 19/32 834 344 P27 SIGNAL INTENSITY: ≧2+ ≦65 years old 0.74(0.56, 0.98)

103/153 484  90/149 672 344 P65 % NUCLEAR STAINING: ≦5% ≦65 years old0.54 (0.29, 1.00)

19/29 374 22/43 975 349 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% ≦65years old 0.71 (0.53, 0.94)

103/154 484  84/142 719 349 P65 INTENSITY CYTOPLASMIC SIGNAL: ≧2+ ≦65years old 0.72 (0.54, 0.96)

101/152 484  82/139 718 349 20S % NUCLEAR STAINING: 0-20 Female 0.53(0.30, 0.93)

35/61 568 19/49 — 259 CD68 OVERALL POSITIVE: 0-25 Female 0.27 (0.10,0.76)

16/26 434  5/18 1103 242 CD68 POSITIVE FOLLICULAR: 0-25 Female 0.45(0.21, 0.96)

23/37 462 10/22 1103 217 CD68 POSITIVE PERIFOLLICULAR: 0-25 Female 0.29(0.11, 0.79)

19/28 374  5/17 1107 215 P65 INTENSITY CYTOPLASMIC SIGNAL: ≧2+ Female0.68 (0.46, 1.00)

 74/129 537 41/87 1047 263 20S % NUCLEAR STAINING: 60-70 Male 0.42(0.19, 0.93)

14/16 247 12/20 518 204 20S INTENSITY CYTOPLASMIC SIGNAL: ≧3+ Male 0.58(0.34, 1.00)

20/27 421 37/62 764 204 CD68 OVERALL POSITIVE: 0-25 Male 0.46 (0.22,0.99)

14/18 251 14/23 975 200 CD68 OVERALL POSITIVE: >75 Male 0.23 (0.07,0.79)

8/9 427  4/11 — 200 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% Male 0.68(0.47, 0.98)

51/72 427 62/97 726 207 CD68 POSITIVE FOLLICULAR: 0-25 Asian 0.13 (0.01,1.09)

5/6 220 2/6 — 30 CD68 POSITIVE PERIFOLLICULAR: 26-50 Other 0.14 (0.01,1.31)

4/4 341 4/5 658 22 CD68 OVERALL POSITIVE: 0-25 White 0.38 (0.20, 0.72)

24/35 409 16/35 1075 385 CD68 POSITIVE FOLLICULAR: 0-25 White 0.57(0.34, 0.98)

32/48 462 25/42 834 335 CD68 POSITIVE PERIFOLLICULAR: 0-25 White 0.43(0.22, 0.82)

19/27 501 19/39 1103 332 P27 SIGNAL INTENSITY: ≧2+ White 0.75 (0.57,0.98)

113/177 533  99/170 718 403 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90%White 0.73 (0.56, 0.96)

113/179 505  95/162 744 406 P65 INTENSITY CYTOPLASMIC SIGNAL: ≧2+ White0.75 (0.57, 0.99)

109/176 533  94/165 744 406 CD68 OVERALL POSITIVE: 0-25 Ann Arbor StageIII 0.35 (0.14, 0.92)

12/16 276  9/12 905 144 CD68 POSITIVE FOLLICULAR: 0-25 Ann Arbor StageIII 0.40 (0.19, 0.83)

19/24 332 13/18 764 135 P27 % NUCLEI POSITIVE: 0-20 Ann Arbor Stage III0.42 (0.17, 1.00)

14/16 418 12/15 613 149 P65 INTENSITY CYTOPLASMIC SIGNAL: ≦1+ Ann ArborStage III 0.36 (0.13, 0.99)

10/11 261  7/11 834 151 CD68 OVERALL POSITIVE: 0-25 Ann Arbor Stage IV0.37 (0.15, 0.92)

15/22 434  8/23 1047 222 CD68 POSITIVE PERIFOLLICULAR: 0-25 Ann ArborStage IV 0.37 (0.14, 0.96)

11/15 374  8/22 1107 183

APPENDIX 2 Table 2.11: Time to Next Anti-Lymphoma Therapy by GermlineGenetic Variant and by Covariate, IRC Review. (All Reported Groups areSignificant (p ≦ 0.05) and at a Frequency of ≧10%) Marker: HR HR R RVc-R Vc-R Subgroup Marker: Level Subgroup (95% CI) (log scale) Evt/NMedian Evt/N Median N Total PSMB1/A171S: G/G No Subgroup 0.78 (0.63,0.97)

173/276 546 152/266 719 542 PSMB1/I208N: T/T No Subgroup 0.78 (0.63,0.97)

173/276 546 152/266 719 542 PSMB1/P11A: C/G No Subgroup 0.68 (0.48,0.94)

 78/127 550  63/115 939 542 PSMB1/P11A: G/G No Subgroup 0.57 (0.34,0.97)

30/37 436 26/43 613 542 PSMB1/P193L: C/C No Subgroup 0.78 (0.63, 0.97)

173/276 546 152/266 719 542 PSMB2/E49X: G/G No Subgroup 0.78 (0.63,0.97)

173/276 546 152/266 719 542 PSMB2/G187V: G/G No Subgroup 0.78 (0.63,0.97)

173/276 546 152/266 719 542 PSMB2/L159F: C/C No Subgroup 0.78 (0.63,0.97)

173/276 546 152/266 719 542 PSMB5/L206M: C/C No Subgroup 0.78 (0.63,0.97)

173/276 546 152/266 719 542 PSMB5/R24C: C/C No Subgroup 0.78 (0.62,0.99)

147/235 546 127/223 719 542 PSMB6/A234D: C/C No Subgroup 0.78 (0.63,0.97)

173/276 546 152/266 719 542 PSMB6/P107A: C/C No Subgroup 0.79 (0.63,0.98)

167/265 550 150/261 717 542 PSMB8/G8R: G/G No Subgroup 0.77 (0.61, 0.96)

165/264 537 144/256 719 542 PSMB8/R141C: C/C No Subgroup 0.78 (0.63,0.97)

173/276 546 152/266 719 542 PSMB8/V182M: G/G No Subgroup 0.78 (0.63,0.97)

173/276 546 152/266 719 542 PSMB9/G9E: G/G No Subgroup 0.78 (0.63, 0.97)

172/274 546 152/265 718 542 PSMB9/V32I: C/C No Subgroup 0.79 (0.63,0.99)

167/266 546 146/254 717 542 PSMB1/A171S: G/G 1 Prior Line of Therapy0.70 (0.50, 0.98)

 72/113 673  61/118 841 231 PSMB1/I208N: T/T 1 Prior Line of Therapy0.70 (0.50, 0.98)

 72/113 673  61/118 841 231 PSMB1/P11A: C/G 1 Prior Line of Therapy 0.56(0.34, 0.95)

32/51 621 27/55 1047 231 PSMBI/P11A: G/G 1 Prior Line of Therapy 0.35(0.13, 0.93)

11/11 443  7/14 700 231 PSMB1/P193L: C/C 1 Prior Line of Therapy 0.70(0.50, 0.98)

 72/113 673  61/118 841 231 PSMB2/E49X: G/G 1 Prior Line of Therapy 0.70(0.50, 0.98)

 72/113 673  61/118 841 231 PSMB2/G187V: G/G 1 Prior Line of Therapy0.70 (0.50, 0.98)

 72/113 673  61/118 841 231 PSMB2/L159F: C/C 1 Prior Line of Therapy0.70 (0.50, 0.98)

 72/113 673  61/118 841 231 PSMB5/L206M: C/C 1 Prior Line of Therapy0.70 (0.50, 0.98)

 72/113 673  61/118 841 231 PSMB6/A234D: C/C 1 Prior Line of Therapy0.70 (0.50, 0.98)

 72/113 673  61/118 841 231 PSMB6/P107A: C/C 1 Prior Line of Therapy0.70 (0.49, 0.99)

 70/108 673  60/116 841 231 PSMB8/G8R: G/G 1 Prior Line of Therapy 0.68(0.47, 0.97)

 69/109 673  55/111 852 231 PSMB8/R141C: C/C 1 Prior Line of Therapy0.70 (0.50, 0.98)

 72/113 673  61/118 841 231 PSMB8/V182M: G/G 1 Prior Line of Therapy0.70 (0.50, 0.98)

 72/113 673  61/118 841 231 PSMB9/G9E: G/G 1 Prior Line of Therapy 0.71(0.50, 1.00)

 71/112 673  61/118 841 231 PSMB1/A171S: G/G 5 Prior Lines of Therapy0.29 (0.08, 0.99)

7/9 235  6/12 939 21 PSMB1/I208N: T/T 5 Prior Lines of Therapy 0.29(0.08, 0.99)

7/9 235  6/12 939 21 PSMB1/P193L: C/C 5 Prior Lines of Therapy 0.29(0.08, 0.99)

7/9 235  6/12 939 21 PSMB2/E49X: G/G 5 Prior Lines of Therapy 0.29(0.08, 0.99)

7/9 235  6/12 939 21 PSMB2/G187V: G/G 5 Prior Lines of Therapy 0.29(0.08, 0.99)

7/9 235  6/12 939 21 PSMB2/L159F: C/C 5 Prior Lines of Therapy 0.29(0.08, 0.99)

7/9 235  6/12 939 21 PSMB5/L206M: C/C 5 Prior Lines of Therapy 0.29(0.08, 0.99)

7/9 235  6/12 939 21 PSMB5/R24C: C/C 5 Prior Lines of Therapy 0.16(0.03, 0.79)

6/7 235 4/9 1235 21 PSMB6/A234D: C/C 5 Prior Lines of Therapy 0.29(0.08, 0.99)

7/9 235  6/12 939 21 PSMB6/P107A: C/C 5 Prior Lines of Therapy 0.29(0.08, 0.99)

7/9 235  6/12 939 21 PSMB8/G8R: G/G 5 Prior Lines of Therapy 0.29 (0.08,1.00)

7/9 235  6/11 939 21 PSMB8/R141C: C/C 5 Prior Lines of Therapy 0.29(0.08, 0.99)

7/9 235  6/12 939 21 PSMB8/V182M: G/G 5 Prior Lines of Therapy 0.29(0.08, 0.99)

7/9 235  6/12 939 21 PSMB9/G9E: G/G 5 Prior Lines of Therapy 0.29 (0.08,0.99)

7/9 235  6/12 939 21 PSMB9/V32I: C/C 5 Prior Lines of Therapy 0.25(0.07, 0.86)

7/8 228  5/11 1235 21 PSMB1/A171S: G/G High Tumor Burden 0.72 (0.55,0.95)

108/147 396  98/149 521 296 PSMB1/I208N: T/T High Tumor Burden 0.72(0.55, 0.95)

108/147 396  98/149 521 296 PSMB1/P11A: C/G High Tumor Burden 0.63(0.41, 0.96)

49/72 358 38/65 675 296 PSMB1/P193L: C/C High Tumor Burden 0.72 (0.55,0.95)

108/147 396  98/149 521 296 PSMB2/E49X: G/G High Tumor Burden 0.72(0.55, 0.95)

108/147 396  98/149 521 296 PSMB2/G187V: G/G High Tumor Burden 0.72(0.55, 0.95)

108/147 396  98/149 521 296 PSMB2/L159F: C/C High Tumor Burden 0.72(0.55, 0.95)

108/147 396  98/149 521 296 PSMB5/L206M: C/C High Tumor Burden 0.72(0.55, 0.95)

108/147 396  98/149 521 296 PSMB5/R24C: C/T High Tumor Burden 0.46(0.24, 0.89)

19/21 317 18/24 536 296 PSMB6/A234D: C/C High Tumor Burden 0.72 (0.55,0.95)

108/147 396  98/149 521 296 PSMB6/P107A: C/C High Tumor Burden 0.73(0.55, 0.96)

104/140 380  97/146 518 296 PSMB8/G8R: G/G High Tumor Burden 0.69 (0.52,0.91)

104/140 374  94/145 521 296 PSMB8/R141C: C/C High Tumor Burden 0.72(0.55, 0.95)

108/147 396  98/149 521 296 PSMB8/V182M: G/G High Tumor Burden 0.72(0.55, 0.95)

108/147 396  98/149 521 296 PSMB9/G9E: G/G High Tumor Burden 0.72 (0.55,0.95)

107/145 396  98/148 518 296 PSMB9/V32I: C/C High Tumor Burden 0.71(0.54, 0.94)

106/142 396  94/142 521 296 PSMBI/A171S: G/G >1 year since last anti-lymphoma treatment 0.69 (0.51, 0.93)

 98/165 688  80/166 969 331 PSMB1/I208N: T/T >1 year since last anti-lymphoma treatment 0.69 (0.51, 0.93)

 98/165 688  80/166 969 331 PSMB1/P11A: G/G >1 year since last anti-lymphoma treatment 0.47 (0.23, 0.97)

17/20 429 13/25 872 331 PSMB1/P193L: C/C >1 year since last anti-lymphoma treatment 0.69 (0.51, 0.93)

 98/165 688  80/166 969 331 PSMB2/E49X: G/G >1 year since last anti-lymphoma treatment 0.69 (0.51, 0.93)

 98/165 688  80/166 969 331 PSMB2/G187V: G/G >1 year since last anti-lymphoma treatment 0.69 (0.51, 0.93)

 98/165 688  80/166 969 331 PSMB2/L159F: C/C >1 year since last anti-lymphoma treatment 0.69 (0.51, 0.93)

 98/165 688  80/166 969 331 PSMB5/L206M: C/C >1 year since last anti-lymphoma treatment 0.69 (0.51, 0.93)

 98/165 688  80/166 969 331 PSMB5/R24C: C/C >1 year since last anti-lymphoma treatment 0.70 (0.51, 0.97)

 81/137 649  68/141 983 331 PSMB6/A234D: C/C >1 year since last anti-lymphoma treatment 0.69 (0.51, 0.93)

 98/165 688  80/166 969 331 PSMB6/P107A: C/C >1 year since last anti-lymphoma treatment 0.70 (0.52, 0.94)

 95/159 702  79/162 969 331 PSMB8/G8R: G/G >1 year since last anti-lymphoma treatment 0.69 (0.51, 0.93)

 91/155 702  74/159 1005 331 PSMB8/R141C: C/C >1 year since last anti-lymphoma treatment 0.69 (0.51, 0.93)

 98/165 688  80/166 969 331 PSMB8/V182M: G/G >1 year since last anti-lymphoma treatment 0.69 (0.51, 0.93)

 98/165 688  80/166 969 331 PSMB9/G9E: G/G >1 year since last anti-lymphoma treatment 0.69 (0.51, 0.93)

 97/163 688  80/165 969 331 PSMB9/V32I: C/C >1 year since last anti-lymphoma treatment 0.68 (0.50, 0.91)

 96/160 649  76/158 969 331 PSMB1/A171S: G/G European Union 0.71 (0.51,0.99)

 75/119 675  66/122 939 241 PSMB1/I208N: T/T European Union 0.71 (0.51,0.99)

 75/119 675  66/122 939 241 PSMB1/P11A: C/G European Union 0.56 (0.34,0.92)

34/49 462 29/51 1005 241 PSMB1/P193L: C/C European Union 0.71 (0.51,0.99)

 75/119 675  66/122 939 241 PSMB2/E49X: G/G European Union 0.71 (0.51,0.99)

 75/119 675  66/122 939 241 PSMB2/G187V: G/G European Union 0.71 (0.51,0.99)

 75/119 675  66/122 939 241 PSMB2/L159F: C/C European Union 0.71 (0.51,0.99)

 75/119 675  66/122 939 241 PSMB5/L206M: C/C European Union 0.71 (0.51,0.99)

 75/119 675  66/122 939 241 PSMB6/A234D: C/C European Union 0.71 (0.51,0.99)

 75/119 675  66/122 939 241 PSMB8/G8R: G/G European Union 0.71 (0.50,1.00)

 70/111 649  62/117 939 241 PSMB8/R141C: C/C European Union 0.71 (0.51,0.99)

 75/119 675  66/122 939 241 PSMB8/V182M: G/G European Union 0.71 (0.51,0.99)

 75/119 675  66/122 939 241 PSMB9/G9E: G/G European Union 0.71 (0.51,0.99)

 75/119 675  66/122 939 241 PSMB1/A171S: G/G ≦65 years old 0.72 (0.56,0.92)

130/198 489 112/194 719 392 PSMB1/I208N: T/T ≦65 years old 0.72 (0.56,0.92)

130/198 489 112/194 719 392 PSMB1/P11A: C/G ≦65 years old 0.62 (0.42,0.91)

63/96 546 47/86 764 392 PSMB1/P11A: G/G ≦65 years old 0.40 (0.21, 0.78)

21/25 409 16/30 834 392 PSMB1/P193L: C/C ≦65 years old 0.72 (0.56, 0.92)

130/198 489 112/194 719 392 PSMB2/E49X: G/G ≦65 years old 0.72 (0.56,0.92)

130/198 489 112/194 719 392 PSMB2/G187V: G/G ≦65 years old 0.72 (0.56,0.92)

130/198 489 112/194 719 392 PSMB2/L159F: C/C ≦65 years old 0.72 (0.56,0.92)

130/198 489 112/194 719 392 PSMB5/L206M: C/C ≦65 years old 0.72 (0.56,0.92)

130/198 489 112/194 719 392 PSMB5/R24C: C/C ≦65 years old 0.71 (0.54,0.93)

113/170 489  97/167 719 392 PSMB6/A234D: C/C ≦65 years old 0.72 (0.56,0.92)

130/198 489 112/194 719 392 PSMB6/P107A: C/C ≦65 years old 0.72 (0.56,0.93)

125/189 504 110/190 718 392 PSMB8/G8R: G/G ≦65 years old 0.72 (0.55,0.93)

123/189 504 106/186 719 392 PSMB8/R141C: C/C ≦65 years old 0.72 (0.56,0.92)

130/198 489 112/194 719 392 PSMB8/V182M: G/G ≦65 years old 0.72 (0.56,0.92)

130/198 489 112/194 719 392 PSMB9/G9E: G/G ≦65 years old 0.72 (0.56,0.93)

129/196 489 112/193 719 392 PSMB9/V32I: C/C ≦65 years old 0.72 (0.56,0.93)

127/192 489 107/186 718 392 PSMB1/P11A: C/G Female 0.58 (0.36, 0.93)

42/75 546 30/66 1103 301 PSMB8/G8R: G/G Female 0.72 (0.52, 0.98)

 94/160 649  65/131 939 301 PSMB1/P11A: G/G Male 0.50 (0.25, 1.01)

17/19 421 15/25 631 241 PSMB9/R60H: A/G Male 0.43 (0.24, 0.76)

22/28 380 30/48 764 241 PSMB1/P11A: C/G Other 0.07 (0.01, 0.81)

2/3 164 6/9 557 27 PSMB1/P11A: C/G White 0.68 (0.47, 0.97)

 67/111 581 54/97 975 473 PSMB1/P11A: G/G White 0.54 (0.31, 0.94)

27/32 421 25/39 599 473 PSMB1/A171S: G/G Ann Arbor Stage IV 0.72 (0.53,0.97)

 86/127 457  78/143 639 270 PSMB1/I208N: T/T Ann Arbor Stage IV 0.72(0.53, 0.97)

 86/127 457  78/143 639 270 PSMB1/P193L: C/C Ann Arbor Stage IV 0.72(0.53, 0.97)

 86/127 457  78/143 639 270 PSMB2/E49X: G/G Ann Arbor Stage IV 0.72(0.53, 0.97)

 86/127 457  78/143 639 270 PSMB2/G187V: G/G Ann Arbor Stage IV 0.72(0.53, 0.97)

 86/127 457  78/143 639 270 PSMB2/L159F: C/C Ann Arbor Stage IV 0.72(0.53, 0.97)

 86/127 457  78/143 639 270 PSMB5/L206M: C/C Ann Arbor Stage IV 0.72(0.53, 0.97)

 86/127 457  78/143 639 270 PSMB5/R24C: C/T Ann Arbor Stage IV 0.45(0.20, 1.01)

11/15 421 13/28 991 270 PSMB6/A234D: C/C Ann Arbor Stage IV 0.72 (0.53,0.97)

 86/127 457  78/143 639 270 PSMB6/P107A: C/C Ann Arbor Stage IV 0.72(0.53, 0.98)

 84/124 485  77/140 602 270 PSMB8/G8R: G/G Ann Arbor Stage IV 0.73(0.53, 1.00)

 80/120 457  74/138 602 270 PSMB8/R141C: C/C Ann Arbor Stage IV 0.72(0.53, 0.97)

 86/127 457  78/143 639 270 PSMB8/V182M: G/G Ann Arbor Stage IV 0.72(0.53, 0.97)

 86/127 457  78/143 639 270 PSMB9/G9E: G/G Ann Arbor Stage IV 0.71(0.52, 0.97)

 86/126 457  78/142 602 270 PSMB9/V32I: C/C Ann Arbor Stage IV 0.72(0.53, 0.98)

 84/123 457  76/138 639 270

APPENDIX 2 Table 2.12: Time to Next Anti-Lymphoma Therapy by SomaticMutation and by Covariate, IRC review. (All Reported Groups areSignificant (p ≦ 0.05) and at a Frequency of ≧10%) Marker: HR HR R RVc-R Vc-R Subgroup Marker: Level Subgroup (95% CI) (log scale) Evt/NMedian Evt/N Median N Total BCL2/A43G: MND No Subgroup 0.66 (0.49, 0.88)

104/161 501  84/154 791 315 BCL2/ C.-11C > T: MND No Subgroup 0.71(0.54, 0.92)

127/192 501 102/179 719 390 BCL2/E29K: MND No Subgroup 0.64 (0.47, 0.86)

 98/150 484  77/139 791 318 BCL2/P46L: MND No Subgroup 0.70 (0.51, 0.95)

 86/135 504  77/139 743 314 BCL2/P46S: MND No Subgroup 0.73 (0.54, 0.98)

 92/147 504  84/147 751 310 BCL2/P59S: MND No Subgroup 0.72 (0.53, 0.96)

 92/145 504  84/147 751 309 BCL2/Q52P: MND No Subgroup 0.71 (0.53, 0.95)

 97/153 501  88/154 751 307 BCL2/R106H: MND No Subgroup 0.66 (0.50,0.88)

108/162 489  84/151 751 372 NOTCH/ G_A1702P: MND No Subgroup 0.73 (0.55,0.96)

113/175 501  93/161 726 337 NOTCH/I1681N: MND No Subgroup 0.73 (0.56,0.97)

113/175 501  94/162 719 337 NOTCH/L1679P: MND No Subgroup 0.73 (0.56,0.97)

113/175 501  94/162 719 337 NOTCH/L1679Q: MND No Subgroup 0.73 (0.56,0.97)

113/175 501  94/162 719 337 NOTCH/L2458V: MND No Subgroup 0.75 (0.56,0.99)

104/162 501  92/157 719 319 NOTCH/P2513L: MND No Subgroup 0.69 (0.50,0.95)

 90/140 501  67/123 791 361 NOTCH/P2515FS4: MND No Subgroup 0.70 (0.53,0.92)

114/176 501  92/166 751 344 NOTCH/Q2441X: MND No Subgroup 0.75 (0.57,1.00)

103/161 501  92/155 719 319 NOTCH/Q2460X: MND No Subgroup 0.72 (0.53,0.96)

 98/151 489  82/143 726 324 NOTCH/X26DEL: MND No Subgroup 0.74 (0.57,0.97)

112/175 505 102/178 744 361 NOTCH/X26INS: MND No Subgroup 0.74 (0.56,0.96)

114/179 505 103/180 744 361 NOTCH/X28DEL: MND No Subgroup 0.72 (0.56,0.93)

128/194 503 109/189 719 400 NOTCH/X28INS: MND No Subgroup 0.70 (0.55,0.90)

132/198 501 112/195 719 401 BCL2/A43G: MND 1 Prior Line of Therapy 0.54(0.34, 0.86)

46/72 550 30/67 991 139 BCL2/C.-11C > T: MND 1 Prior Line of Therapy0.61 (0.40, 0.92)

57/86 568 38/78 988 170 BCL2/E29K: MND 1 Prior Line of Therapy 0.54(0.34, 0.88)

41/64 546 29/62 991 139 BCL2/P46L: MND 1 Prior Line of Therapy 0.59(0.37, 0.97)

37/58 589 30/63 991 140 BCL2/P46S: MND 1 Prior Line of Therapy 0.61(0.38, 0.97)

40/64 550 33/68 991 138 BCL2/P59S: MND 1 Prior Line of Therapy 0.62(0.39, 0.99)

41/66 573 32/66 988 138 BCL2/Q52P: MND 1 Prior Line of Therapy 0.62(0.39, 0.97)

42/67 550 35/71 988 138 BCL2/R106H: MND 1 Prior Line of Therapy 0.58(0.37, 0.90)

49/73 550 33/68 991 162 NOTCH/P2515FS4: MND 1 Prior Line of Therapy 0.62(0.40, 0.97)

48/75 573 35/72 988 149 NOTCH/X28DEL: MND 1 Prior Line of Therapy 0.67(0.45, 1.00)

56/85 568 44/84 756 177 NOTCH/X28INS: MND 1 Prior Line of Therapy 0.63(0.42, 0.93)

56/84 568 45/88 841 178 BCL2/C.-11C > T: MND 5 Prior Lines of Therapy0.17 (0.03, 1.05)

3/3 221 3/7 939 11 NOTCH/X28DEL: MND 5 Prior Lines of Therapy 0.20(0.04, 1.12)

4/4 342 3/7 939 11 BCL2/A43G: MND No High Tumor Burden 0.61 (0.37, 0.98)

42/78 774 27/64 — 142 BCL2/R106H: MND No High Tumor Burden 0.60 (0.37,0.98)

46/79 690 26/58 1185 163 NOTCH/P2513L: MD No High Tumor Burden 0.44(0.19, 0.99)

17/26 593  9/21 — 163 NOTCH/X28INS: MND No High Tumor Burden 0.63 (0.41,0.96)

55/98 734 37/82 1107 184 BCL2/A43G: MND High Tumor Burden 0.60 (0.42,0.86)

62/83 380 57/90 534 173 BCL2/C.-11C > T: MND High Tumor Burden 0.65(0.47, 0.90)

 76/101 380  69/107 484 217 BCL2/E29K: MND High Tumor Burden 0.56 (0.38,0.81)

60/79 374 52/82 542 174 BCL2/P46L: MND High Tumor Burden 0.57 (0.38,0.84)

51/67 374 51/83 534 173 BCL2/P46S: MND High Tumor Burden 0.63 (0.43,0.92)

52/73 374 56/89 488 170 BCL2/P59L: MND High Tumor Burden 0.66 (0.44,0.97)

52/72 396 50/80 455 172 BCL2/P59S: MND High Tumor Burden 0.62 (0.42,0.90)

53/73 396 54/87 534 170 BCL2/Q52P: MND High Tumor Burden 0.62 (0.42,0.89)

55/76 374 58/92 534 168 BCL2/R106H: MND High Tumor Burden 0.59 (0.41,0.84)

62/83 380 58/93 542 209 NOTCH/F1593S: MND High Tumor Burden 0.69 (0.48,1.00)

55/77 410 60/91 488 168 NOTCH/G_A1702P: MND High Tumor Burden 0.62(0.44, 0.88)

67/90 374 62/96 534 187 NOTCH/I1681N: MND High Tumor Burden 0.63 (0.45,0.89)

67/90 374 63/97 534 187 NOTCH/L1586P: MND High Tumor Burden 0.69 (0.48,1.00)

55/77 410 60/91 488 168 NOTCH/L1586Q: MND High Tumor Burden 0.65 (0.45,0.94)

56/78 396 60/94 534 172 NOTCH/L1594P: MND High Tumor Burden 0.69 (0.48,1.00)

55/77 410 60/91 488 168 NOTCH/L1597H: MND High Tumor Burden 0.65 (0.45,0.94)

56/78 396 60/94 534 172 NOTCH/ L1597_S1598I NSG: MND High Tumor Burden0.69 (0.48, 1.00)

55/77 410 60/91 488 168 NOTCH/L1601P: MND High Tumor Burden 0.68 (0.47,0.98)

55/77 410 59/90 488 168 NOTCH/L1679P: MND High Tumor Burden 0.63 (0.45,0.89)

67/90 374 63/97 534 187 NOTCH/L1679Q: MND High Tumor Burden 0.63 (0.45,0.89)

67/90 374 63/97 534 187 NOTCH/L2458V: MND High Tumor Burden 0.64 (0.45,0.91)

61/83 380 61/95 534 178 NOTCH/P2513L: MND High Tumor Burden 0.54 (0.36,0.80)

58/76 380 43/71 542 198 NOTCH/P2515FS4: MND High Tumor Burden 0.61(0.43, 0.87)

67/90 380 61/98 534 189 NOTCH/Q2441X: MND High Tumor Burden 0.64 (0.45,0.91)

61/83 380 61/95 534 178 NOTCH/Q2460X: MND High Tumor Burden 0.61 (0.42,0.88)

59/79 380 54/87 542 181 NOTCH/R1599 > QS: MND High Tumor Burden 0.69(0.48, 1.00)

55/77 410 60/91 488 168 NOTCH/R1599P: MND High Tumor Burden 0.65 (0.45,0.94)

56/78 396 60/94 534 172 NOTCH/V1579DEL: MND High Tumor Burden 0.69(0.48, 1.00)

55/77 410 60/91 488 168 NOTCH/V1579E: MND High Tumor Burden 0.65 (0.45,0.94)

56/78 396 60/94 534 172 NOTCH/V1579G: MND High Tumor Burden 0.69 (0.48,1.00)

55/77 410 60/91 488 168 NOTCH/X26DEL: MND High Tumor Burden 0.67 (0.47,0.94)

63/88 396  68/107 518 198 NOTCH/X26INS: MND High Tumor Burden 0.66(0.47, 0.93)

64/89 396  68/107 518 198 NOTCH/X28DEL: MND High Tumor Burden 0.64(0.46, 0.89)

74/99 374  72/111 488 216 NOTCH/X28INS: MND High Tumor Burden 0.64(0.47, 0.88)

 77/100 343  75/113 474 217 BCL2/P59L: MD High FLIPI Score 0.18 (0.03,1.06)

4/6 211 6/7 658 125 BCL2/A43G: MND Intermediate FLIPI Score 0.60 (0.36,1.00)

34/53 504 26/52 939 105 BCL2/C.-11C > T: MND Intermediate FLIPI Score0.59 (0.38, 0.93)

44/66 504 33/63 939 136 BCL2/P46S: MND Intermediate FLIPI Score 0.59(0.35, 1.00)

31/50 505 26/52 988 105 BCL2/P59S: MND Intermediate FLIPI Score 0.60(0.35, 1.00)

31/48 505 27/52 939 105 BCL2/Q52P: MND Intermediate FLIPI Score 0.60(0.36, 0.99)

32/51 505 28/54 988 105 BCL2/R106H: MND Intermediate FLIPI Score 0.51(0.31, 0.82)

40/55 501 28/54 988 130 NOTCH/X28DEL: MND Intermediate FLIPI Score 0.65(0.42, 1.00)

44/65 505 38/70 756 143 BCL2/E29K: MND No Prior Rituximab Therapy 0.65(0.43, 0.97)

57/93 534 41/76 883 186 BCL2/P59L: MD No Prior Rituximab Therapy 0.15(0.03, 0.80)

3/5 211  7/13 947 178 BCL2/A43G: MND Prior Rituximab Therapy 0.59 (0.38,0.92)

44/63 428 37/69 719 132 BCL2/C.-11C > T: MND Prior Rituximab Therapy0.58 (0.39, 0.86)

57/78 396 43/77 718 165 BCL2/E29K: MND Prior Rituximab Therapy 0.59(0.37, 0.92)

41/57 428 36/63 719 132 BCL2/P59S: MND Prior Rituximab Therapy 0.60(0.38, 0.95)

39/56 450 37/69 719 133 BCL2/R106H: MND Prior Rituximab Therapy 0.54(0.36, 0.83)

50/67 421 39/72 719 159 NOTCH/G_A1702P: MND Prior Rituximab Therapy 0.60(0.40, 0.91)

51/72 434 41/74 719 147 NOTCH/I1681N: MND Prior Rituximab Therapy 0.61(0.41, 0.93)

51/72 434 42/75 719 147 NOTCH/L1586Q: MND Prior Rituximab Therapy 0.63(0.41, 0.97)

44/63 443 41/73 719 136 NOTCH/L1597H: MND Prior Rituximab Therapy 0.63(0.41, 0.97)

44/63 443 41/73 719 136 NOTCH/L1679P: MND Prior Rituximab Therapy 0.61(0.41, 0.93)

51/72 434 42/75 719 147 NOTCH/L1679Q: MND Prior Rituximab Therapy 0.61(0.41, 0.93)

51/72 434 42/75 719 147 NOTCH/L2458V: MND Prior Rituximab Therapy 0.61(0.40, 0.93)

47/66 443 42/75 719 141 NOTCH/P2513L: MND Prior Rituximab Therapy 0.57(0.35, 0.95)

39/57 450 25/51 751 154 NOTCH/P2515FS4: MND Prior Rituximab Therapy 0.61(0.41, 0.92)

51/72 434 42/77 719 149 NOTCH/Q2441X: MND Prior Rituximab Therapy 0.61(0.40, 0.93)

47/66 443 42/73 719 141 NOTCH/Q2460X: MND Prior Rituximab Therapy 0.58(0.37, 0.90)

45/62 434 36/66 719 143 NOTCH/R1599P: MND Prior Rituximab Therapy 0.63(0.41, 0.97)

44/63 443 41/73 719 136 NOTCH/V1579E: MND Prior Rituximab Therapy 0.63(0.41, 0.97)

44/63 443 41/73 719 136 NOTCH/X26DEL: MND Prior Rituximab Therapy 0.65(0.44, 0.98)

50/70 434 46/82 718 158 NOTCH/X26INS: MND Prior Rituximab Therapy 0.64(0.43, 0.94)

52/74 434 47/84 719 158 NOTCH/X28DEL: MND Prior Rituximab Therapy 0.61(0.42, 0.89)

60/83 427 49/86 672 175 NOTCH/X28INS: MND Prior Rituximab Therapy 0.60(0.41, 0.87)

62/86 427 50/88 672 175 BCL2/A43G: MND >1 year since last anti- lymphomatreatment 0.63 (0.43, 0.94)

57/91 589 44/94 878 185 BCL2/C.-11C > T: MND >1 year since last anti-lymphoma treatment 0.62 (0.44, 0.88)

 73/112 560  55/112 878 233 BCL2/E29K: MND >1 year since last anti-lymphoma treatment 0.59 (0.39, 0.90)

52/82 550 39/83 883 185 BCL2/R106H: MND >1 year since last anti-lymphoma treatment 0.57 (0.39, 0.83)

65/96 534 45/94 878 217 NOTCH/P2513L: MND >1 year since last anti-lymphoma treatment 0.60 (0.39, 0.92)

50/78 560 37/81 878 213 NOTCH/P2515FS4: MND >1 year since last anti-lymphoma treatment 0.65 (0.44, 0.94)

 64/102 593  48/102 878 205 NOTCH/Q2460X: MND >1 year since last anti-lymphoma treatment 0.66 (0.44, 0.99)

53/84 573 43/86 841 185 NOTCH/X26INS: MND >1 year since last anti-lymphoma treatment 0.69 (0.48, 1.00)

 62/102 643  54/110 883 212 NOTCH/X28DEL: MND >1 year since last anti-lymphoma treatment 0.70 (0.49, 0.99)

 70/112 589  58/116 872 236 NOTCH/X28INS: MND >1 year since last anti-lymphoma treatment 0.64 (0.45, 0.90)

 73/113 573  59/119 872 237 BCL2/A43G: MND European Union 0.53 (0.33,0.84)

41/66 649 32/72 1103 138 BCL2/C.-11C > T: MND European Union 0.57 (0.38,0.86)

53/79 505 41/83 983 169 BCL2/E29K: MND European Union 0.58 (0.36, 0.94)

37/61 533 32/67 1075 138 BCL2/P46L: MND European Union 0.58 (0.35, 0.96)

34/56 533 29/64 1185 139 BCL2/P46S: MND European Union 0.59 (0.37, 0.94)

37/61 504 33/68 1075 136 BCL2/P59S: MND European Union 0.60 (0.37, 0.96)

36/60 505 34/69 983 136 BCL2/Q52P: MND European Union 0.60 (0.38, 0.94)

38/63 504 36/73 983 136 BCL2/R106H: MND European Union 0.57 (0.36, 0.89)

44/65 533 35/70 1005 160 NOTCH/G_A1702P: MND European Union 0.61 (0.39,0.95)

44/72 533 36/74 983 147 NOTCH/I1681N: MND European Union 0.63 (0.40,0.97)

44/72 533 37/75 983 147 NOTCH/L1586Q: MND European Union 0.63 (0.40,0.99)

40/66 505 36/72 983 138 NOTCH/L1597H: MND European Union 0.63 (0.40,0.99)

40/66 505 36/72 983 138 NOTCH/L1679P: MND European Union 0.63 (0.40,0.97)

44/72 533 37/75 983 147 NOTCH/L1679Q: MND European Union 0.63 (0.40,0.97)

44/72 533 37/75 983 147 NOTCH/P2513L: MND European Union 0.47 (0.28,0.80)

39/59 504 22/52 — 159 NOTCH/P2515FS4: MND European Union 0.58 (0.38,0.90)

48/77 533 36/77 1075 155 NOTCH/R1599P: MND European Union 0.63 (0.40,0.99)

40/66 505 36/72 983 138 NOTCH/V1579E: MND European Union 0.63 (0.40,0.99)

40/66 505 36/72 983 138 NOTCH/X26DEL: MND European Union 0.64 (0.42,0.99)

44/72 552 42/84 1005 159 NOTCH/X26INS: MND European Union 0.63 (0.42,0.96)

46/74 552 42/84 1005 159 NOTCH/X28DEL: MND European Union 0.62 (0.41,0.92)

53/82 533 45/87 983 177 NOTCH/X28INS: MND European Union 0.61 (0.41,0.90)

56/85 533 46/89 983 177 BCL2/A43G: MND ≦65 years old 0.66 (0.48, 0.91)

 84/124 484  65/115 743 239 BCL2/C.-11C > T: MND ≦65 years old 0.70(0.52, 0.94)

101/147 484  81/135 718 296 BCL2/E29K: MND ≦65 years old 0.60 (0.43,0.85)

 81/117 450  58/103 751 241 BCL2/P46L: MND ≦65 years old 0.69 (0.48,0.97)

 71/105 485  59/104 743 238 BCL2/P46S: MND ≦65 years old 0.71 (0.51,0.99)

 73/111 489  66/113 726 236 BCL2/P59S: MND ≦65 years old 0.71 (0.51,0.99)

 74/110 489  68/114 726 235 BCL2/Q52P: MND ≦65 years old 0.71 (0.51,0.98)

 78/117 485  69/117 726 234 BCL2/R106H: MND ≦65 years old 0.61 (0.44,0.84)

 86/124 450  61/112 751 281 NOTCH/G_A1702P: MND ≦65 years old 0.69(0.51, 0.95)

 91/133 462  71/121 719 255 NOTCH/11681N: MND ≦65 years old 0.70 (0.51,0.96)

 91/133 462  72/122 719 255 NOTCH/L1679P: MND ≦65 years old 0.70 (0.51,0.96)

 91/133 462  72/122 719 255 NOTCH/L1679Q: MND ≦65 years old 0.70 (0.51,0.96)

 91/133 462  72/122 719 255 NOTCH/L2458V: MND ≦65 years old 0.71 (0.52,0.98)

 82/120 462  70/117 719 237 NOTCH/P2513L: MND ≦65 years old 0.62 (0.43,0.89)

 74/107 462 50/90 751 269 NOTCH/P2515FS4: MND ≦65 years old 0.67 (0.49,0.92)

 92/134 484  70/123 726 259 NOTCH/Q2441X: MND ≦65 years old 0.72 (0.52,0.99)

 82/120 462  70/115 719 237 NOTCH/Q2460X: MND ≦65 years old 0.68 (0.48,0.95)

 77/110 449  61/104 719 239 NOTCH/X26DEL: MND ≦65 years old 0.70 (0.52,0.95)

 92/137 489  76/132 726 273 NOTCH/X26INS: MND ≦65 years old 0.70 (0.52,0.95)

 93/138 501  77/133 726 273 NOTCH/X28DEL: MND ≦65 years old 0.68 (0.51,0.90)

104/149 462  83/140 719 298 NOTCH/X28INS: MND ≦65 years old 0.67 (0.50,0.89)

106/149 462  85/143 718 298 BCL2/P46L: MND Female 0.61 (0.39, 0.96)

51/86 535 31/68 1185 180 BCL2/P59S: MND Female 0.65 (0.43, 1.00)

57/97 533 36/73 947 178 BCL2/R106H: MND Female 0.65 (0.42, 0.99)

58/96 534 35/70 883 203 BCL2/A43G: MND Male 0.55 (0.36, 0.82)

45/59 343 47/76 743 135 BCL2/C.-11C > T: MND Male 0.62 (0.43, 0.90)

57/77 380 58/93 651 182 BCL2/E29K: MND Male 0.51 (0.33, 0.77)

43/55 337 43/68 743 138 BCL2/P46L: MD Male 0.11 (0.02, 0.63)

4/4 382  6/10 878 134 BCL2/P46S: MND Male 0.64 (0.42, 0.99)

38/52 396 49/75 695 133 BCL2/Q52P: MND Male 0.62 (0.41, 0.95)

39/53 396 50/78 695 131 BCL2/R106H: MND Male 0.61 (0.41, 0.90)

50/66 396 49/81 695 169 NOTCH/G_A1702P: MND Male 0.60 (0.40, 0.89)

47/63 337 51/81 726 145 NOTCH/I1681N: MND Male 0.61 (0.41, 0.90)

47/63 337 52/82 695 145 NOTCH/L1586Q: MND Male 0.65 (0.43, 0.98)

41/56 396 51/79 695 135 NOTCH/L1597H: MND Male 0.65 (0.43, 0.98)

41/56 396 51/79 695 135 NOTCH/L1679P: MND Male 0.61 (0.41, 0.90)

47/63 337 52/82 695 145 NOTCH/L1679Q: MND Male 0.61 (0.41, 0.90)

47/63 337 52/82 695 145 NOTCH/L2458V: MND Male 0.60 (0.40, 0.91)

44/59 337 51/80 695 139 NOTCH/P2513L: MND Male 0.52 (0.33, 0.82)

41/54 343 37/63 791 155 NOTCH/P2515FS4: MND Male 0.57 (0.38, 0.85)

47/62 380 51/84 743 148 NOTCH/Q2441X: MND Male 0.61 (0.40, 0.91)

44/59 337 51/79 695 139 NOTCH/Q2460X: MD Male 0.14 (0.03, 0.71)

3/3 127  8/12 645 142 NOTCH/Q2460X: MND Male 0.60 (0.39, 0.93)

42/57 343 43/70 726 142 NOTCH/R1599P: MND Male 0.65 (0.43, 0.98)

41/56 396 51/79 695 135 NOTCH/V1579E: MND Male 0.65 (0.43, 0.98)

41/56 396 51/79 695 135 NOTCH/X26DEL: MND Male 0.58 (0.39, 0.85)

49/65 396 58/95 726 162 NOTCH/X26INS: MND Male 0.56 (0.38, 0.82)

50/66 396 58/95 743 162 NOTCH/X28DEL: MND Male 0.63 (0.44, 0.91)

56/75 396 61/97 695 180 NOTCH/X28INS: MND Male 0.62 (0.44, 0.89)

59/78 396  63/100 651 181 BCL2/A43G: MND White 0.67 (0.49, 0.91)

 89/140 504  76/139 834 279 BCL2/C.-11C > T: MND White 0.70 (0.53, 0.93)

110/168 504  90/158 726 342 BCL2/E29K: MND White 0.63 (0.46, 0.87)

 83/129 485  70/127 834 282 BCL2/P46L: MND White 0.68 (0.49, 0.95)

 74/117 505  68/125 791 279 BCL2/P46S: MND White 0.70 (0.51, 0.96)

 81/130 505  74/131 834 275 BCL2/P59L: MND White 0.72 (0.52, 0.99)

 80/129 533  69/123 791 278 BCL2/P59S: MND White 0.68 (0.50, 0.94)

 81/128 505  73/130 834 274 BCL2/Q52P: MND White 0.69 (0.50, 0.94)

 85/135 504  77/137 834 272 BCL2/R106H: MND White 0.68 (0.50, 0.92)

 93/140 501  77/135 743 327 NOTCH/G_A1702P: MND White 0.72 (0.54, 0.97)

 97/152 504  82/143 743 295 NOTCH/I1681N: MND White 0.72 (0.54, 0.97)

 97/152 504  82/143 743 295 NOTCH/L1679P: MND White 0.72 (0.54, 0.97)

 97/152 504  82/143 743 295 NOTCH/L1679Q: MND White 0.72 (0.54, 0.97)

 97/152 504  82/143 743 295 NOTCH/L2458V: MND White 0.73 (0.54, 0.99)

 89/140 504  81/139 743 279 NOTCH/P2513L: MND White 0.67 (0.48, 0.94)

 78/122 504  59/108 841 319 NOTCH/P2515FS4: MND White 0.68 (0.50, 0.91)

 99/154 505  81/148 834 304 NOTCH/Q2441X: MND White 0.74 (0.54, 1.00)

 88/139 501  81/137 726 279 NOTCH/Q2460X: MND White 0.70 (0.51, 0.96)

 85/131 501  73/127 743 284 NOTCH/X26DEL: MND White 0.73 (0.55, 0.97)

 99/155 505  91/158 751 321 NOTCH/X26INS: MND White 0.72 (0.54, 0.96)

101/159 533  92/160 751 321 NOTCH/X28DEL: MND White 0.73 (0.55, 0.95)

111/169 504  98/167 726 351 NOTCH/X28INS: MND White 0.70 (0.53, 0.92)

115/174 504  99/171 743 352 BCL2/A43G: MND Ann Arbor Stage IV 0.60(0.40, 0.91)

48/71 450 42/83 658 154 BCL2/C.-11C > T: MND Ann Arbor Stage IV 0.64(0.44, 0.93)

60/84 450  54/100 639 193 BCL2/E29K: MND Ann Arbor Stage IV 0.59 (0.38,0.91)

46/67 450 37/73 651 154 BCL2/P46L: MND Ann Arbor Stage IV 0.62 (0.39,0.99)

35/52 449 38/74 651 148 BCL2/P59L: MD Ann Arbor Stage IV 0.17 (0.03,0.88)

3/5 182  8/12 725 149 BCL2/R106H: MND Ann Arbor Stage IV 0.59 (0.39,0.89)

50/72 449 42/83 651 186 NOTCH/G_A1702P: MND Ann Arbor Stage IV 0.61(0.41, 0.90)

52/75 428 47/87 649 163 NOTCH/I1681N: MND Ann Arbor Stage IV 0.62 (0.42,0.92)

52/75 428 48/88 649 163 NOTCH/L1679P: MND Ann Arbor Stage IV 0.62 (0.42,0.92)

52/75 428 48/88 649 163 NOTCH/L1679Q: MND Ann Arbor Stage IV 0.62 (0.42,0.92)

52/75 428 48/88 649 163 NOTCH/L2458V: MND Ann Arbor Stage IV 0.63 (0.42,0.95)

46/68 434 46/86 651 154 NOTCH/P2513L: MND Ann Arbor Stage IV 0.55 (0.35,0.87)

42/61 449 34/69 791 176 NOTCH/P2515FS4: MND Ann Arbor Stage IV 0.59(0.39, 0.87)

51/74 434 46/91 658 167 NOTCH/Q2441X: MND Ann Arbor Stage IV 0.63 (0.42,0.95)

46/68 434 46/85 651 154 NOTCH/Q2460X: MND Ann Arbor Stage IV 0.61 (0.39,0.93)

43/64 449 41/79 658 156 NOTCH/X26DEL: MND Ann Arbor Stage IV 0.63 (0.43,0.93)

53/76 457  54/101 651 180 NOTCH/X26INS: MND Ann Arbor Stage IV 0.63(0.43, 0.91)

54/79 450  54/101 651 180 NOTCH/X28DEL: MND Ann Arbor Stage IV 0.63(0.44, 0.91)

61/85 449  56/103 644 195 NOTCH/X28INS: MND Ann Arbor Stage IV 0.60(0.42, 0.86)

64/87 434  57/105 644 196

APPENDIX 2 Table 2.13: Treatment Free Interval by Protein Expression andby Covariate, IRC Review. (All Reported Groups are Significant ( p ≦0.05) and at a Frequency of ≧10%) Marker: Sub- group HR (95% R R Vc-RVc-R N Marker: Level Subgroup CI) HR (log scale) Evt/N Median Evt/NMedian Total CD68 OVERALL POSITIVE: 0-25 No Subgroup 0.42 (0.23, 0.75)

30/44 269 19/41  883 442 CD68 POSITIVE FOLLICULAR: 0-25 No Subgroup 0.56(0.34, 0.90)

40/60 307 29/51  671 387 CD68 POSITIVE PERIFOLLICULAR: 0-25 No Subgroup0.49 (0.27, 0.89)

26/39 234 20/41  924 384 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% NoSubgroup 0.77 (0.60, 1.00)

129/204 363 108/186  581 470 CD68 POSITIVE PERIFOLLICULAR: >75 1 PriorLine of Therapy 0.45 (0.20, 1.01)

15/18 297 10/16  587 174 P27 % NUCLEI POSITIVE: 0-20 1 Prior Line ofTherapy 0.40 (0.16, 1.01)

19/26 293  6/16  883 204 P65 % NUCLEAR STAINING: 0 1 Prior Line ofTherapy 0.66 (0.43, 0.99)

54/79 406 39/73  673 203 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% 1 PriorLine of Therapy 0.63 (0.43, 0.93)

59/89 409 47/88  673 203 P65 INTENSITY CYTOPLASMIC SIGNAL: ≧2+ 1 PriorLine of Therapy 0.66 (0.45, 0.98)

54/85 427 47/91  673 203 CD68 OVERALL POSITIVE: 0-25 2 Prior Lines ofTherapy 0.20 (0.04, 1.02)

6/8  80 2/7  844 111 CD68 POSITIVE PERIFOLLICULAR: 0-25 2 Prior Lines ofTherapy 0.09 (0.01, 0.81)

6/8  64 1/7 — 98 P65 % NUCLEAR STAINING: ≦5% 2 Prior Lines of Therapy0.32 (0.11, 0.96)

7/9  85  7/12  542 125 P27 % NUCLEI POSITIVE: 60-70 3 Prior Lines ofTherapy 8.31 (0.95, 72.50)

1/6 — 5/5  65 74 P27 SIGNAL INTENSITY: ≧2+ 5 Prior Lines of Therapy 0.22(0.04, 1.13)

5/6  88 3/8  778 16 P65 % NUCLEAR STAINING: ≦5% 5 Prior Lines of Therapy0.13 (0.01, 1.34)

3/3  95 2/4 1058 16 CD68 OVERALL POSITIVE: 0-25 No High Tumor Burden0.23 (0.07, 0.80)

 8/14 411  5/19 — 204 CD68 OVERALL POSITIVE: 51-75 No High Tumor Burden2.33 (1.00, 5.41)

10/25 — 12/18  349 204 CD68 POSITIVE FOLLICULAR: 0-25 No High TumorBurden 0.40 (0.18, 0.91)

14/22 432 12/15 1058 182 CD68 POSITIVE PERIFOLLICULAR: 0-25 No HighTumor Burden 0.23 (0.07, 0.78)

 8/13 361  5/16 1058 182 P27 % NUCLEI POSITIVE: 30-50 High Tumor Burden0.49 (0.24, 1.01)

17/22 280 13/25  483 248 P27 SIGNAL INTENSITY: ≦1+ High Tumor Burden0.45 (0.20, 1.00)

16/18 122 11/17  818 248 CD68 OVERALL POSITIVE: 0-25 Intermediate FLIPIScore 0.27 (0.08, 0.98)

 7/11 343  5/15 1058 159 CD68 POSITIVE PERIFOLLICULAR: 0-25 IntermediateFLIPI Score 0.27 (0.08, 0.95)

 7/13 361  5/17 1058 139 CD68 OVERALL POSITIVE: 0-25 Low FLIPI Score0.32 (0.10, 1.01)

 8/10 281  5/11  907 102 CD68 OVERALL POSITIVE: 0-25 No Prior RituximabTherapy 0.38 (0.15, 0.99)

12/19 393  7/21  942 241 CD68 POSITIVE FOLLICULAR: 0-25 No PriorRituximab Therapy 0.41 (0.19, 0.87)

23/36 344 10/25  942 210 CD68 POSITIVE PERIFOLLICULAR: 0-25 No PriorRituximab Therapy 0.33 (0.12, 0.97)

12/18 393  5/15 — 208 20S % NUCLEAR STAINING 60-70 Prior RituximabTherapy 0.40 (0.16, 1.02)

17/21 190  6/12  907 212 CD68 OVERALL POSITIVE: 0-25 Prior RituximabTherapy 0.42 (0.20, 0.90)

18/25 115 12/20  671 201 P27 SIGNAL INTENSITY: ≧2+ Prior RituximabTherapy 0.67 (0.46, 0.98)

60/88 272 48/85  554 210 P65 % NUCLEAR STAINING: ≦5% Prior RituximabTherapy 0.31 (0.14, 0.67)

16/21  93 13/27  818 215 CD68 OVERALL POSITIVE: 0-25 >1 year since lastanti- lymphoma treatment 0.27 (0.12, 0.63)

17/26 269  9/28 1058 269 CD68 POSITIVE FOLLICULAR: 0-25 >1 year sincelast anti- lymphoma treatment 0.50 (0.26, 0.97)

22/34 409 16/33  907 235 CD68 POSITIVE PERIFOLLICULAR: 0-25 >1 yearsince last anti- lymphoma treatment 0.42 (0.19, 0.92)

15/24 393 11/27 1058 234 20S INTENSITY CYTOPLASMIC SIGNAL: ≦3+ EuropeanUnion 0.59 (0.35, 0.99)

34/52 393 25/52  907 214 CD68 OVERALL POSITIVE: 0-25 European Union 0.41(0.18, 0.92)

14/22 234 11/25  942 211 CD68 POSITIVE PERIFOLLICULAR: >75 EuropeanUnion 0.37 (0.14, 1.00)

13/17 533  7/14 1023 185 CD68 OVERALL POSITIVE: 0-25 ≦65 years old 0.39(0.20, 0.76)

24/34 234 15/32  844 329 CD68 POSITIVE FOLLICULAR: 0-25 ≦65 years old0.46 (0.27, 0.78)

33/46 190 24/41  603 292 CD68 POSITIVE PERIFOLLICULAR: 0-25 ≦65 yearsold 0.50 (0.24, 1.01)

20/31 143 13/29  907 289 CD68 POSITIVE PERIFOLLICULAR: >75 ≦65 years old0.46 (0.22, 0.94)

19/23 297 13/23  587 289 P27 % NUCLEI POSITIVE: 0-20 ≦65 years old 0.53(0.29, 0.97)

26/34 187 19/32  671 344 P65 % NUCLEAR STAINING: ≦5% ≦65 years old 0.54(0.29, 1.00)

19/29 234 22/43  818 349 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% ≦65years old 0.73 (0.55, 0.97)

103/154 343  84/142  557 349 P65 INTENSITY CYTOPLASMIC SIGNAL: ≦2+ ≦65years old 0.74 (0.55, 0.99)

101/152 343  82/139  554 349 20S % NUCLEAR STAINING 0-20 Female 0.55(0.32, 0.97)

35/61 427 19/49 — 259 CD68 OVERALL POSITIVE: 0-25 Female 0.28 (0.10,0.76)

16/26 293  5/18  942 242 CD68 POSITIVE FOLLICULAR: 0-25 Female 0.46(0.22, 0.96)

23/37 307 10/22  942 217 CD68 POSITIVE PERIFOLLICULAR: 0-25 Female 0.28(0.10, 0.77)

19/28 234  5/17  942 215 20S % NUCLEAR STAINING 60-70 Male 0.43 (0.20,0.95)

14/16 110 12/20  390 204 CD68 OVERALL POSITIVE: >75 Male 0.25 (0.07,0.87)

8/9 272  4/11 — 200 CD68 POSITIVE FOLLICULAR: 0-25 Asian 0.13 (0.02,1.17)

5/6 148 2/6 — 30 CD68 POSITIVE PERIFOLLICULAR: 26-50 Other 0.14 (0.01,1.31)

4/4 217 4/5  495 22 CD68 OVERALL POSITIVE: 0-25 White 0.38 (0.20, 0.73)

24/35 269 16/35 907 385 CD68 POSITIVE FOLLICULAR: 0-25 White 0.59 (0.35,1.00)

32/48 307 25/42 671 335 CD68 POSITIVE PERIFOLLICULAR: 0-25 White 0.43(0.23, 0.83)

19/27 361 19/39 924 332 P65 % POSITIVE CYTOPLASMIC SIGNAL: >90% White0.76 (0.58, 1.00)

113/179 363  95/162 587 406 CD68 OVERALL POSITIVE: 0-25 Ann Arbor StageIII 0.36 (0.14, 0.92)

12/16 135  9/12 745 144 CD68 POSITIVE FOLLICULAR: 0-25 Ann Arbor StageIII 0.44 (0.21, 0.90)

19/24 190 13/18 603 135 P27 % NUCLEI POSITIVE: 0-20 Ann Arbor Stage III0.42 (0.17, 1.00)

14/16 275 12/15 449 149 P65 INTENSITY CYTOPLASMIC SIGNAL: ≦1+ Ann ArborStage III 0.38 (0.14, 1.02)

10/11 119  7/11 671 151 CD68 OVERALL POSITIVE: 0-25 Ann Arbor Stage IV0.39 (0.16, 0.97)

15/22 293  8/23 883 222 CD68 POSITIVE PERIFOLLICULAR: 0-25 Ann ArborStage IV 0.37 (0.14, 0.96)

11/15 234  8/22 924 183

APPENDIX 2 Table 2.14: Treatment Free Interval by Germline GeneticVariant and by Covariate, IRC Review. (All Reported Groups areSignificant (p ≦ 0.05) and at a Frequency of ≧10%) Marker: Sub- group HR(95% R R Vc-R Vc-R N Marker: Level Subgroup CI) HR (log scale) Evt/NMedian Evt/N Median Total PSMB1/A171S: G/G No Subgroup 0.80 (0.65, 1.00)

173/276 406 152/266 581 542 PSMB1/I208N: T/T No Subgroup 0.80 (0.65,1.00)

173/276 406 152/266 581 542 PSMB1/P11A: C/G No Subgroup 0.69 (0.50,0.97)

 78/127 409  63/115 778 542 PSMB1/P193L: C/C No Subgroup 0.80 (0.65,1.00)

173/276 406 152/266 581 542 PSMB2/E49X: G/G No Subgroup 0.80 (0.65,1.00)

173/276 406 152/266 581 542 PSMB2/G187V: G/G No Subgroup 0.80 (0.65,1.00)

173/276 406 152/266 581 542 PSMB2/L159F: C/C No Subgroup 0.80 (0.65,1.00)

173/276 406 152/266 581 542 PSMB5/L206M: C/C No Subgroup 0.80 (0.65,1.00)

173/276 406 152/266 581 542 PSMB6/A234D: C/C No Subgroup 0.80 (0.65,1.00)

173/276 406 152/266 581 542 PSMB8/G8R: G/G No Subgroup 0.79 (0.63, 0.99)

165/264 396 144/256 581 542 PSMB8/R141C: C/C No Subgroup 0.80 (0.65,1.00)

173/276 406 152/266 581 542 PSMB8/V182M: G/G No Subgroup 0.80 (0.65,1.00)

173/276 406 152/266 581 542 PSMB1/P11A: C/G 1 Prior Line of Therapy 0.58(0.35, 0.97)

32/51 480 27/55 883 231 PSMB1/P11A: G/G 1 Prior Line of Therapy 0.37(0.14, 0.98)

11/11 302  7/14 522 231 PSMB8/G8R: G/G 1 Prior Line of Therapy 0.70(0.49, 0.99)

 69/109 533  55/111 690 231 PSMB1/A171S: G/G 5 Prior Lines of Therapy0.29 (0.08, 1.01)

7/9 95  6/12 778 21 PSMB1/I208N: T/T 5 Prior Lines of Therapy 0.29(0.08, 1.01)

7/9 95  6/12 778 21 PSMB1/P193L: C/C 5 Prior Lines of Therapy 0.29(0.08, 1.01)

7/9 95  6/12 778 21 PSMB2/E49X: G/G 5 Prior Lines of Therapy 0.29 (0.08,1.01)

7/9 95  6/12 778 21 PSMB2/G187V: G/G 5 Prior Lines of Therapy 0.29(0.08, 1.01)

7/9 95  6/12 778 21 PSMB2/L159F: C/C 5 Prior Lines of Therapy 0.29(0.08, 1.01)

7/9 95  6/12 778 21 PSMB5/L206M: C/C 5 Prior Lines of Therapy 0.29(0.08, 1.01)

7/9 95  6/12 778 21 PSMB5/R24C: C/C 5 Prior Lines of Therapy 0.17 (0.03,0.86)

6/7 95 4/9 1058 21 PSMB6/A234D: C/C 5 Prior Lines of Therapy 0.29 (0.08,1.01)

7/9 95  6/12 778 21 PSMB6/P107A: C/C 5 Prior Lines of Therapy 0.29(0.08, 1.01)

7/9 95  6/12 778 21 PSMB8/G8R: G/G 5 Prior Lines of Therapy 0.29 (0.08,1.01)

7/9 95  6/11 778 21 PSMB8/R141C: C/C 5 Prior Lines of Therapy 0.29(0.08, 1.01)

7/9 95  6/12 778 21 PSMB8/V182M: G/G 5 Prior Lines of Therapy 0.29(0.08, 1.01)

7/9 95  6/12 778 21 PSMB9/G9E: G/G 5 Prior Lines of Therapy 0.29 (0.08,1.01)

7/9 95  6/12 778 21 PSMB9/V32I: C/C 5 Prior Lines of Therapy 0.25 (0.07,0.87)

7/8 88  5/11 1058 21 PSMB1/A171S: G/G High Tumor Burden 0.75 (0.57,0.99)

108/147 234  98/149 366 296 PSMB1/I208N: T/T High Tumor Burden 0.75(0.57, 0.99)

108/147 234  98/149 366 296 PSMB1/P11A: C/G High Tumor Burden 0.65(0.42, 1.00)

49/72 218 38/65 499 296 PSMB1/P193L: C/C High Tumor Burden 0.75 (0.57,0.99)

108/147 234  98/149 366 296 PSMB2/E49X: G/G High Tumor Burden 0.75(0.57, 0.99)

108/147 234  98/149 366 296 PSMB2/G187V: G/G High Tumor Burden 0.75(0.57, 0.99)

108/147 234  98/149 366 296 PSMB2/L159F: C/C High Tumor Burden 0.75(0.57, 0.99)

108/147 234  98/149 366 296 PSMB5/L206M: C/C High Tumor Burden 0.75(0.57, 0.99)

108/147 234  98/149 366 296 PSMB5/R24C: C/T High Tumor Burden 0.48(0.25, 0.93)

19/21 148 18/24 391 296 PSMB6/A234D: C/C High Tumor Burden 0.75 (0.57,0.99)

108/147 234  98/149 366 296 PSMB6/P107A: C/C High Tumor Burden 0.76(0.57, 1.00)

104/140 234  97/146 365 296 PSMB8/G8R: G/G High Tumor Burden 0.71 (0.54,0.94)

104/140 218  94/145 390 296 PSMB8/R141C: C/C High Tumor Burden 0.75(0.57, 0.99)

108/147 234  98/149 366 296 PSMB8/V182M: G/G High Tumor Burden 0.75(0.57, 0.99)

108/147 234  98/149 366 296 PSMB9/G9E: G/G High Tumor Burden 0.75 (0.57,0.99)

107/147 234  98/148 365 296 PSMB9/V32I: C/C High Tumor Burden 0.74(0.56, 0.98)

106/142 234  94/142 366 296 PSMB1/A171S: G/G >1 year since last anti-lymphoma treatment 0.71 (0.53, 0.95)

 98/165 547  80/166 800 331 PSMB1/I208N: T/T >1 year since last anti-lymphoma treatment 0.71 (0.53, 0.95)

 98/165 547  80/166 800 331 PSMB1/P193L: C/C >1 year since last anti-lymphoma treatment 0.71 (0.53, 0.95)

 98/165 547  80/166 800 331 PSMB2/E49X: G/G >1 year since last anti-lymphoma treatment 0.71 (0.53, 0.95)

 98/165 547  80/166 800 331 PSMB2/G187V: G/G >1 year since last anti-lymphoma treatment 0.71 (0.53, 0.95)

 98/165 547  80/166 800 331 PSMB2/L159F: C/C >1 year since last anti-lymphoma treatment 0.71 (0.53, 0.95)

 98/165 547  80/166 800 331 PSMB5/L206M: C/C >1 year since last anti-lymphoma treatment 0.71 (0.53, 0.95)

 98/165 547  80/166 800 331 PSMB5/R24C: C/C >1 year since last anti-lymphoma treatment 0.72 (0.52, 1.00)

 81/137 507  68/141 843 331 PSMB6/A234D: C/C >1 year since last anti-lymphoma treatment 0.71 (0.53, 0.95)

 98/165 547  80/166 800 331 PSMB6/P107A: C/C >1 year since last anti-lymphoma treatment 0.72 (0.53, 0.97)

 95/159 561  79/162 800 331 PSMB8/G8R: G/G >1 year since last anti-lymphoma treatment 0.71 (0.52, 0.96)

 91/155 562  74/159 843 331 PSMB8/R141C: C/C >1 year since last anti-lymphoma treatment 0.71 (0.53, 0.95)

 98/165 547  80/166 800 331 PSMB8/V182M: G/G >1 year since last anti-lymphoma treatment 0.71 (0.53, 0.95)

 98/165 547  80/166 800 331 PSMB9/G9E: G/G >1 year since last anti-lymphoma treatment 0.71 (0.53, 0.95)

 97/163 547  80/165 800 331 PSMB9/V32I: C/C >1 year since last anti-lymphoma treatment 0.70 (0.51, 0.94)

 96/160 507  76/158 800 331 PSMB1/P11A: C/G European Union 0.56 (0.34,0.93)

34/49 309 29/51 844 241 PSMB1/A171S: G/G ≦65 years old 0.74 (0.57, 0.95)

130/198 344 112/194 557 392 PSMB1/I208N: T/T ≦65 years old 0.74 (0.57,0.95)

130/198 344 112/194 557 392 PSMB1/P11A: C/G ≦65 years old 0.63 (0.43,0.92)

63/96 406 47/86 603 392 PSMB1/P11A: G/G ≦65 years old 0.42 (0.22, 0.81)

21/25 269 16/30 671 392 PSMB1/P193L: C/C ≦65 years old 0.74 (0.57, 0.95)

130/198 344 112/194 557 392 PSMB2/E49X: G/G ≦65 years old 0.74 (0.57,0.95)

130/198 344 112/194 557 392 PSMB2/G187V: G/G ≦65 years old 0.74 (0.57,0.95)

130/198 344 112/194 557 392 PSMB2/L159F: C/C ≦65 years old 0.74 (0.57,0.95)

130/198 344 112/194 557 392 PSMB5/L206M: C/C ≦65 years old 0.74 (0.57,0.95)

130/198 344 112/194 557 392 PSMB5/R24C: C/C ≦65 years old 0.73 (0.56,0.96)

113/170 344  97/167 581 392 PSMB6/A234D: C/C ≦65 years old 0.74 (0.57,0.95)

130/198 344 112/194 557 392 PSMB6/P107A: C/C ≦65 years old 0.74 (0.57,0.96)

125/189 363 110/190 554 392 PSMB8/G8R: G/G ≦65 years old 0.74 (0.57,0.96)

123/189 344 106/186 581 392 PSMB8/R141C: C/C ≦65 years old 0.74 (0.57,0.95)

130/198 344 112/194 557 392 PSMB8/V182M: G/G ≦65 years old 0.74 (0.57,0.95)

130/198 344 112/194 557 392 PSMB9/G9E: G/G ≦65 years old 0.74 (0.57,0.95)

129/196 344 112/193 557 392 PSMB9/V32I: C/C ≦65 years old 0.74 (0.57,0.96)

127/192 344 107/186 554 392 PSMB1/P11A: C/G Female 0.59 (0.37, 0.95)

42/75 406 30/66 924 301 PSMB9/R60H: A/G Male 0.45 (0.25, 0.79)

22/28 234 30/48 603 241 PSMB1/P11A: C/G Other 0.09 (0.01, 1.06)

2/3 76 6/9 394 27 PSMB1/P11A: C/G White 0.69 (0.48, 0.99)

 67/111 432 54/97 818 473 PSMB1/P11A: G/G White 0.57 (0.33, 0.98)

27/32 272 25/39 449 473 PSMB1/P11A: C/G Ann Arbor Stage III 0.53 (0.28,0.98)

29/44 206 16/28 818 172

APPENDIX 2 Table 2.15: Treatment-Free Interval by Somatic Mutation andby Covariate, IRC Review. (All Reported Groups are Significant (p ≦0.05) and at a Frequency of ≧10%) Marker: Sub- HR (95% R R Vc-R Vc-Rgroup Marker: Level Subgroup CI) HR (log scale) Evt/N Median Evt/NMedian N Total BCL2/A43G: MND No Subgroup 0.67 (0.50, 0.90)

104/161 344 84/154  649 315 BCL2/C.-11C > T: MND No Subgroup 0.72 (0.56,0.94)

127/192 361 102/179  587 390 BCL2/E29K: MND No Subgroup 0.65 (0.48,0.87)

 98/150 343  77/139  649 318 BCL2/P46L: MND No Subgroup 0.72 (0.53,0.98)

 86/135 362  77/139  595 314 BCL2/P59S: MND No Subgroup 0.73 (0.54,0.99)

 92/145 362  84/147  629 309 BCL2/Q52P: MND No Subgroup 0.73 (0.55,0.97)

 97/153 361  88/154  629 307 BCL2/R106H: MND No Subgroup 0.68 (0.51,0.90)

108/162 344  84/151  629 372 NOTCH/G_A1702P: MND No Subgroup 0.74 (0.57,0.98)

113/175 361  93/161  589 337 NOTCH/I1681N: MND No Subgroup 0.75 (0.57,0.99)

113/175 361  94/162  587 337 NOTCH/L1679P: MND No Subgroup 0.75 (0.57,0.99)

113/175 361  94/162  587 337 NOTCH/L1679Q: MND No Subgroup 0.75 (0.57,0.99)

113/175 361  94/162  587 337 NOTCH/P2513L: MND No Subgroup 0.71 (0.52,0.97)

 90/140 360  67/123  649 361 NOTCH/P2515FS4: MND No Subgroup 0.71 (0.54,0.94)

114/176 361  92/166  629 344 NOTCH/Q2460X: MND No Subgroup 0.74 (0.55,0.99)

 98/151 344  82/143  589 324 NOTCH/X26DEL: MND No Subgroup 0.76 (0.58,0.99)

112/175 363 102/178  595 361 NOTCH/X26INS: MND No Subgroup 0.75 (0.58,0.99)

114/179 363 103/180  595 361 NOTCH/X28DEL: MND No Subgroup 0.74 (0.57,0.96)

128/194 361 109/189  583 400 NOTCH/X28INS: MND No Subgroup 0.72 (0.56,0.93)

132/198 361 112/195  583 401 BCL2/A43G: MND 1 Prior Line of Therapy 0.55(0.35, 0.88)

46/72 409 30/67  907 139 BCL2/C.-11C > T: MND 1 Prior Line of Therapy0.63 (0.42, 0.95)

57/86 427 38/78  827 170 BCL2/E29K: MND 1 Prior Line of Therapy 0.56(0.34, 0.90)

41/64 406 29/62  828 139 BCL2/P46L: MND 1 Prior Line of Therapy 0.61(0.38, 1.00)

37/58 449 30/63  828 140 BCL2/P46S: MND 1 Prior Line of Therapy 0.62(0.39, 0.99)

40/64 409 33/68  828 138 BCL2/Q52P: MND 1 Prior Line of Therapy 0.63(0.40, 0.99)

42/67 409 35/71  827 138 BCL2/R106H: MND 1 Prior Line of Therapy 0.59(0.38, 0.92)

49/73 409 33/68  828 162 NOTCH/P2515FS4: MND 1 Prior Line of Therapy0.64 (0.41, 0.99)

48/75 432 35/72  827 149 NOTCH/X28INS: MND 1 Prior Line of Therapy 0.65(0.44, 0.96)

56/84 427 45/88  673 178 BCL2/A43G: MND No High Tumor Burden 0.61 (0.38,1.00)

42/78 632 27/64 — 142 BCL2/R106H: MND No High Tumor Burden 0.61 (0.38,0.99)

46/79 549 26/58 1023 163 NOTCH/P2513L: MD No High Tumor Burden 0.45(0.20, 1.01)

17/26 452  9/21 — 163 NOTCH/X28INS: MND No High Tumor Burden 0.64 (0.42,0.98)

55/98 592 37/82  924 184 BCL2/A43G: MND High Tumor Burden 0.62 (0.43,0.89)

62/83 234 57/90  379 173 BCL2/C.-11C > T: MND High Tumor Burden 0.68(0.49, 0.94)

 76/101 234  69/107  326 217 BCL2/E29K: MND High Tumor Burden 0.57(0.40, 0.84)

60/79 234 52/82  392 174 BCL2/P46L: MND High Tumor Burden 0.59 (0.40,0.87)

51/67 234 51/83  379 173 BCL2/P46S: MND High Tumor Burden 0.64 (0.44,0.94)

52/73 234 56/89  337 170 BCL2/P59L: MND High Tumor Burden 0.67 (0.45,0.99)

52/72 254 50/80  318 172 BCL2/P59S: MND High Tumor Burden 0.63 (0.43,0.93)

53/73 254 54/87  379 170 BCL2/Q52P: MND High Tumor Burden 0.63 (0.44,0.92)

55/76 234 58/92  379 168 BCL2/R106H: MND High Tumor Burden 0.61 (0.43,0.88)

62/83 234 58/93  392 209 NOTCH/G_A1702P: MND High Tumor Burden 0.64(0.45, 0.91)

67/90 234 62/96  379 187 NOTCH/I1681N: MND High Tumor Burden 0.65 (0.46,0.92)

67/90 234 63/97  379 187 NOTCH/L1586Q: MND High Tumor Burden 0.67 (0.47,0.97)

56/78 254 60/94  379 172 NOTCH/L1597H: MND High Tumor Burden 0.67 (0.47,0.97)

56/78 254 60/94  379 172 NOTCH/L1679P: MND High Tumor Burden 0.65 (0.46,0.92)

67/90 234 63/97  379 187 NOTCH/L1679Q: MND High Tumor Burden 0.65 (0.46,0.92)

67/90 234 63/97  379 187 NOTCH/L2458V: MND High Tumor Burden 0.66 (0.46,0.94)

61/83 234 61/95  379 178 NOTCH/P2513L: MND High Tumor Burden 0.56 (0.37,0.83)

58/76 234 43/71  392 198 NOTCH/P2515FS4: MND High Tumor Burden 0.63(0.45, 0.90)

67/90 234 61/98  379 189 NOTCH/Q2441X: MND High Tumor Burden 0.66 (0.46,0.94)

61/83 234 61/95  379 178 NOTCH/Q2460X: MND High Tumor Burden 0.63 (0.43,0.91)

59/79 234 54/87  392 181 NOTCH/R1599P: MND High Tumor Burden 0.67 (0.47,0.97)

56/78 254 60/94  379 172 NOTCH/V1579E: MND High Tumor Burden 0.67 (0.47,0.97)

56/78 254 60/94  379 172 NOTCH/X26DEL: MND High Tumor Burden 0.69 (0.49,0.98

63/88 254 68/107  379 198 NOTCH/X26INS: MND High Tumor Burden 0.68(0.49, 0.96)

64/89 254 68/107  379 198 NOTCH/X28DEL: MND High Tumor Burden 0.67(0.48, 0.92)

74/99 234  72/111  326 216 NOTCH/X28INS: MND High Tumor Burden 0.67(0.49, 0.92)

 77/100 190  75/113  318 217 BCL2/A43G: MND Intermediate FLIPI Score0.60 (0.36, 1.00)

34/53 362 26/52  778 105 BCL2/C.-11C > T: MND Intermediate FLIPI Score0.60 (0.38, 0.95)

44/66 362 33/63  778 136 BCL2/R106H: MND Intermediate FLIPI Score 0.52(0.32, 0.84)

40/55 361 28/54  671 130 BCL2/E29K: MND No Prior Rituximab Therapy 0.66(0.44, 0.98)

57/93 393 41/76  718 186 BCL2/P59L: MD No Prior Rituximab Therapy 0.17(0.03, 0.91)

3/5 217  7/13  779 178 BCL2/A43G: MND Prior Rituximab Therapy 0.62(0.40, 0.96)

44/63 287 37/69  589 132 BCL2/C.-11C > T: MND Prior Rituximab Therapy0.60 (0.40, 0.89)

57/78 254 43/77  554 165 BCL2/E29K: MND Prior Rituximab Therapy 0.62(0.39, 0.97)

41/57 287 36/63  581 132 BCL2/P59S: MND Prior Rituximab Therapy 0.63(0.40, 0.98)

39/56 307 37/69  589 133 BCL2/R106H: MND Prior Rituximab Therapy 0.57(0.38, 0.88)

50/67 272 39/72  581 159 NOTCH/G_A1702P: MND Prior Rituximab Therapy0.62 (0.41, 0.94)

51/72 288 41/74  589 147 NOTCH/I1681N: MND Prior Rituximab Therapy 0.64(0.42, 0.96)

51/72 288 42/75  581 147 NOTCH/L1679P: MND Prior Rituximab Therapy 0.64(0.42, 0.96)

51/72 288 42/75  581 147 NOTCH/L1679Q: MND Prior Rituximab Therapy 0.64(0.42, 0.96)

51/72 288 42/75  581 147 NOTCH/L2458V: MND Prior Rituximab Therapy 0.63(0.41, 0.96)

47/66 302 42/75  581 141 NOTCH/P2513L: MND Prior Rituximab Therapy 0.59(0.36, 0.98)

39/57 307 25/51  649 154 NOTCH/P2515FS4: MND Prior Rituximab Therapy0.63 (0.42, 0.96)

51/72 288 42/77  581 149 NOTCH/Q2441X: MND Prior Rituximab Therapy 0.63(0.42, 0.97)

47/66 302 42/73  581 141 NOTCH/Q2460X: MND Prior Rituximab Therapy 0.60(0.39, 0.93)

45/62 288 36/66  589 143 NOTCH/X26INS: MND Prior Rituximab Therapy 0.66(0.45, 0.98)

52/74 288 47/84  581 158 NOTCH/X28DEL: MND Prior Rituximab Therapy 0.64(0.43, 0.93)

60/83 280 49/86  554 175 NOTCH/X28INS: MND Prior Rituximab Therapy 0.62(0.43, 0.91)

62/86 280 50/88  554 175 BCL2/A43G: MND >1 year since last anti-lymphoma treatment 0.65 (0.44, 0.96)

57/91 449 44/94  716 185 BCL2/C.-11C > T: MND >1 year since last anti-lymphoma treatment 0.64 (0.45, 0.90)

 73/112 419  55/112  716 233 BCL2/E29K: MND >1 year since last anti-lymphoma treatment 0.60 (0.40, 0.91)

52/82 409 39/83  718 185 BCL2/R106H: MND >1 year since last anti-lymphoma treatment 0.58 (0.40, 0.85)

65/96 392 45/94  716 217 NOTCH/P2513L: MND >1 year since last anti-lymphoma treatment 0.61 (0.40, 0.94)

50/78 419 37/81  716 213 NOTCH/P2515FS4: MND >1 year since last anti-lymphoma treatment 0.66 (0.45, 0.96)

 64/102 452  48/102  716 205 NOTCH/X28INS: MND >1 year since last anti-lymphoma treatment 0.66 (0.47, 0.93)

 73/113 432  59/119  709 237 BCL2/A43G: MND European Union 0.54 (0.34,0.86)

41/66 507 32/72  942 138 BCL2/C.-11C > T: MND European Union 0.58 (0.38,0.87)

53/79 363 41/83  843 169 BCL2/E29K: MND European Union 0.60 (0.37, 0.96)

37/61 393 32/67  907 138 BCL2/P46L: MND European Union 0.59 (0.36, 0.97)

34/56 393 29/64 1023 139 BCL2/P46S: MND European Union 0.60 (0.37, 0.96)

37/61 362 33/68  907 136 BCL2/P59S: MND European Union 0.61 (0.38, 0.97)

36/60 363 34/69  843 136 BCL2/Q52P: MND European Union 0.61 (0.38, 0.96)

38/63 362 36/73  843 136 BCL2/R106H: MND European Union 0.58 (0.37,0.90)

44/65 393 35/70  844 160 NOTCH/G_A1702P: MND European Union 0.62 (0.40,0.96)

44/72 393 36/74  843 147 NOTCH/I1681N: MND European Union 0.64 (0.41,0.99)

44/72 393 37/75  843 147 NOTCH/L1679P: MND European Union 0.64 (0.41,0.99)

44/72 393 37/75  843 147 NOTCH/L1679Q: MND European Union 0.64 (0.41,0.99)

44/72 393 37/75  843 147 NOTCH/P2513L: MND European Union 0.48 (0.28,0.81)

39/59 362 22/52  942 159 NOTCH/P2515FS4: MND European Union 0.59 (0.38,0.91)

48/77 393 36/77  907 155 NOTCH/X26INS: MND European Union 0.64 (0.42,0.98)

46/74 411 42/84  844 159 NOTCH/X28DEL: MND European Union 0.63 (0.42,0.94)

53/82 393 45/87  843 177 NOTCH/X28INS: MND European Union 0.62 (0.42,0.91)

56/85 393 46/89  843 177 BCL2/A43G: MND ≦65 years old 0.67 (0.48, 0.93)

 84/124 343  65/115  595 239 BCL2/C.-11C > T: MND ≦65 years old 0.72(0.54, 0.96)

101/147 341  81/135  554 296 BCLW/E29K: MND ≦65 years old 0.61 (0.44,0.86)

 81/117 307  58/103  649 241 BCL2/P46L: MND ≦65 years old 0.70 (0.49,0.99)

 71 /105 344  59/104  589 238 BCL2/Q52P: MND ≦65 years old 0.72 (0.52,1.00)

 78/117 344  69/117  589 234 BCL2/R106H: MND ≦65 years old 0.62 (0.44,0.86)

 86/124 309  61/112  649 281 NOTCH/G_A1702P: MND ≦65 years old 0.71(0.52, 0.96)

 91/133 309  71/121  587 255 NOTCH/I1681N: MND ≦65 years old 0.72 (0.52,0.98)

 91/133 309  72/122  581 255 NOTCH/L1679P: MND ≦65 years old 0.72 (0.52,0.98)

 91/133 309  72/122  581 255 NOTCH/L1679Q: MND ≦65 years old 0.72 (0.52,0.98)

 91/133 309  72/122  581 255 NOTCH/L2458V: MND ≦65 years old 0.73 (0,53,1.00)

 82/120 309  70/117  581 237 NOTCH/P2513L: MND ≦65 years old 0.63 (0.44,0.91)

 74/107 309 50/90  649 269 NOTCH/P2515FS4: MND ≦65 years old 0.68 (0.50,0.93)

 92/134 341  70/123  589 259 NOTCH/Q2460X: MND ≦65 years old 0.69 (0.49,0.96)

 77/110 307  61/104  581 259 NOTCH/X26DEL: MND ≦65 years old 0.71 (0.53,0.97)

 92/137 344  76/132  595 273 NOTCH/X26INS: MND ≦65 years old 0.72 (0.53,0.97)

 93/138 344  77/133  589 273 NOTCH/X28DEL: MND ≦65 years old 0.69 0.52,0.93)

104/149 309  83/140  581 298 NOTCH/X28INS: MND ≦65 years old 0.68 (0.51,0.91)

106/149 309  85/143  554 298 BCL2/P46L: MND Female 0.62 (0.40, 0.98)

51/86 393 31/68 1023 180 BCL2/A43G: MND Male 0.56 (0.37, 0.84)

45/59 215 47/76  587 135 BCL2/C.-11C > T: MND Male 0.63 (0.44, 0.92)

57/77 234 58/93  534 182 BCL2/E29K: MND Male 0.52 (0.34, 0.79)

43/55 190 43/68  587 138 BCL2/P46L: MD Male 0.11 (0.02, 0.63)

4/4 244 6/10  716 134 BCL2/Q52P: MND Male 0.64 (0.42, 0.98)

39/53 254 50/78  543 131 BCL2/R106H: MND Male 0.62 (0.42, 0.93)

50/66 254 49/81  543 169 NOTCH/G_A1702P: MND Male 0.61 (0.41, 0.91)

47/63 190 51/81  581 145 NOTCH/I1681N: MND Male 0.62 (0.42, 0.92)

47/63 190 52/82  543 145 NOTCH/L1679P: MND Male 0.62 (0.42, 0.92)

47/63 190 52/82  543 145 NOTCH/L1679Q: MND Male 0.62 (0.42, 0.92)

47/63 190 52/82  543 145 NOTCH/L2458V: MND Male 0.62 (0.41, 0.93)

44/59 190 51/80  543 139 NOTCH/P2513L: MND Male 0.54 (0.35, 0.85)

41/54 190 37/63  629 155 NOTCH/P2515FS4: MND Male 0.58 (0.39, 0.87)

47/62 234 51/84  587 148 NOTCH/Q2441X: MND Male 0.62 (0.41, 0.93)

44/59 190 51/79  543 139 NOTCH/Q2460X: MD Male 0.14 (0.03, 0.71)

. 3/3 55  8/12  504 142 NOTCH/Q2460X: MND Male 0.62 (0.40, 0.95)

42/57 190 43/70  581 142 NOTCH/X26DEL: MND Male 0.59 (0.40, 0.87)

49/65 254 58/95  583 162 NOTCH/X26INS: MND Male 0.57 (0.39, 0.84)

50/66 234 58/95  583 162 NOTCH/X28DEL: MND Male 0.65 (0.45, 0.94)

56/75 254 61/97  543 180 NOTCH/X28INS: MND Male 0.64 (0.45, 0.91)

59/78 234  63/100  534 181 BCL2/A43G: MND White 0.68 (0.50, 0.93)

 89/140 361  76/139  671 279 BCL2/C.-11C T: MND White 0.72 (0.54, 0.95)

110/168 362  90/158  589 342 BCL2/E29K: MND White 0.64 (0.47, 0.88)

 83/129 344  70/127  671 282 BCL2/P46L: MND White 0.70 (0.50, 0.97)

 74/117 363  68/125  649 279 BCL2/P46S: MND White 0.71 (0.52, 0.98)

 81/130 363  74/131  671 275 BCL2/P59S: MND White 0.70 (0.51, 0.96)

 81/128 363  73/130  671 274 BCL2/Q52P: MND White 0.70 (0.51, 0.96)

 85/135 362  77/137  671 272 BCL2/R106H: MND White 0.70 (0.51, 0.94)

 93/140 361  77/135  629 327 NOTCH/G_A1702P: MND White 0.73 (0.55, 0.99)

 97/152 362  82/143  629 295 NOTCH/I1681N: MND White 0.73 (0.55, 0.99)

 97/152 362  82/143  629 295 NOTCH/L1679P: MND White 0.73 (0.55, 0.99)

 97/152 362  82/143  629 295 NOTCH/L1679Q: MND White 0.73 (0.55, 0.99)

 97/152 362  82/143  629 295 NOTCH/P2513L: MND White 0.69 (0.49, 0.96)

 78/122 362  59/108  673 319 NOTCH/P2515FS4: MND White 0.69 (0.51, 0.93)

 99/154 363  81/148  671 304 NOTCH/Q2460X: MND White 0.71 (0.52, 0.98)

 85/131 361  73/127  589 284 NOTCH/X26DEL: MND White 0.75 (0.56, 0.99)

 99/155 363  91/158  649 321 NOTCH/X26INS: MND White 0.74 (0.56, 0.98)

101/159 392  92/160  649 321 NOTCH/X28DEL: MND White 0.75 (0.57, 0.98)

111/169 362  98/167  587 351 NOTCH/X28INS: MND White 0.72 (0.55, 0.94)

115/174 362  99/171  589 352 BCL2/A43G: MND Ann Arbor Stage IV 0.62(0.41, 0.93)

48/71 309 42/83  495 154 BCL2/C.-11C > T: MND Ann Arbor Stage IV 0.66(0.46, 0.95)

60/84 309  54/100  471 193 BCL2/E29K: MND Ann Arbor Stage IV 0.60 (0.39,0.93)

46/67 307 37/73  490 154 BCL2/P59L: MD Ann Arbor Stage IV 0.19 (0.03,1.00)

3/5 145  8/12  562 149 BCL2/R106H: MND Ann Arbor Stage IV 0.60 (0.40,0.91)

50/72 307 42/83  490 186 NOTCH/G_A1702P: MND Ann Arbor Stage IV 0.62(0.42, 0.93)

52/75 287 47/87  487 163 NOTCH/I1681N: MND Ann Arbor Stage IV 0.64(0.43, 0.94)

52/75 287 48/88  487 163 NOTCH/L1679P: MND Ann Arbor Stage IV 0.64(0.43, 0.94)

52/75 287 48/88  487 163 NOTCH/L1679Q: MND Ann Arbor Stage IV 0.64(0.43, 0.94)

52/75 287 48/88  487 163 NOTCH/L2458V: MND Ann Arbor Stage IV 0.65(0.43, 0.98)

46/68 293 46/86  490 154 NOTCH/P2513L: MND Ann Arbor Stage IV 0.57(0.36, 0.90)

42/61 307 34/69  629 176 NOTCH/P2515FS4: MND Ann Arbor Stage IV 0.60(0.40, 0.90)

51/74 293 46/91  495 167 NOTCH/Q2441X: MND Ann Arbor Stage IV 0.65(0.43, 0.98)

46/68 293 46/85  490 154 NOTCH/Q2460X: MND Ann Arbor Stage IV 0.63(0.41, 0.96)

43/64 307 41/79  495 156 NOTCH/X26DEL: MND Ann Arbor Stage IV 0.65(0.45, 0.95)

53/76 317  54/101  490 180 NOTCH/X26INS: MND Ann Arbor Stage IV 0.65(0.44, 0.94)

54/79 309  54/101  490 180 NOTCH/X28DEL: MND Ann Arbor Stage IV 0.66(0.46, 0.94)

61/85 307  56/103  483 195 NOTCH/X28INS: MND Ann Arbor Stage IV 0.62(0.43, 0.89)

64/87 293  57/105  183 196

APPENDIX 3 Pair-Wise Combinations of Markers

The following table outlines the data for all significant pair-wisecombinations.Note: Selected=Biomarker positive, Not Selected=Biomarker negative

APPENDIX 3, TABLE 3.1 Significant Pair-Wise Combinations Median MedianOS N N PFS OS Log- Marker Marker Marker Marker N N Un- (Vc-R % (Vc-R PFS% PFS PFS (Vc-R rank A Marker A B Marker B Com- Se- Ex- eval- vs of vsDiffer- Differ- Logrank PFS vs P- Type A Level Type B Level binationlected cluded uable R) ITT R) ence ence P-value HR R) value OS HR B_DPSMB1/ C/G Protein CD68 0-50 Selected 118 238 319 N: % in 506d 229(82.7% P- HR = NAd 0.0550 0.426 NA P11A POSITIVE 57 ITT: vs improve-value = 0.407 vs (0.174- FOLLICULAR vs 17.5% 277d ment) 1e−04 (0.266-NAd 1.046) 61 0.639) B_D PSMB1/ C/G Protein CD68 0-50 Excluded 118 238319 N: % in 380d −1 (−0.3% P- HR = NAd 0.9645 1.011 NA P11A POSITIVE 118ITT: vs improve- value = 1.04 vs (0.617- FOLLICULAR vs 35.3% 381d ment)0.8097 (0.759- NAd 1.658) 120 1.425) B_D PSMB1/ C/G Protein CD68 0-50Total 118 238 319 N: % in 414d 69 (20% P- HR = NAd 0.3270 0.808 NA P11APOSITIVE 175 ITT: vs improve- value = 0.801 vs (0.527- FOLLICULAR vs52.7% 345d ment) 0.0855 (0.621- NAd 1.239) 181 1.032) B_D PSMB5/ C/TProtein P65 INTENSITY <=1+ Selected 12 425 238 N: % in 827d 512.5 (163%P- HR = NAd 0.3026 0.333 NA R24C CYTOPLASMIC 5 ITT: vs improve- value =0.149 vs (0.037- SIGNAL vs 1.8% 314.5d ment) 0.0439 (0.018- 717d 2.994)7 1.253) B_D PSMB5/ C/T Protein P65 <=1+ Excluded 12 425 238 N: % in406d 68 (20.1% P- HR = NAd 0.9151 0.979 NA R24C INTENSITY 208 ITT: vsimprove- value = 0.803 vs (0.663- CYTOPLASMIC vs 63% 338d ment) 0.0641(0.637- NAd 1.446) SIGNAL 217 vs 1.013) B_D PSMB5/ C/T Protein P65 <=1+Total 12 425 238 N: % in 414d 76 (22.5% P- HR = NAd 0.7048 0.929 NA R24CINTENSITY 213 ITT: vs improve- value = 0.782 vs (0.634- CYTOPLASMIC vs64.7% 338d ment) 0.0354 (0.622- Nad 1.36) SIGNAL 224 0.984) B_D PSMB1/C/G Protein 20S % 95-100 Selected 100 330 245 N: % in 576d 288 (100% P-HR = NAd 0.0949 0.516 NA P11A POSITIVE 50 ITT: vs improve- value = 0.543vs (0.234- CYTOPLASMIC vs 14.8% 288d ment) 0.0145 (0.33- NAd 1.138)SIGNAL 50 0.894) B_D PSMB1/ C/G Protein 20S % 95-100 Excluded 100 330245 N: % in 355d 9 (2.6% P- HR= NAd 0.5966 1.127 NA P11A POSITIVE 159ITT: vs impove- value = 0.882 vs (0.723- CYTOPLASMIC vs 48.9% 346d ment)0.3458 (0.679- NAd 1.758) SIGNAL 171 1.145) B_D PSMB1/ C/G Protein 20S %95-100 Total 100 330 245 N: % in 406d 61 (17.7% P- HR = NAd 0.7080 0.929NA P11A POSITIVE 209 ITT: vs improve- value = 0.785 vs (0.632-CYTOPLASMIC vs 63.7% 345d ment) 0.0397 (0.624- NAd 1.365) SIGNAL 2210.989) Clinical PRIORTX 1 Protein CD68 0-50 Selected 132 254 289 N: % in553d 271 (96.1% P- HR = NAd 0.3616 0.675 POSITIVE 63 ITT: vs improve-value = 0.567 vs (0.288- FOLLICULAR vs 19.6% 282d ment) 0.0129 (0.36-NAd 1.58) 69 0.893) Clinical PRIORTX 1 Protein CD68 0-50 Excluded 132254 289 N: % in 346d −2 (−0.6% P- HR = NAd 0.6993 0.91 POSITIVE 127 ITT:vs improve- value = 1 vs (0.566- FOLLICULAR vs 37.6% 348d ment) 0.9957(0.746- NAd 1.466) 127 1.339) Clinical PRIORTX 1 Protein CD68 0-50 Total132 254 289 N: % in 396d 50 (14.5% P- HR = NAd 0.4068 0.839 POSITIVE 190ITT: vs improve- value = 0.846 vs (0.554- FOLLICULAR vs 57.2% 346d ment)0.1781 (0.663- NAd 1.27) 196 1.08) B_D PSMB1/ C/G Clinical TLAST >1Selected 146 396 133 N: % in 554d 232 (72% P- HR = NAd 0.8289 1.091 NAP11A year 72 ITT: vs improve- value = 0.615 vs (0.498- vs 21.6% 322dment) 0.0198 (0.407- NAd 2.391) 74 0.929) B_D PSMB1/ C/G ClinicalTLAST >1 Excluded 146 396 133 N: % in 352d 7 (2% P- HR = NAd 0.94301.014 NA P11A year 194 ITT: vs improve- value = 0.923 vs (0.694- vs58.7% 345d ment) 0.512 (0.726- NAd 1.482) 202 1.174) B_D PSMB1/ C/GClinical TLAST >1 Total 146 396 133 N: % in 414d 69 (20% P- HR = NAd0.8540 1.033 NA P11A year 266 ITT: vs improve- value = 0.828 vs (0.734-vs 80.3% 345d ment) 0.0744 (0.673- NAd 1.453) 276 1.019) ClinicalRACEGRP OTHER Protein 20S% 30-90 Selected 18 445 212 N: % in 346d 232(203.5% P- HR = 928d 0.7517 1.309 NUCLEAR 11 ITT: vs improve- value =0.272 vs (0.246- STAINING vs 2.7% 114d ment) 0.032 (0.077- NAd 6.958) 70.963) Clinical RACEGRP OTHER Protein 20S % 30-90 Excluded 18 445 212 N:% in 396d 49 (14.1% P- HR = NAd 0.5139 0.879 NUCLEAR 214 ITT: vsimprove- value = 0.836 vs (0.598- STAINING vs 65.9% 347d ment) 0.1229(0.665- NAd 1.293) 231 1.05) Clinical RACEGRP OTHER Protein 20S % 30-90Total 18 445 212 N: % in 367d 22 (6.4% P- HR = NAd 0.6640 0.921 NUCLEAR225 ITT: vs improve- value = 0.83 vs (0.634- STAINING vs 68.6% 345dment) 0.1 (0.665- NAd 1.336) 238 1.037) B_D PSMB1/ C/G Protein CD68 >50Selected 52 302 321 N: % in 506d 226 (80.7% P- HR = NAd 0.3998 0.648 NAP11A POSITIVE 24 ITT: vs improve- value = 0.484 vs (0.235- PERI- vs 7.7%280d ment) 0.0365 (0.241- 1175d 1.791) FOLLICUIAR 28 0.971) B_D PSMB1/C/G Protein CD68 >50 Excluded 52 302 321 N: % in 414d 67 (19.3% P- HR =NAd 0.5170 0.855 NA P11A POSITIVE 150 ITT: vs improve- value = 0.862 vs(0.533- PERI- vs 44.7% 347d ment) 0.2937 (0.653- NAd 1.373) FOLLICULAR152 1.138) B_D PSMB1/ C/G Protein CD68 >50 Total 52 302 321 N: % in 417d72 (20.9% P- HR = NAd 0.3311 0.809 NA P11A POSITIVE 174 ITT: vs improve-value = 0.8 vs (0.528- PERI- vs 52.4% 345d ment) 0.0849 (0.619- NAd1.241) FOLLICUIAR 180 1.032) Clinical HITUBD NO Protein CD68 0-50Selected 132 309 234 N: % in 693d 207 (42.6% P- HR = NAd 0.0204 0.316OVERALL 64 ITT: vs improve- value = 0.576 vs (0.113- POSITIVE vs 19.6%486d ment) 0.0177 (0.363- NAd 0.882) 68 0.915) Clinical HITUBD NOProtein CD68 0-50 Excluded 132 309 234 N: % in 346d 59 (20.6% P- HR =NAd 0.6702 1.096 OVERALL 153 ITT: vs improve- value = 0.927 vs (0.718-POSITIVE vs 45.8% 287d ment) 0.5759 (0.712- NAd 1.674) 156 1.207)Clinical HITUBD NO Protein CD68 0-50 Total 132 309 234 N: % in 360d 15(4.2999- P- HR = NAd 0.5387 0.887 OVERALL 217 ITT: vs 999999- value =0.819 vs (0.604- POSITIVE vs 65.3% 345d 9999% 0.0864 (0.652- NAd 1.301)224 improve- 1.029) ment) B_D PSMB9/ G/G Protein P65% >0 Selected 63 374238 N: % in 491d 203 (70.5% P- HR = NAd 0.3042 0.578 NA R60H NUCLEAR 35ITT: vs improve- value = 0.511 vs (0.2- STAINING vs 9.3% 288d ment)0.0303 (0.275- NAd 1.667) 28 0.952) B_D PSMB9/ G/G Protein P65% >0Excluded 63 374 238 N: % in 367d 22 (6.4% P- HR = NAd 0.9516 1.013 NAR60H NUCLEAR 178 ITT: vs improve- value = 0.85 vs (0.673- STAINING vs55.4% 345d ment) 0.1982 (0.664- NAd 1.525) 196 1.088) B_D PSMB9/ G/GProtein P65% >0 Total 63 374 238 N: % in 414d 76 (22.5% P- HR = NAd0.7048 0.929 NA R60H NUCLEAR 213 ITT: vs improve- value = 0.782 vs(0.634- STAINING vs 64.7% 338d ment) 0.0354 (0.622- NAd 1.36) 224 0.984)Clinical HITUBD NO Protein CD68 0-50 Selected 130 256 289 N: % in 624d203 (48.2% P- HR = NAd 0.0222 0.288 POSITIVE 64 ITT: vs improve- value =0.604 vs (0.092- FOLLICULAR vs 19.3% 421d ment) 0.031 (0.38- NAd 0.896)66 096) Clinical HITUBD NO Protein CD68 0-50 Excluded 130 256 289 N: %in 346d 63 (22.3% P- HR = NAd 0.8758 1.037 POSITIVE 126 ITT: vs improve-value = 0.974 vs (0.657- FOLLICULAR vs 37.9% 283d ment) 0.8569 (0.729-NAd 1.636) 130 1.3) Clinical HITUBD NO Protein CD68 0-50 Total 130 256289 N: % in 396d 50 (14.5% P- HR = NAd 0.4068 0.839 POSITIVE 190 ITT: vsimprove- value = 0.846 vs (0.554- FOLLICULAR vs 57.2% 346d ment) 0.1781(0.663- NAd 127) 196 1.08) Clinical PRITUX NO Protein CD68 0-50 Selected159 227 289 N: % in 483d 202 (71.9% P- HR = NAd 0.0713 0.53 POSITIVE 73ITT: vs improve- value = 0.586 vs (0.262- FOLLICULAR vs 23.6% 281d ment)0.0066 (0.397- NAd 1.069) 86 0.866) Clinical PRITUX NO Protein CD68 0-50Excluded 159 227 289 N: % in 346d −3 (−0.9% P- HR = NAd 0.6426 1.134POSITIVE 117 ITT: vs improve- value = 1.079 vs (0.667- FOLLICULAR vs33.6% 349d ment) 0.6451 (0.782- NAd 1.928) 110 1.487) Clinical PRITUX NOProtein CD68 0-50 Total 159 227 289 N: % in 396d 50 (14.5% P- HR = NAd0.4068 0.839 POSITIVE 190 ITT: vs improve- value = 0.846 vs (0.554-FOLLICULAR vs 57.2% 346d ment) 0.1781 (0.663- NAd 1.27) 196 1.08) B_DPSMB5/ C/T Protein CD68 0-50 Selected 39 317 319 N: % in 417d 197 (89.5%P- HR = NAd 0.0557 0.247 NA R24C POSITIVE 18 ITT: vs improve- value =0.415 vs (0.052- FOLLICULAR vs 5.8% 220d ment) 0.022 (0.19- NAd 1.165)21 0.903) B_D PSMB5/ C/T Protein CD68 0-50 Excluded 39 317 319 N: % in414d 66 (19% P- HR = NAd 0.7320 0.924 NA R24C POSITIVE 157 ITT: vsimprove- value = 0.849 vs (0.587- FOLLICULAR vs 47% 348d ment) 0.2328(0.648- NAd 1.454) 160 1.112) B_D PSMB5/ C/T Protein CD68 0-50 Total 39317 319 N: % in 414d 69 (20% P- HR = NAd 0.3270 0.808 NA R24C POSITIVE175 ITT: vs improve- value = 0.801 vs (0.527- FOLLICULAR vs 52.7% 345dment) 0.0855 (0.621- NAd 1.239) 18 1.032) B_D PSMB1/ C/G Clinical AGEGRP<=65 Selected 182 360 133 N: % in 464d 185 (66.3% P- HR = NAd 0.56500.822 NA P11A 86 ITT: vs improve- value = 0.605 vs (0.421- vs 27% 279dment) 0.0071 (0.418- NAd 1.605) 96 0.875) B_D PSMB1/ C/G Clinical AGEGRP<=65 Excluded 182 360 133 N: % in 355d 7 (2% P- HR = NAd 0.6392 1.1 NAP11A 180 ITT: vs improve- value = 0.962 vs (0.738- vs 53.3% 348d ment)0.766 (0.748- NAd 1.64) 180 1.238) B_D PSMB1/ C/G Clinical AGEGRP <=65Total 182 360 133 N: % in 414d 69 (20% P- HR = NAd 0.8540 1.033 NA P11A266 ITT: vs improve- value = 0.828 vs 0.734- vs 80.3% 345d ment) 0.0744(0.673- NAd 1.453) 276 1.019) Clinical SEX MALE Protein 20S % 30-90Selected 111 352 212 N: % in 415d 180 (76.6% P- HR = NAd 0.0324 0.482NUCLEAR 63 ITT vs improve- value = 0.534 vs (0.243- STAINING vs 16.4%235d ment) 0.005 (0.342- 1263d 0.955) 48 0.832) Clinical SEX MALEProtein 20S % 30-90 Excluded 111 352 212 N: % in 360d 3 (0.8% P- HR =NAd 0.5157 1.16 NUCLEAR 162 ITT: vs improve- value = 0.903 vs (0.742-STAINING vs 52.1% 357d ment) 0.4394 (0.697- NAd 1.813) 190 1.169)Clinical SEX MALE Protein 20S % 30-90 Total 111 352 212 N: % in 367d 22(6.4% P- HR = NAd 0.6640 0.921 NUCLEAR 225 ITT: vs improve- value = 0.83vs (0.634- STAINING vs 68.6% 345d ment) 0.1 (0.665- NAd 1336) 238 1.037)B_D PSMB1/ G/G B_D PSMB5/ C/T Selected 14 528 133 N: % in 417d 179.5(75.6% P- HR = 1037d 0.6740 0.6 NA P11A NA R24C 7 ITT: vs improve- value= 0.18 vs (0.054- vs 2.1% 237.5d ment) 0.0221 (0.035- NAd 6.662) 70.921) B_D PSMB1/ G/G B_D PSMB5/ C/T Excluded 14 528 133 N: % in 414d 69(20% P- HR = NAd 0.7952 1.047 NA P11A NA R24C 259 ITT: vs improve- value= 0.845 vs (0.741- vs 78.2% 345d ment) 0.1175 (0.685- NAd 1.479) 2691.043) B_D PSMB1/ G/G B_D PSMB5/ C/T Total 14 528 133 N: % in 414d 69(20% P- HR = NAd 0.8540 1.033 NA P11A NA R24C 266 ITT: vs improve- value= 0.828 vs (0.734- vs 80.3% 345d ment) 0.0744 (0.673- NAd 1.453) 2761.019) B_D PSMB1/ C/G Protein P27% 0-70 Selected 110 320 245 N: % in444d 167 (60.3% P- HR = NAd 0.3082 0.67 NA P11A NUCLEI 53 ITT: vsimprove- value = 0.456 vs (0.307- POSITIVE vs 16.3% 277d ment) 7e-04(0.286- NAd 1.459) 57 0.727) B_D PSMB1/ C/G Protein P27% 0-70 Excluded110 320 245 N: % in 360d 12 (3.4% P- HR = NAd 0.9580 0.988 NA P11ANUCLEI 158 ITT: vs improve- value = 0.9 vs (0.637- POSITIVE vs 47.4%348d ment) 0.4399 (0.689- NAd 1.532) 162 1.176) B_D PSMB1/ C/G ProteinP27% 0-70 Total 110 320 245 N: % in 396d 58 (17.2% P- HR = NAd 0.59870.903 NA P11A NUCLEI 211 ITT: vs improve- value = 0.777 vs (0.617-POSITIVE vs 63.7% 338d ment) 0.0319 (0.617- NAd 1.322) 219 0.979) B_DPSMB1/ C/G Protein P27 SIGNAL >=2+ Selected 155 275 245 N: % in 444d 164(58.6% P- HR = NAd 0.3831 0.749 NA P11A INTENSITY 75 ITT: vs improve-value = 0.593 vs (0.391- vs 23% 280d ment) 0.0085 (0.4- NAd 1.436) 800.879) B_D PSMB1/ C/G Protein P27 SIGNAL >=2+ Excluded 155 275 245 N: %in 352d 6 (1.6999- P- HR = NAd 0.9691 0.991 NA P11A INTENSITY 136 ITT:vs 999999- value = 0.897 vs (0.618- vs 40.7% 346d 9999% 0.4562 (0.674-NAd 1.589) 139 improve- 1.194) ment) B_D PSMB1/ C/G Protein P27SIGNAL >=2+ Total 155 275 245 N: % in 396d 58 (17.2% P- HR = NAd 0.59870.903 NA P11A INTENSITY 211 ITT: vs improve- value = 0.777 vs (0.617- vs63.7% 338d ment) 0.0319 (0.617- NAd 1.322) 219 0.979) Clinical TLAST >1year Protein CD68 0-50 Selected 176 210 289 N: % in 519d 162 (45.4% P-HR = NAd 0.2048 0.587 POSITIVE 86 ITT: vs improve- value = 0.633 vs(0.256- FOLLICULAR vs 26.1% 357d ment) 0.0185 (0.431- NAd 1.35) 900.929) Clinical TLAST >1 year Protein CD68 0-50 Excluded 176 210 289 N:% in 346d 58 (20.1% P- HR = NAd 0.7189 0.915 POSITIVE 104 ITT: vsimprove- value = 1.038 vs (0.565- FOLLICULAR vs 31.1% 2S8d ment) 0.8222(0.755- NAd 1.483) 106 1.428) Clinical TLAST >1 year Protein CD68 0-50Total 176 210 289 N: % in 396d 50 (14.5% P- HR = NAd 0.4068 0.839POSITIVE 190 ITT: vs improve- value = 0.846 vs (0.554- FOLLICULAR vs57.2% 346d ment) 0.1781 (0.663- NAd 1.27) 196 1.08) B_D PSMB1/ C/GProtein 20S % 30-90 Selected 108 322 245 N: % in 431d 156 (56.7% P- HR =NAd 0.1377 0.54 NA P11A NUCLEAR 45 ITT: vs improve- value = 0.621 vs(0.236- STAINING vs 16% 275d ment) 0.0428 (0.39- NAd 1.234) 63 0.989)B_D PSMB1/ C/G Protein 20S % 30-90 Excluded 108 322 245 N: % in 380d 34(9.8% P- HR = NAd 0.6667 1.104 NA P11A NUCLEAR 164 ITT: vs improve-value = 0.849 vs (0.704- STAINING vs 47.7% 346d ment) 0.231 (0.65- NAd1.729) 158 1.11) B_D PSMB1/ C/G Protein 20S % 30-90 Total 108 322 245 N:% in 406d 61 (17.7% P- HR = NAd 0.7080 0.929 NA P11A NUCLEAR 209 ITT: vsimprove- value = 0.785 vs (0.632- STAINING vs 63.7% 345d ment) 0.0397(0.624- NAd 1.365) 221 0.989) Clinical AGEGRP <=65 Protein CD68 0-50Selected 215 171 289 N: % in 429d 154 (56% P- HR = NAd 0.1020 0.62POSITIVE 102 ITT: vs improve- value = 0.57 vs (0.348- FOLLICULAR vs31.9% 275d ment) 8e-04 (0.408- NAd 1.105) 113 0.797) Clinical AGEGRP<=65 Protein CD68 0-50 Excluded 215 171 289 N: % in 348d −79 (−18.5% P-HR = NAd 0.5681 1.196 POSITIVE 88 ITT: vs improve- value = 1.383 vs(0.646- FOLLICULAR vs 25.3% 427d ment) 0.0837 (0.955- NAd 2.217) 832.003) Clinical AGEGRP <=65 Protein CD68 0-50 Total 215 171 289 N: % in396d 50 (14.5% P- HR = NAd 0.4068 0.839 POSITIVE 190 ITT: vs improve-value = 0.846 vs (0.554- FOLLICULAR vs 57.2% 346d ment) 0.1781 (0.663-NAd 1.27) 196 1.08) B_D PSMB1/ C/G Protein P65% >90% Selected 157 280238 N: % in 431d 153 (55% P- HR = NAd 0.2892 0.7 NA P11A POSITIVE 75ITT: vs improve- value = 0.574 vs (0.361- CYTOPLASMIC vs 23.3% 278dment) 0.0048 (0.389- NAd 1.358) SIGNAL 82 0.848) B_D PSMB1/ C/G ProteinP65% >90% Excluded 157 280 238 N: % in 355d 7 (2% P- HR = NAd 0.77431.071 NA P11A POSITIVE 138 ITT: vs improve- value = 0.909 vs (0.67-CYTOPLASMIC vs 41.5% 348d ment) 0.513 (0.684- NAd 1.712) SIGNAL 1421.209) B_D PSMB1/ C/G Protein P65% >90% Total 157 280 238 N: % in 414d76 (22.5% P- HR = NAd 0.7048 0.929 NA P11A POSITIVE 213 ITT: vs improve-value = 0.782 vs (0.634- CYTOPLASMIC vs 64.7% 338d ment) 0.0354 (0.622-NAd 1.36) SIGNAL 224 0.984) B_D PSMB9/ A/G Protein 20S % 95-100 Selected89 341 245 N: % in 426d 153 (56% P- HR = NAd 0.2901 0.659 NA R60HPOSITIVE 45 ITT: vs improve- value = 0.544 vs (0.302- CYTOPLASMIC vs13.2% 273d ment) 0.0222 (0.32- NAd 1.436) SIGNAL 44 0.925) B_D PSMB9/A/G Protein 20S % 95-100 Excluded 89 341 245 N: % in 396d 49 (14.1% P-HR = NAd 0.9020 1.028 NA R60H POSITIVE 164 ITT: vs improve- value =0.855 vs (0.659- CYTOPLASMIC vs 50.5% 347d ment) 0.2336 (0.661- NAd1.603) SIGNAL 177 1.106) B_D PSMB9/ A/G Protein 20S % 95-100 Total 89341 245 N: % in 406d 61 (17.7% P- HR = NAd 0.7080 0.929 NA R60H POSITIVE209 ITT: vs improve- value = 0.785 vs (0.632- CYTOPLASMIC vs 63.7% 345dment) 0.0397 (0.624- NAd 1.365) SIGNAL 221 0.989) B_D PSMB1/ C/G Protein20S <=2+ Selected 108 322 245 N: % in 431d 153 (55% P- HR = NAd 0.47100.724 NA P11A INTENSITY 55 ITT: vs improve- value = 0.601 vs (0.3-CYTOPLASMIC vs 16% 278d ment) 0.0269 (0.381- NAd 1.749) SIGNAL 53 0.948)B_D PSMB1/ C/G Protein 20S <=2+ Excluded 108 322 245 N: % in 380d 35(10.1% P- HR = NAd 0.9958 0.999 NA P11A INTENSITY 154 ITT: vs improve-value = 0.852 vs (0.651- CYTOPLASMIC vs 47.7% 345d ment) 0.2403 (0.651-NAd 1.533) SIGNAL 168 1.114) B_D PSMB1/ C/G Protein 20S <=2+ Total 108322 245 N: % in 406d 61 (17.7% P- HR = NAd 0.7080 0.929 NA P11AINTENSITY 209 ITT: vs improve- value = 0.785 vs (0.632- CYTOPLASMIC vs63.7% 345d ment) 0.0397 (0.624- NAd 1.365) SIGNAL 221 0.989) B_D PSMB9/A/G Protein CD68 0-50 Selected 104 252 319 N: % 426d 153 (56% P- HR =NAd 0.1848 0.537 NA R60H POSITIVE 51 ITT: vs improve- value = 0.592 vs(0.211- FOLLICULAR vs 15.4% 273d ment) 0.0339 (0.362- NAd 1.366) 530.968) B_D PSMB9/ A/G Protein CD68 0-50 Excluded 104 252 319 N: % in414d 65 (18.6% P- HR = NAd 0.7690 0.93 NA R60H POSITIVE 124 ITT: vsimprove- value = 0.888 vs (0.574- FOLLICULAR vs 37.3% 349d ment) 0.435(0.659- NAd 1.508) 128 1.197) B_D PSMB9/ A/G Protein CD68 0-50 Total 104252 319 N: % in 414d 69 (20% P- HR = NAd 0.3270 0.808 NA R60H POSITIVE175 ITT: vs improve- value = 0.801 vs (0.527- FOLLICULAR vs 52.7% 345dment) 0.0855 (0.621- NAd 1.239) 181 1.032) B_D PSMB9/ G/G Protein 20S%30-90 Selected 145 285 245 N: % in 431d 151 (53.9% P- HR = NAd 0.27820.702 NA R60H NUCLEAR 74 ITT: vs improve- value = 0.647 vs (0.368-STAINING vs 21.5% 280d ment) 0.0262 (0.439- NAd 1.336) 71 0.953) B_DPSMB9/ G/G Protein 20S % 30-90 Excluded 145 285 245 N: % in 360d 15(4.2999- P- HR = NAd 0.7758 1.073 NA R60H NUCLEAR 135 ITT: vs 999999-value = 0.86 vs (0.661- STAINING vs 42.2% 345d 9999% 0.3045 (0.644- NAd1.741) 150 improve- 1.148) ment) B_D PSMB9/ G/G Protein 20S % 30-90Total 145 285 245 N: % in 406d 61 (17.7% P- HR = NAd 0.7080 0.929 NAR60H NUCLEAR 209 ITT: vs improve- value = 0.785 vs (0.632- STAINING vs63.7% 345d ment) 0.0397 (0.624- NAd 1.365) 221 0.989) Protein CD68 0-50Protein P65% >90% Selected 250 136 289 N: % in 429d 150 (53.8% P- HR =NAd 0.0605 0.593 POSITIVE POSITIVE 114 ITT: vs improve- value = 0.616 vs(0.342- FOLLICULAR CYTOPLASMIC vs 37% 279d ment) 0.0019 (0.452- NAd1.029) SIGNAL 136 0.839) Protein CD68 0-50 Protein P65% >90% Excluded250 136 289 N: % in 324d −162 (−33.3% P- HR = NAd 0.3261 1.408 POSITIVEPOSITIVE 76 ITT: vs improve- value = 1.52 vs (0.709- FOLLICULARCYTOPLASMIC vs 20.1% 486d ment) 0.0545 (0.989- NAd 2.795) SIGNAL 602.335) Protein CD68 0-50 Protein P65% >90% Total 250 136 289 N: % in396d 50 (14.5% P- HR = NAd 0.4068 0.839 POSITIVE POSITIVE 190 ITT: vsimprove- value = 0.846 vs (0.554- FOLLICULAR CYTOPLASMIC vs 57.2% 346dment) 0.1781 (0.663- NAd 1.27) SIGNAL 196 1.08) Clinical AGEGRP <=65Protein CD68 0-50 Selected 177 207 291 N: % in 431d 150 (53.4% P- HR =NAd 0.7612 0.91 POSITIVE 89 ITT: vs improve- value = 0.663 vs (0.496-PERI- vs 26.2% 281d ment) 0.0274 (0.458- NAd 1.67) FOLLICULAR 88 0.959)Clinical AGEGRP <=65 Protein CD68 0-50 Excluded 177 207 291 N: % in 348d−3 (−0.9% P- HR = NAd 0.3903 0.779 POSITIVE 100 ITT: vs improve- value =1.027 vs (0.44- PERI- vs 30.7% 351d ment) 0.874 (0.739- NAd 1.379)FOLLICULAR 107 1.428) Clinical AGEGRP <=65 Protein CD68 0-50 Total 177207 291 N: % in 406d 60 (17.3% P- HR = NAd 0.4116 0.841 POSITIVE 189ITT: vs improve- value = 0.845 vs (0.555- PERI- vs 56.9% 346d ment)0.1772 (0.662- NAd 1.273) FOLLICULAR 195 1.08) Clinical TLAST >1 yearProtein P65% >90% Selected 229 241 205 N: % in 506d 149 (41.7% P- HR =NAd 0.3300 0.713 POSITIVE 112 ITT: vs improve- value = 0.698 vs (0.36-CYTOPLASMIC vs 33.9% 357d ment) 0.0331 (0.5- NAd 1.413) SIGNAL 1170.973) Clinical TLAST >1 year Protein P65% >90% Excluded 229 241 205 N:% in 345d 65 (23.2% P- HR = NAd 0.9927 1.002 POSITIVE 117 ITT: vsimprove- value = 0.941 vs (0.644- CYTOPLASMIC vs 35.7% 280d ment) 0.6849(0.699- NAd 1.557) SIGNAL 124 1.266) Clinical TLAST >1 year ProteinP65% >90% Total 229 241 205 N: % in 367d 22 (6.4% P- HR = NAd 0.66120.921 POSITIVE 229 ITT: vs improve- value = 0.826 vs (0.636- CYTOPLASMICvs 69.6% 345d ment) 0.0902 (0.663- NAd 1.332) SIGNAL 241 1.03) B_DPSMB1/ C/G Protein CD68 0-50 Selected 129 280 266 N: % in 426d 148(53.2% P- HR = NAd 0.2690 0.647 NA P11A OVERALL 64 ITT: vs improve-value = 0.525 vs (0.297- POSITIVE vs 19.1% 278d ment) 0.0025 (0.343- NAd1.409) 65 0.804) B_D PSMB1/ C/G Protein CD68 0-50 Excluded 129 280 266N: % in 355d 7 (2% P- HR = NAd 0.9914 1.002 NA P11A OVERALL 137 ITT: vsimprove- value = 0.894 vs (0.633- POSITIVE vs 41.5% 348d ment) 0.4433(0.672- NAd 1.587) 143 1.191) B_D PSMB1/ C/G Protein CD68 0-50 Total 129280 266 N: % in 396d 51 (14.8% P- HR = NAd 0.5159 0.877 NA P11A OVERALL201 ITT: vs improve- value = 0.768 vs (0.591- POSITIVE vs 60.6% 345dment) 0.0281 (0.606- NAd 1.302) 208 0.973) Protein CD68 0-50 ProteinCD68 0-50 Selected 193 191 291 N: % in 429d 147 (52.1% P- HR = NAd0.0947 0.596 POSITIVE POSITIVE 94 ITT: vs improve- value = 0.625 vs(0.323- FOLLICULAR PERI- vs 28.6% 282d ment) 0.0075 (0.441- NAd 1.101)FOLLICULAR 99 0.885) Protein CD68 0-50 Protein CD68 0-50 Excluded 193191 291 N: % in 344d −7 (−2% P- HR = NAd 0.6374 1.148 POSITIVE POSITIVE95 ITT: vs improve- value = 1.098 vs (0.647- FOLLICULAR PERI- vs 28.3%351d ment) 0.5972 (0.775- NAd 2.036) FOLLICUI.AR 96 1.556) Protein CD680-50 Protein CD68 0-50 Total 193 191 291 N: % in 406d 60 (17.3% P- HR =NAd 0.4116 0.841 POSITIVE POSITIVE 189 ITT: vs improve- value = 0.845 vs(0.555- FOLLICULAR PERI- vs 56.9% 346d ment) 0.1772 (0.662- NAd 1.273)FOLLICULAR 195 1.08) Clinical FLIPI High Protein P27% 0-70 Selected 113350 212 N: % in 358d 146 (68.9% P- HR = 1103d 0.8099 0.934 NUCLEI 53ITT: vs improve- value = 0.588 vs (0.539- POSITIVE vs 16.7% 212d ment)0.0156 (0.381- 1111d 1.619) 60 0.908) Clinical FLIPI High Protein P27%0-70 Excluded 113 350 212 N: % in 406d 55 (15.7% P- HR = NAd 0.55190.859 NUCLEI 174 ITT: vs improve- value = 0.905 vs (0.522- POSITIVE vs51.9% 351d ment) 0.4522 (0.698- NAd 1.416) 176 1.174) Clinical FLIPIHigh Protein P27% 0-70 Total 113 350 212 N: % in 366d 21 (6.1% P- HR =NAd 0.5615 0.896 NUCLEI 227 ITT: vs improve- value = 0.822 vs (0.62-POSITIVE vs 68.6% 345d ment) 0.0844 (0.659- NAd 1.297) 236 1.027)Clinical SEX MALE Protein P65% >90% Selected 169 301 205 N: % in 414d143 (52.8% P- HR = NAd 0.0574 0.571 POSITIVE 97 ITT: vs improve- value =0.622 vs (0.317- CYTOPLASMIC vs 25% 271d ment) 0.0094 (0.433- NAd 1.025)SIGNAL 72 0.894) Clinical SEX MALE Protein P65% >90% Excluded 169 301205 N: % in 355d −20 (−5.3% P- HR = NAd 0.4521 1.2 POSITIVE 132 ITT: vsimprove- value = 0.9 vs (0.746- CYTOPLASMIC vs 44.6% 375d ment) 0.4653(0.678- NAd 1.931) SIGNAL 169 1.194) Clinical SEX MALE Protein P65% >90%Total 169 301 205 N: % in 367d 22 (6.4% P- HR = NAd 0.6612 0.921POSITIVE 229 ITT: vs improve- value = 0.826 vs (0.636- CYTOPLASMIC vs69.6% 345d ment) 0.0902 (0.663- NAd 1.332) SIGNAL 241 1.03) B_D PSMB1/C/G B_D PSMB9/ G/G Selected 150 392 133 N: % in 431d 143 (49.7% P- HR =NAd 0.7239 0.888 NA P11A NA R60H 66 ITT: vs improve- value = 0.65 vs(0.458- vs 22.2% 288d ment) 0.0335 (0.436- NAd 1.722) 84 0.97) B_DPSMB1/ C/G B_D PSMB9/ G/G Excluded 150 392 133 N: % in 380d 34 (9.8% P-HR = NAd 0.6731 1.09 NA P11A NA R60H 200 ITT: vs improve- value = 0.906vs (0.73- vs 58.1% 346d ment) 0.4293 (0.71- NAd 1.629) 192 1.157) B_DPSMB1/ C/G B_D PSMB9/ G/G Total 150 392 133 N: % in 414d 69 (20% P- HR =NAd 0.8540 1.033 NA P11A NA R60H 266 ITT: vs improve- value = 0.828 vs(0.734- vs 80.3% 345d ment) 0.0744 (0.673- NAd 1.453) 276 1.019)Clinical AGEGRP <=65 Protein P27% 0-70 Selected 194 269 212 N: % in 422d143 (51.3% P- HR = NAd 0.8473 0.946 NUCLEI 93 ITT: vs improve- value =0.7 vs (0.54- POSITIVE vs 28.7% 279d ment) 0.0458 (0.493- NAd 1.658) 1010.996) Clinical AGEGRP <=65 Protein P27% 0-70 Excluded 194 269 212 N: %in 352d 4 (1.0999- P- HR = NAd 0.5476 0.86 NUCLEI 134 ITT: vs 999999-value = 0.923 vs (0.526- POSITIVE vs 39.9% 348d 9999% 0.5904 (0.693- NAd1.406) 135 improve- 1.231) ment) Clinical AGEGRP <=65 Protein P27% 0-70Total 194 269 212 N: % in 366d 21 (6.1% P- HR = NAd 0.5615 0.896 NUCLEI227 ITT: vs improve- value = 0.822 vs (0.62- POSITIVE vs 68.6% 345dment) 0.0844 (0.659- NAd 1.297) 236 1.027) Protein 20S % 30-90 Protein20S >=3+ Selected 153 310 212 N: % in 422d 142 (50.7% P- HR = NAd 0.09060.568 NUCLEAR INTENSITY 79 ITT: vs improve- value = 0.681 vs (0.292-STAINING CYTOPLASMIC vs 22.7% 280d ment) 0.0462 (0.467- NAd 1.103)SIGNAL 74 0.994) Protein 20S % 30-90 Protein 20S >=3+ Excluded 153 310212 N: % in 351d 4 (1.2% P- HR = NAd 0.5534 1.148 NUCLEAR INTENSITY 146ITT: vs improve- value = 0.921 vs (0.727- STAINING CYTOPLASMIC vs 45.9%347d ment) 0.5581 (0.7- NAd 1.815) SIGNAL 164 1.213) Protein 20S % 30-90Protein 20S >=3+ Total 153 310 212 N: % in 367d 22 (6.4% P- HR = NAd0.6640 0.921 NUCLEAR INTENSITY 225 ITT: vs improve- value = 0.83 vs(0.634- STAINING CYTOPLASMIC vs 68.6% 345d ment) 0.1 (0.665- NAd 1.336)SIGNAL 238 1.037) B_D PSMB9/ A/G Protein CD68 0-50 Selected 112 297 266N: % in 414d 141 (51.6% P- HR = NAd 0.2509 0.61 NA R60H OVERALL 56 ITT:vs improve- value = 0.501 vs (0.26- POSITIVE vs 16.6% 273d ment) 0.0031(0.313- NAd 1.43) 56 0.8) B_D PSMB9/ A/G Protein CD68 0-50 Excluded 112297 266 N: % in 358d 9 (2.6% P- HR = NAd 0.9776 1.006 NA R60H OVERALL145 ITT: vs improve- value = 0.876 vs (0.644- POSITIVE vs 44% 349d ment)0.3488 (0.665- NAd 1.573) 152 1.155) B_D PSMB9/ A/G Protein CD68 0-50Total 112 297 266 N: % in 396d 51 (14.8% P- HR = NAd 0.5159 0.877 NAR60H OVERALL 201 ITT: vs improve- value = 0.768 vs (0.591- POSITIVE vs60.6% 345d ment) 0.0281 (0.606- NAd 1.302) 208 0.973) B_D PSMB5/ C/CProtein 20S % 30-90 Selected 199 231 245 N: % in 422d 141 (50.2% P- HR =NAd 0.6988 0.896 NA R24C NUCLEAR 95 ITT: vs improve- value = 0.701 vs(0.513- STAINING vs 29.5% 281d ment) 0.0385 (0.5- NAd 1.563) 104 0.983)B_D PSMB5/ C/C Protein 20S % 30-90 Excluded 199 231 245 N: % in 355d 9(2.6% P- HR = NAd 0.8760 0.958 NA R24AC NUCLEAR 114 ITT: vs improve-value = 0.869 vs (0.562- STAINING vs 34.2% 346d ment) 0.384 (0.633- NAd1.635) 117 1.193) B_D PSMB5/ C/C Protein 20S % 30-90 Total 199 231 245N: % in 406d 61 (17.7% P- HR = NAd 0.7080 0.929 NA R24C NUCLEAR 209 ITT:vs improve- value = 0.785 vs (0.632- STAINING vs 63.7% 345d ment) 0.0397(0.624- NAd 1.365) 221 0.989) B_D PSMB1/ C/G Clinical ANNARBOR >=IIISelected 199 343 133 N: % in 415d 140 (50.9% P- HR = NAd 0.7606 0.92 NAP11A 96 ITT: vs improve- value = 0.639 vs (0.536- vs 29.5% 275d ment)0.0076 (0.459- NAd 1.577) 103 0.89) B_D PSMB1/ C/G ClinicalANNARBOR >=III Excluded 199 343 133 N: % in 414d 39 (10.4% P- HR = NAd0.6663 1.102 NA P11A 170 ITT: vs improve- value = 0.931 vs (0.708- vs50.8% 375d ment) 0.6023 (0.712- NAd 1.716) 173 1.218) B_D PSMB1/ C/GClinical ANNARBOR >=III Total 199 343 133 N: % in 414d 69 (20% P- HR =NAd 0.8540 1.033 NA P11A 266 ITT: vs improve- value = 0.828 vs (0.734-vs 80.3% 345d ment) 0.0744 (0.673- NAd 1.453) 276 1.019) Clinical FLIPIHigh Protein P65% >90% Selected 160 310 205 N: % in 352d 140 (66% P- HR= 1343d 0.4043 0.808 POSITIVE 77 ITT: vs improve- value = 0.644 vs(0.49- CYTOPLASMIC vs 23.7% 212d ment) 0.0168 (0.448- 1263d 1.333)SIGNAL 83 0.926) Clinical FLIPI High Protein P65% >90% Excluded 160 310205 N: % in 429d 51 (13.5% P- HR = NAd 0.8360 1.06 POSITIVE 152 ITT: vsimprove- value = 0.919 vs (0.612- CYTOPLASMIC vs 45.9% 378d ment) 0.5531(0.695- NAd 1.836) SIGNAL 158 1.215) Clinical FLIPI High ProteinP65% >90% Total 160 310 205 N: % in 367d 22 (6.4% P- HR = NAd 0.66120.921 POSITIVE 229 ITT: vs improve- value = 0.826 vs (0.636- CYTOPLASMICvs 69.6% 345d ment) 0.0902 (0.663- NAd 1.332) SIGNAL 241 1.03) ClinicalAGEGRP <=65 Protein P65% >90% Selected 296 174 205 N: % in 415d 138(49.8% P- HR = NAd 0.6825 0.907 POSITIVE 142 ITT: vs improve- value =0.684 vs (0.569- CYTOPLASMIC vs 43.9% 277d ment) 0.0078 (0.515- NAd1.447) SIGNAL 154 0.906) Clinical AGEGRP <=65 Protein P65% >90% Excluded296 174 205 N: % in 352d −62 (−15% P- HR = NAd 0.8391 0.94 POSITIVE 87ITT: vs improve- value = 1.159 vs (0.513- CYTOPLASMIC vs 25.8% 414dment) 0.4179 (0.809- NAd 1.721) SIGNAL 87 1.66) Clinical AGEGRP <=65Protein P65% >90% Total 296 174 205 N: % in 367d 22 (6.4% P- HR = NAd0.6612 0.921 POSITIVE 229 ITT: vs improve- value = 0.826 vs (0.636-CYTOPLASMIC vs 69.6% 345d ment) 0.0902 (0.663- NAd 1.332) SIGNAL 2411.03) Protein 20S % 30-90 Protein P65% >90% Selected 232 231 212 N: %in: 414d 137 (49.5% P- HR = NAd 0.5718 0.86 NUCLEAR POSITIVE 109 ITT: vsimprove- value = 0.7 vs (0.509- STAINING CYTOPLASMIC vs 34.4% 277d ment)0.0249 (0.512- NAd 1.451) SIGNAL 123 0.957) Protein 20S % 30-90 ProteinP65% >90% Excluded 232 231 212 N: % in 351d −68 (−16.2% P- HR = NAd0.9292 0.976 NUCLEAR POSITIVE 116 ITT: vs improve- value = 0.983 vs(0.571- STAINING CYTOPLASMIC vs 34.2% 419d ment) 0.9146 (0.714- NAd1.668) SIGNAL 115 1.353) Protein 20S % 30-90 Protein P65% >90% Total 232231 212 N: % in 367d 22 (6.4% P- HR = NAd 0.6640 0.921 NUCLEAR POSITIVE225 ITT: vs improve- value = 0.83 vs (0.634- STAINING CYTOPLASMIC vs68.6% 345d ment) 0.1 (0.665- NAd 1.336) SIGNAL 238 1.037) B_D PSMB1/ C/GProtein P65% 0 Selected 144 293 238 N: % in 415d 136 (48.7% P- HR = NAd0.5700 0.825 NA P11A NUCLEAR 70 ITT: vs improve- value = 0.641 vs(0.424- STAINING vs 21.3% 279d ment) 0.0243 (0.434- NAd 1.605) 74 0.947)B_D PSMB1/ C/G Protein P65% 0 Excluded 144 293 238 N: % in 406d 60(17.3% P- HR = NAd 0.9159 0.975 NA P11A NUCLEAR 143 ITT: vs improve-value = 0.853 vs (0.612- STAINING vs 43.4% 346d ment) 0.2722 (0.642- NAd1.554) 150 1.133) B_D PSMB1/ C/G Protein P65% 0 Total 144 293 238 N: %in 414d 76 (22.5% P- HR = NAd 0.7048 0.929 NA P11A NUCLEAR 213 ITT: vsimprove- value = 0.782 vs (0.634- STAINING vs 64.7% 338d ment) 0.0354(0.622- NAd 1.36) 224 0.984) Protein CD68 0-50 Protein P65% >90%Selected 255 185 235 N: % in 414d 135 (48.4% P- HR = NAd 0.3681 0.798OVERALL POSITIVE 126 ITT: vs improve- value = 0.671 vs (0.488- POSITIVECYTOPLASMIC vs 37.8% 279d ment) 0.0086 (0.498- NAd 1.305) SIGNAL 1290.906) Protein CD68 0-50 Protein P65% >90% Excluded 255 185 235 N: % in352d −23 (−6.1% P- HR = NAd 0.8468 1.062 OVERALL POSITIVE 90 ITT: vsimprove- value = 1.052 vs (0.575- POSITIVE CYTOPLASMIC vs 27.4% 375dment) 0.7752 (0.736- NAd 1.96) SIGNAL 95 1.503) Protein CD68 0-50Protein P65% >90% Total 255 185 235 N: % in 366d 21 (6.1% P- HR = NAd0.5608 0.892 OVERALL POSITIVE 216 ITT: vs improve- value = 0.814 vs(0.608- POSITIVE CYTOPLASMIC vs 65.2% 345d ment) 0.0769 (0.648- NAd1.309) SIGNAL 224 1.023) Clinical AGEGRP <=65 Protein CD68 0-50 Selected226 215 234 N: % in 414d 135 (48.4% P- HR = NAd 0.7470 0.915 OVERALL 115ITT: vs improve- value = 0.658 vs (0.533- POSITIVE vs 33.5% 279d ment)0.0104 (0.476- NAd 1.569) 111 0.909) Clinical AGEGRP <=65 Protein CD680-50 Excluded 226 215 234 N: % in 352d 1 (0.2999- P- HR = NAd 0.59740.863 OVERALL 102 ITT: vs 9999999- value = 1.03 vs (0.499- POSITIVE vs31.9% 351d 9989% 0.8542 (0.745- NAd 1.492) 113 improve- 1.424) ment)Clinical AGEGRP <=65 Protein CD68 0-50 Total 226 215 234 N: % in 360d 15(4.2999- P- HR = NAd 0.5387 0.887 OVERALL 217 ITT: vs 999999- value =0.819 vs (0.604- POSITIVE vs 65.3% 345d 9999% 0.0864 (0.652- NAd 1.301)224 improve- 1.029) ment) Clinical PRITUX NO Protein P65% 0 Selected 194276 205 N: % in 422d 135 (47% P- HR = NAd 0.6357 0.877 NUCLEAR 92 ITT:vs improve- value = 0.702 vs (0.511- STAINING vs 28.7% 287d ment) 0.0407(0.5- NAd 1.508) 102 0.987) Clinical PRITUX NO Protein P65% 0 Excluded194 276 205 N: % in 351d 5 (1.4% P- HR = NAd 0.9900 0.997 NUCLEAR 137ITT: vs improve- value = 0.942 vs (0.601- STAINING vs 40.9% 346d ment)0.6871 (0.703- NAd 1.653) 139 1.262) Clinical PRITUX NO Protein P65% 0Total 194 276 205 N: % in 367d 22 (6.4% P- HR = NAd 0.6612 0.921 NUCLEAR229 ITT: vs improve- value = 0.826 vs (0.636- STAINING vs 69.6% 345dment) 0.0902 (0.663- NAd 1.332) 241 1.03) Clinical TLAST >1 year ProteinCD68 0-50 Selected 189 252 234 N: % in 483d 135 (38.8% P- HR = NAd0.4895 0.789 OVERALL 99 ITT: vs improve- value = 0.695 vs (0.402-POSITIVE vs 28% 348d ment) 0.0451 (0.486- NAd 1.549) 90 0.994) ClinicalTLAST >1 year Protein CD68 0-50 Excluded 189 252 234 N: % in 347d 59(20.5% P- HR = NAd 0.8742 0.963 OVERALL 118 ITT: vs improve- value =0.944 vs (0.604- POSITIVE vs 37.3% 2S8d ment) 0.7048 (0.702- NAd 1.534)134 1.27) Clinical TLAST >1 year Protein CD68 0-50 Total 189 252 234 N:% in 360d 15 (4.2999- P- HR = NAd 0.5387 0.887 OVERALL 217 ITT: vs999999- value = 0.819 vs (0.604- POSITIVE vs 65.3% 345d 9999% 0.0864(0.652- NAd 1.301) 224 improve- 1.029) ment) Protein CD68 0-50 ProteinCD68 0-50 Selected 231 155 289 N: % in 414d 133 (47.3% P- HR = NAd0.0725 0.604 OVERALL POSITIVE 113 ITT: vs improve- value = 0.63 vs(0.346- POSITIVE FOLLICULAR vs 34.2% 281d ment) 0.0037 (0.459- NAd1.053) 118 0.863) Protein CD68 0-50 Protein CD68 0-50 Excluded 231 155289 N: % in 380d −1 (−0.3% P- HR = NAd 0.3788 1.331 OVERALL POSITIVE 77ITT: vs improve- value = 1.254 vs (0.702- POSITIVE FOLLICULAR vs 23%381d ment) 0.257 (0.846- NAd 2.524) 78 1.858) Protein CD68 0-50 ProteinCD68 0-50 Total 231 155 289 N: % in 396d 50 (14.5% P- HR = NAd 0.40680.839 OVERALL POSITIVE 190 ITT: vs improve- value = 0.846 vs (0.554-POSITIVE FOLLICULAR vs 57.2% 346d ment) 0.1781 (0.663- NAd 1.27) 1961.08) Protein CD68 0-50 Protein P65 >=2+ Selected 242 144 2S9 N: % in414d 133 (47.3% P- HR = NAd 0.0511 0.58 POSITIVE INTENSITY 114 ITT: vsimprove- value = 0.653 vs (0.333- FOLLICULAR CYTOPLASMIC vs 35.9% 281dment) 0.0064 (0.48- NAd 1.009) SIGNAL 128 0.89) Protein CD68 0-50Protein P65 >=2+ Excluded 242 144 289 N: % in 351d −88 (−20% P- HR = NAd0.2917 1.432 POSITIVE INTENSITY 76 ITT: vs improve- value = 1.334 vs(0.732- FOLLICULAR CYTOPLASMIC vs 21.3% 439d ment) 0.1744 (0.879- NAd2.8) SIGNAL 68 2.024) Protein CD68 0-50 Protein P65 >=2+ Total 242 144289 N: % in 396d 50 (14.5% P- HR = NAd 0.4068 0.839 POSITIVE INTENSITY190 ITT: vs improve- value = 0.846 vs (0.554- FOLLICULAR CYTOPLASMIC vs57.2% 346d ment) 0.1781 (0.663- NAd 1.27) SIGNAL 196 1.08) B_D PSMB9/A/G Protein P65% >90% Selected 130 307 238 N: % in 406d 133 (48.7% P- HR= NAd 0.1673 0.589 NA R60H POSITIVE 64 ITT: vs improve- value = 0.616 vs(0.275- CYTOPLASMIC vs 19.3% 273d ment) 0.0268 (0.4- NAd 1.26) SIGNAL 660.95) B_D PSMB9/ A/G Protein P65% >90% Excluded 130 307 238 N: % in 414d66 (19% P- HR = NAd 0.6468 1.11 NA R60H POSITIVE 149 ITT: vs improve-value = 0.853 vs (0.711- CYTOPLASMIC vs 45.5% 348d ment) 0.2491 (0.65-NAd 1.73) SIGNAL 158 1.118) B_D PSMB9/ A/G Protein P6S% >90% Total 130307 238 N: % in 414d 76 (22.5% P- HR = NAd 0.7048 0.929 NA R60H POSITIVE213 ITT: vs improve- value = 0.782 vs (0.634- CYTOPLASMIC vs 64.7% 338dment) 0.0354 (0.622- NAd 1.36) SIGNAL 224 0.984) Protein CD68 0-50Protein P27 SIGNAL >=2+ Selected 251 135 289 N: % in 414d 132 (46.8% P-HR = NAd 0.0695 0.612 POSITIVE INTENSITY 121 ITT: vs improve- value =0.651 vs (0.359- FOLLICULAR vs 37.2% 282d ment) 0.0058 (0.479- NAd1.045) 130 0.885) Protein CD68 0-50 Protein P27 SIGNAL >=2+ Excluded 251135 289 N: % in 351d −114 (−24.5% P- HR = NAd 0.2852 1.46 POSITIVEINTENSITY 69 ITT: vs improve- value = 1.363 vs (0.726- FOLLICULAR vs 20%465d ment) 0.1445 (0.898- NAd 2.936) 66 2.07) Protein CD68 0-50 ProteinP27 SIGNAL >=2+ Total 251 135 289 N: % in 396d 50 (14.5% P- HR = NAd0.4068 0.839 POSITIVE INTENSITY 190 ITT: vs improve- value = 0.846 vs(0.554- FOLLICULAR vs 57.2% 346d ment) 0.1781 (0.663- NAd 1.27) 1961.08) Clinical FLIPI High Protein CD68 0-50 Selected 119 267 289 N: % in347d 127 (57.7% P- HR = NAd 0.2401 0.692 POSITIVE 53 ITT: vs improve-value = 0.655 vs (0.374- FOLLICULAR vs 17.6% 220d ment) 0.0481 (0.4291263d 1.282 66 -1) Clinical FLIPI High Protein CD68 0-50 Excluded 119267 289 N: % in 431d 50 (13.1% P- HR = NAd 0.8997 1.038 POSITIVE 137ITT: vs improve- value = 0.974 vs (0.585- FOLLICULAR vs 39.6% 381d ment)0.8607 (0.72- NAd 1.841) 130 1.318) Clinical FLIPI High Protein CD680-50 Total 119 267 289 N: % in 396d 50 (14.5% P- HR = NAd 0.4068 0.839POSITIVE 190 ITT: vs improve- value = 0.846 vs (0.554- FOLLICULAR vs57.2% 346d ment) 0.1781 (0.663- NAd 1.27) 196 1.08) B_D PSMB9/ G/GClinical AGEGRP <=65 Selected 232 310 133 N: % in 456d 126 (38.2% P- HR= NAd 0.9809 0.993 NA R60H 113 ITT: vs improve- value = 0.706 vs (0.574-vs 34.4% 330d ment) 0.032 (0.513- NAd 1.72) 119 0.972) B_D PSMB9/ G/GClinical AGEGRP <=65 Excluded 232 310 133 N: % in 355d 10 (2.8999- P- HR= NAd 0.8407 1.046 NA R60H 153 ITT: vs 999999- value = 0.931 vs (0.676-vs 45.9% 345d 9999% 0.6085 (0.708- NAd 1.618) 157 improve- 1.223) ment)B_D PSMB9/ G/G Clinical AGEGRP <=65 Total 232 310 133 N: % in 414d 69(20% P- HR = NAd 0.8540 1.033 NA R60H 266 ITT: vs improve- value = 0.828vs (0.734- vs 80.3% 345d ment) 0.0744 (0.673- NAd 1.453) 276 1.019)Protein CD68 0-50 Protein P27% 0-70 Selected 156 230 289 N: % in 406d125 (44.5% P- HR = NAd 0.4918 0.796 POSITIVE NUCLEI 66 ITT: vs improve-value = 0.655 vs (0.415- FOLLICULAR POSITIVE vs 23.1% 281d ment) 0.034(0.44- NAd 1.527) 90 0.973) Protein CD68 0-50 Protein P27% 0-70 Excluded156 230 289 N: % in 367d 2 (0.49999- P- HR = NAd 0.6162 0.87 POSITIVENUCLEI 124 ITT: vs 999999- value = 1.013 vs (0.505- FOLLICULAR POSITIVEvs 34.1% 365d 9989% 0.9376 (0.738- NAd 1.499) 106 improve- 1.39) ment)Protein CD68 0-50 Protein P27% 0-70 Total 156 230 289 N: % in 396d 50(14.5% P- HR = NAd 0.4068 0.839 POSITIVE NUCLEI 190 ITT: vs improve-value = 0.846 vs (0.554- FOLLICULAR POSITIVE vs 57.2% 346d ment) 0.1781(0.663- NAd 1.27) 196 1.08) B_D PSMB1/ C/G Clinical RACEGRP WHITESelected 208 334 133 N: % in 444d 118 (36.2% P- HR = NAd 0.6910 0.889 NAP11A 97 ITT: vs improve- value = 0.714 vs (0.498- vs 30.8% 326d ment)0.0499 (0.509- NAd 1.589) 111 1.001) B_D PSMB1/ C/G Clinical RACEGRPWHITE Excluded 208 334 133 N: % in 360d 15 (4.2999- P- HR = NAd 0.63091.109 NA P11A 169 ITT: vs 999999- value = 0.887 vs (0.726- vs 49-5% 345d9999% 0.3716 (0.68- NAd 1.695) 165 improve- 1.155) ment) B_D PSMB1/ C/GClinical RACEGRP WHITE Total 208 334 133 N: % in 414d 69 (20% P- HR =NAd 0.8540 1.033 NA P11A 266 ITT: vs improve- value = 0.828 vs (0.734-vs 80.3% 345d ment) 0.0744 (0.673- NAd 1.453) 276 1.019) Clinical AGEGRP<=65 Protein P27 SIGNAL >=2+ Selected 302 161 212 N: % in 396d 117(41.9% P- HR = NAd 0.4996 0.855 INTENSITY 149 ITT: vs improve- value =0.742 vs (0.543- vs 44.7% 279d ment) 0.0348 (0.561- NAd 1.347) 153 0.98)Clinical AGEGRP <=65 Protein P27 SIGNAL >=2+ Excluded 302 161 212 N: %in 355d 6 (1.6999- P- HR = NAd 0.9211 0.968 INTENSITY 78 ITT: vs 999999-value = 1 vs (0.512- vs 23.9% 349d 9999% 0.9982 (0.691- NAd 1.831) 83improve- 1.446) ment) Clinical AGEGRP <=65 Protein P27 SIGNAL >=2+ Total302 161 212 N: % in 366d 21 (6.1% P- HR = NAd 0.5615 0.896 INTENSITY 227ITT: vs improve- value = 0.822 vs (0.62- vs 68.6% 345d ment) 0.0844(0.659- NAd 1.297) 236 1.027) Clinical SEX MALE Protein P27% 0-70Selected 120 343 212 N: % in 351d 116 (49.4% P- HR = NAd 0.2905 0.703NUCLEI 64 ITT: vs improve- value = 0.639 vs (0.365- POSITIVE vs 17.8%235d ment) 0.0331 (0.423- NAd 1.355) 56 0.967) Clinical SEX MALE ProteinP27% 0-70 Excluded 120 343 212 N: % in 380d 29 (8.3% P- HR = NAd 0.81080.947 NUCLEI 163 ITT: vs improve- value = 0.849 vs (0.605- POSITIVE vs50.8% 351d ment) 0.2275 (0.651- NAd 1.482) 180 1.107) Clinical SEX MALEProtein P27% 0-70 Total 120 343 212 N: % in 366d 21 (6.1% P- HR = NAd0.5615 0.896 NUCLEI 227 ITT: vs improve- value = 0.822 vs (0.62-POSITIVE vs 68.6% 345d ment) 0.0844 (0.659- NAd 1.297) 236 1.027)Clinical AGEGRP <=65 Protein P65 >=2+ Selected 291 179 205 N: % in 396d115 (40.9% P- HR = NAd 0.6033 0.883 INTENSITY 139 ITT: vs improve- value= 0.749 vs (0.551- CYTOPLASMIC vs 43.1% 281d ment) 0.0438 (0.564- NAd1.413) SIGNAL 152 0.993) Clinical AGEGRP <=65 Protein P65 >=2+ Excluded291 179 205 N: % in 360d 11 (3.2% P- HR = NAd 0.9236 0.971 INTENSITY 90ITT: vs improve- value = 0.978 vs (0.534- CYTOPLASMIC vs 26.5% 349dment) 0.9045 (0.685- NAd 1.767) SIGNAL 89 1.395) Clinical AGEGRP <=65Protein P65 >=2+ Total 291 179 205 N: % in 367d 22 (6.4% P- HR = NAd0.6612 0.921 INTENSITY 229 ITT: vs improve- value = 0.826 vs (0.636-CYTOPLASMIC vs 69.6% 345d ment) 0.0902 (0.663- NAd 1.332) SIGNAL 2411.03) Protein CD68 0-50 Protein P65% 0 Selected 208 178 289 N: % in 396d114 (40.4% P- HR = NAd 0.3965 0.78 POSITIVE NUCLEAR 94 ITT: vs improve-value = 0.699 vs (0.439- FOLLICULAR STAINING vs 30.8% 282d ment) 0.0366(0.499- NAd 1.387) 114 0.98) Protein CD68 0-50 Protein P65% 0 Excluded208 178 289 N: % in 406d 27 (7.1% P- HR = NAd 0.8015 0.925 POSITIVENUCLEAR 96 ITT: vs improve- value = 1.094 vs (0.505- FOLLICULAR STAININGvs 26.4% 379d ment) 0.6341 (0.757- NAd 1.695) 82 1.581) Protein CD680-50 Protein P65% 0 Total 208 178 289 N: % in 396d 50 (14.5% P- HR = NAd0.4068 0.839 POSITIVE NUCLEAR 190 ITT: vs improve- value = 0.846 vs(0.554- FOLLICULAR STAINING vs 57.2% 346d ment) 0.1781 (0.663- NAd 1.27)196 1.08) Clinical FLIPI High Protein P65 >=2+ Selected 156 314 205 N: %in 352d 113 (47.3% P- HR = 1343d 0.5476 0.856 INTENSITY 76 ITT: vsimprove- value = 0.653 vs (0.515- CYTOPLASMIC vs 23.1% 239d ment) 0.0229(0.451- NAd 1.421) SIGNAL 80 0.945) Clinical FLIPI High Protein P65 >=2+Excluded 156 314 205 N: % in 429d 81 (23.3% P- HR = NAd 0.9311 0.977INTENSITY 153 ITT: vs improve- value = 0.919 vs (0.57- CYTOPLASMIC vs46.5% 348d ment) 0.5476 (0.697- NAd 1.674) SIGNAL 161 1.211) ClinicalFLIPI High Protein P65 >=2+ Total 156 314 205 N: % in 367d 22 (6.4% P-HR = NAd 0.6612 0.921 INTENSITY 229 ITT: vs improve- value = 0.826 vs(0.636- CYTOPLASMIC vs 69.6% 345d ment) 0.090 (0.663- NAd 1.332) SIGNAL241 1.03) B_D PSMB1/ C/G Clinical HITUBD YES Selected 137 405 133 N: %in 351d 110 (45.6% P- HR = NAd 0.8487 0.942 NA P11A 65 ITT: vs improve-value = 0.643 vs (0.514- vs 20.3% 241d ment) 0.0273 (0.433- NAd 1.728)72 0.955) B_D PSMB1/ C/G Clinical HITUBD YES Excluded 137 405 133 N: %in 429d 54 (14.4% P- HR = NAd 0.7275 1.076 NA P11A 201 ITT: vs improve-value= 0.893 vs (0.711- vs 60% 375d ment) 0.3654 (0.7- NAd 1.629) 2041.14) B_D PSMB1/ C/G Clinical HITUBD YES Total 137 405 133 N: % in 414d69 (20% P- HR = NAd 0.8540 1.033 NA P11A 266 ITT: vs improve- value =0.828 vs (0.734- vs 80.3% 345d ment) 0.0744 (0.673- NAd 1.453) 2761.019) Protein 20S >=3+ Protein CD68 0-50 Selected 138 248 289 N: % in435d 109 (33.4% P- HR = NAd 0.1965 0.624 INTENSITY POSITIVE 66 ITT: vsimprove- value = 0.657 vs (0.302- CYTOPLASMIC FOLLICULAR vs 20.4% 326dment) 0.048 (0.432- NAd 1.285) SIGNAL 72 0.999) Protein 20S >=3+ ProteinCD68 0-50 Excluded 138 248 289 N: % in 352d 4 (1.0999- P- HR = NAd0.9537 0.985 INTENSITY POSITIVE 124 ITT: vs 999999- value = 0.976 vs(0.591- CYTOPLASMIC FOLLICULAR vs 36.7% 348d 9999% 0.8748 (0.721- NAd1.641) SIGNAL 124 improve- 1.322) ment) Protein 20S >=3+ Protein CD680-50 Total 138 248 289 N: % in 396d 50 (14.5% P- HR = NAd 0.4068 0.839INTENSITY POSITIVE 190 ITT: vs improve- value = 0.846 vs (0.554-CYTOPLASMIC FOLLICULAR vs 57.2% 346d ment) 0.1781 (0.663- NAd 1.27)SIGNAL 196 1.08) Clinical FLIPI High Protein P27 SIGNAL >=2+ Selected164 299 212 N: % in 346d 107 (44.8% P- HR = 1343d 0.2893 0.761 INTENSITY81 ITT: vs improve- value = 0.694 vs (0.459- vs 24.3% 239d ment) 0.0449(0.485- 1263d 1.262) 83 0.993) Clinical FLIPI High Protein P27SIGNAL >=2+ Excluded 164 299 212 N: % in 429d 72 (20.2% P- HR = NAd0.8014 1.072 INTENSITY 146 ITT: vs improve- value = 0.883 vs (0.622- vs44.3% 357d ment) 0.3899 (0.665- NAd 1.848) 153 1.173) Clinical FLIPIHigh Protein P27 SIGNAL >=2+ Total 164 299 212 N: % in 366d 21 (6.1% P-HR = NAd 0.5615 0.896 INTENSITY 227 ITT: vs improve- value = 0.822 vs(0.62- vs 68.6% 345d ment) 0.0844 (0.659- NAd 1.297) 236 1.027) ClinicalPRITUX NO Protein P65% >90% Selected 217 253 205 N: % in 426d 104 (32.3%P- HR = NAd 0.2559 0.732 POSITIVE 105 ITT: vs improve- value = 0.677 vs(0.427- CYTOPLASMIC vs 32.1% 322d ment) 0.0193 (0.488- NAd 1.256) SIGNAL112 0.94) Clinical PRITUX NO Protein P65% >90% Excluded 217 253 205 N: %in 345d −1 (−0.3% P- HR = NAd 0.5660 1.161 POSITIVE 124 ITT: vs improve-value = 0.987 vs (0.697- CYTOPLASMIC vs 37.5% 346d ment) 0.9336 (0.731-NAd 1.936) SIGNAL 129 1.333) Clinical PRITUX NO Protein P65% >90% Total217 253 205 N: % in 367d 22 (6.4% P- HR = NAd 0.6612 0.921 POSITIVE 229ITT: vs improve- value = 0.826 vs (0.636- CYTOPLASMIC vs 69.6% 345dment) 0.0902 (0.663- NAd 1.332) SIGNAL 241 1.03) B_D PSMB1/ C/G ProteinP65 >=2+ Selected 154 283 238 N: % in 426d 104 (32.3% P- HR = NAd 0.32330.71 NA P11A INTENSITY 73 ITT: vs improve- value = 0.645 vs (0.358-CYTOPLASMIC vs 22.8% 322d ment) 0.027 (0.435- NAd 1.406) SIGNAL 810.955) B_D PSMB1/ C/G Protein P65 >=2+ Excluded 154 283 238 N: % in 360d14 (4% P- HR = NAd 0.8398 1.049 NA P11A INTENSITY 140 ITT: vs improve-value = 0.86 vs (0.66- CYTOPLASMIC vs 41.9% 346d ment) 0.2961 (0.648-NAd 1.666) SIGNAL 143 1.141) B_D PSMB1/ C/G Protein P65 >=2+ Total 154283 238 N: % in 414d 76 (22.5% P- HR = NAd 0.7048 0.929 NA P11AINTENSITY 213 ITT: vs improve- value = 0.782 vs (0.634- CYTOPLASMIC vs64.7% 338d ment) 0.0354 (0.622- NAd 1.36) SIGNAL 224 0.984) B_D PSMB1/C/G Clinical PRITUX NO Selected 138 404 133 N: % in 426d 104 (32.3% P-HR = NAd 0.4750 0.786 NA P11A 70 ITT: vs improve- value = 0.658 vs(0.404- vs 20.4% 322d ment) 0.0388 (0.44- NAd 1.528) 68 0.982) B_DPSMB1/ C/G Clinical PRITUX NO Excluded 138 404 133 N: % in 363d 18 (5.2%P- HR = NAd 0.5551 1.127 NA P11A 196 ITT: vs improve- value = 0.898 vs(0.757- vs 59.9% 345d ment) 0.3874 (0.705- NAd 1.68) 208 1.145) B_DPSMB1/ C/G Clinical PRITUX NO Total 138 404 133 N: % in 414d 69 (20% P-HR = NAd 0.8540 1.033 NA P11A 266 ITT: vs improve- value = 0.828 vs(0.734- vs 80.3% 345d ment) 0.0744 (0.673- NAd 1.453) 276 1.019) B_DPSMB9/ G/G Protein CD68 0-50 Selected 145 211 319 N: % in 429d 103(31.6% P- HR = NAd 0.1089 0.565 NA R60H POSITIVE 66 ITT: vs improve-value = 0.641 vs (0.279- FOLLICULAR vs 21.5% 326d ment) 0.0269 (0.43-NAd 1.146) 79 0.954) B_D PSMB9/ G/G Protein CD68 0-50 Excluded 145 211319 N: % in 406d 59 (17% P- HR = NAd 0.9946 0.998 NA R60H POSITIVE 109ITT: vs improve- value = 0.947 vs (0.576- FOLLICULAR vs 31.3% 347d ment)0.7477 (0.677- NAd 1.731) 102 1.324) B_D PSMB9/ G/G Protein CD68 0-50Total 145 211 319 N: % in 414d 69 (20% P- HR = NAd 0.3270 0.808 NA R60HPOSITIVE 175 ITT: vs improve- value = 0.801 vs (0.527- FOLLICULAR vs52.7% 345d ment) 0.0855 (0.621- NAd 1.239) 181 1.032) Protein 20S >=3+Protein P65% >90% Selected 195 268 212 N: % in 435d 101 (30.2% P- HR =NAd 0.1802 0.66 INTENSITY POSITIVE 95 ITT: vs improve- value = 0.681 vs(0.358- CYTOPLASMIC CYTOPLASMIC vs 28.9% 334d ment) 0.0304 (0.481- NAd1.217) SIGNAL SIGNAL 100 0.965) Protein 20S >=3+ Protein P65% >90%Excluded 195 268 212 N: % in 351d 6 (1.6999- P- HR = NAd 0.5860 1.141INTENSITY POSITIVE 130 ITT: vs 999999- value = 0.959 vs (0.709-CYTOPLASMIC CYTOPLASMIC vs 39.7% 345d 9999% 0.7745 (0.718- NAd 1.838)SIGNAL SIGNAL 138 improve- 1.28) ment) Protein 20S >=3+ ProteinP65% >90% Total 195 268 212 N: % in 367d 22 (6.4% P- HR = NAd 0.66400.921 INTENSITY POSITIVE 225 ITT: vs improve- value = 0.83 vs (0.634-CYTOPLASMIC CYTOPLASMIC vs 68.6% 345d ment) 0.1 (0.665- NAd 1.336)SIGNAL SIGNAL 238 1.037) Clinical RACEGRP WHITE Protein CD68 0-50Selected 239 147 289 N: % in 431d 97 (29% P- HR = NAd 0.0785 0.592POSITIVE 114 ITT: vs improve- value = 0.63 vs (0.328- FOLLICULAR vs35.4% 334d ment) 0.0043 (0.458- NAd 1.069) 125 0.868) Clinical RACEGRPWHITE Protein CD68 0-50 Excluded 239 147 289 N: % in 324d −51 (−13.6% P-HR = NAd 0.5253 1.215 POSITIVE 76 ITT: vs improve- value = 1.294 vs(0.665- FOLLICULAR vs 21.8% 375d ment) 0.1919 (0.878- NAd 2.219) 711.908) Clinical RACEGRP WHITE Protein CD68 0-50 Total 239 147 289 N: %in 396d 50 (14.5% P- HR = NAd 0.4068 0.839 POSITIVE 190 ITT: vs improve-value = 0.846 vs (0.554- FOLLICULAR vs 57.2% 346d ment) 0.1781 (0.663-NAd 1.27) 196 1.08) Protein 20S % 30-90 Protein CD68 0-50 Selected 168271 236 N: % in 367d 96 (35.4% P- HR = NAd 0.3345 0.753 NUCLEAR OVERALL82 ITT: vs improve- value = 0.647 vs (0.424- STAINING POSITIVE vs 24.9%271d ment) 0.0181 (0.45- NAd 1.34) 86 0.931) Protein 20S % 30-90 ProteinCD68 0-50 Excluded 168 271 236 N: % in 355d −10 (−2.7% P- HR = NAd0.8394 1.055 NUCLEAR OVERALL 134 ITT: vs improve- value = 0.949 vs(0.627- STAINING POSITIVE vs 40.1% 365d ment) 0.7301 (0.706- NAd 1.774)137 1.276) Protein 20S % 30-90 Protein CD68 0-50 Total 168 271 236 N: %in 366d 21 (6.1% P- HR = NAd 0.6244 0.908 NUCLEAR OVERALL 216 ITT: vsimprove- value = 0.818 vs (0.618- STAINING POSITIVE vs 65% 345d ment)0.0853 (0.651- NAd 1.335) 223 1.029) Clinical AGEGRP <=65 Protein 20S %30-90 Selected 193 270 212 N: % in 367d 96 (35.4% P- HR = NAd 0.61800.865 NUCLEAR 96 ITT: vs improve- value = 0.703 vs (0.49- STAINING vs28.6% 271d ment) 0.0413 (0.5- NAd 1.527) 97 0.988) Clinical AGEGRP <=65Protein 20S % 30-90 Excluded 193 270 212 N: % in 380d 23 (6.4% P- HR =NAd 0.8251 0.946 NUCLEAR 129 ITT: vs improve- valne = 0.925 vs (0.576-STAINING vs 40% 357d ment) 0.6011 (0.689- NAd 1.552) 141 1.241) ClinicalAGEGRP <=65 Protein 20S % 30-90 Total 193 270 212 N: % in 367d 22 (6.4%P- HR = NAd 0.6640 0.921 NUCLEAR 225 ITT: vs improve- value = 0.83 vs(0.634- STAINING vs 68.6% 345d ment) 0.1 (0.665- NAd 1.336) 238 1.037)Clinical HITUBD YES Protein P65% >90% Selected 202 268 205 N: % in 346d93 (36.8% P- HR = 1343d 0.7230 0.917 POSITIVE 100 ITT: vs improve- value= 0.728 vs (0.567- CYTOPLASMIC vs 29.9% 253d ment) 0.0486 (0.531- NAd1.481) SIGNAL 102 0.999) Clinical HITUBD YES Protein P65% >90% Excluded202 268 205 N: % in 4S7d 65 (15.4% P- HR = NAd 0.6827 0.886 POSITIVE 129ITT: vs improve- value = 0.88 vs (0.496- CYTOPLASMIC vs 39.7% 422d ment)0.4198 (0.646- NAd 1.584) SIGNAL 139 1.199) Clinical HITUBD YES ProteinP65% >90% Total 202 268 205 N: % in 367d 22 (6.4% P- HR = NAd 0.66120.921 POSITIVE 229 ITT: vs improve- value = 0.826 vs (0.636- CYTOPLASMICvs 69.6% 345d ment) 0.0902 (0.663- NAd 1.332) SIGNAL 241 1.03) Protein20S % 30-90 Protein CD68 0-50 Selected 164 222 289 N: % in 366d 92(33.6% P- HR = NAd 0.2666 0.702 NUCLEAR POSITIVE 75 ITT: vs improve-value = 0.631 vs (0.374- STAINING FOLLICULAR vs 24.3% 274d ment) 0.0133(0.437- NAd 1.315) 89 0.911) Protein 20S % 30-90 Protein CD68 0-50Excluded 164 222 289 N: % in 422d −5 (−1.2% P- HR = NAd 0.9562 0.984NUCLEAR POSITIVE 115 ITT: vs improve- value = 1.072 vs (0.561- STAININGFOLLICULAR vs 32.9% 427d ment) 0.6841 (0.769- NAd 1.727) 107 1.494)Protein 20S % 30-90 Protein CD68 0-50 Total 164 222 289 N: % in 396d 50(14.5% P- HR = NAd 0.4068 0.839 NUCLEAR POSITIVE 190 ITT: vs improve-value = 0.846 vs (0.554- STAINING FOLLICUIAR vs 57.2% 346d ment) 0.1781(0.663- NAd 1.27) 196 1.08) B_D PSMBS/ C/C Clinical AGEGRP <=65 Selected337 205 133 N: % in 422d 92 (27.9% P- HR = NAd 0.9869 1.004 NA R24C 167ITT: vs improve- value = 0.722 vs (0.638- vs 49.9% 330d ment) 0.0146(0.555- NAd 1.579) 170 0.939) B_D PSMB5/ C/C Clinical AGEGRP <=65Excluded 337 205 133 N: % in 355d 7 (2% P- HR = NAd 0.7965 1.071 NA R24C99 ITT: vs improve- value = 1.037 vs (0.636- vs 30.4% 348d ment) 0.8278(0.739- NAd 1.801) 106 1.457) B_D PSMB5/ C/C Clinical AGEGRP <=65 Total337 205 133 N: % in 414d 69 (20% P- HR = NAd 0.8540 1.033 NA R24C 266ITT: vs improve- value = 0.828 vs (0.734- vs 80.3% 345d ment) 0.0744(0.673- NAd 1.453) 276 1.019) B_D PSMB5/ C/C Protein CD68 0-50 Selected225 131 319 N: % in 426d 92 (27.5% P- HR = NAd 0.2817 0.729 NA R24CPOSITIVE 104 ITT: vs improve- value = 0.691 vs (0.41- FOLLICULAR vs33.3% 334d ment) 0.0247 (0.499- NAd 1.298) 121 0.956) B_D PSMB5/ C/CProtein CD68 0-50 Excluded 225 131 319 N: % in 414d 66 (19% P- HR = NAd0.7179 0.888 NA R24C POSITIVE 71 ITT: vs improve- value = 1.046 vs(0.466- FOLLICULAR vs 19.4% 348d ment) 0.8308 (0.687- NAd 1.692) 601.594) B_D PSMB5/ C/C Protein CD68 0-50 Total 225 131 319 N: % in 414d69 (20% P- HR = NAd 0.3270 0.808 NA R2AC POSITIVE 175 ITT: vs improve-value = 0.801 vs (0.527- FOLLICULAR vs 52.7% 345d ment) 0.0855 (0.621-NAd 1.239) 181 1.032) Clinical SEX FEMALE Protein CD68 0-50 Selected 163223 239 N: % in 435d 90 (26.1% P- HR = NAd 0.5324 0.794 POSITIVE 69 ITT:vs improve- value = 0.609 vs (0.385- FOLLICULAR vs 24.1% 345d ment)0.015 (0.406- NAd 1.639) 94 0.913) Clinical SEX FEMALE Protein CD68 0-50Excluded 163 223 239 N: % in 352d 5 (1.4% P- HR = NAd 0.4476 0.821POSITIVE 121 ITT: vs improve- value = 1.031 vs (0.493- FOLLICULAR vs 33%347d ment) 0.854 (0.75- NAd 1.368) 102 1.416) Clinical SEX FEMALEProtein CD68 0-50 Total 163 223 289 N: % in 396d 50 (14.5% P- HR = NAd0.4068 0.839 POSITIVE 190 ITT: vs improve- value = 0.846 vs (0.554-FOLLICULAR vs 57.2% 346d ment) 0.1781 (0.663- NAd 1.27) 196 1.08) B_DPSMB9/ A/G Protein P65% 0 Selected 120 317 238 N: % in 366d 89 (32.1% P-HR = NAd 0.2104 0.635 NA R60H NUCLEAR 60 ITT: vs improve- value = 0.6 vs(0.31- STAINING vs 17.8% 277d ment) 0.0212 (0.386- NAd 1.3) 60 0.93) B_DPSMB9/ A/G Protein P65% 0 Excluded 120 317 238 N: % in 415d 67 (19.3% P-HR = NAd 0.7295 1.083 NA R60H NUCLEAR 153 ITT: vs improve- value = 0.851vs (0.689- STAINING vs 47% 348d ment) 0.2428 (0.65- NAd 1.704) 1641.115) B_D PSMB9/ A/G Protein P65% 0 Total 120 317 238 N: % in 414d 76(22.5% P- HR = NAd 0.7048 0.929 NA R60H NUCLEAR 213 ITT: vs improve-value = 0.782 vs (0.634- STAINING vs 64.7% 338d ment) 0.0354 (0.622- NAd1.36) 224 0.984) Protein 20S% 95-100 Protein CD68 0-50 Selected 183 203289 N: % in 426d 88 (26% P- HR = NAd 0.0772 0.578 POSITIVE POSITIVE 90ITT: vs improve- value = 0.646 vs (0.313- CYTOPLASMIC FOLLICULAR vs27.1% 338d ment) 0.0168 (0.449- NAd 1.069) SIGNAL 93 0.928) Protein 20S%95-100 Protein CD68 0-50 Excluded 183 203 289 N: % in 351d 4 (1.2% P- HR= NAd 0.5747 1.178 POSITIVE POSITIVE 100 ITT: vs improve- value = 1.066vs (0.664- CYTOPLASMIC FOLLICULAR vs 30.1% 347d ment) 0.7086 (0.762- NAd2.09) SIGNAL 103 1.49) Protein 20S% 95-100 Protein CD68 0-50 Total 183203 289 N: % in 396d 50 (14.5% P- HR = NAd 0.4068 0.839 POSITIVEPOSITIVE 190 ITT: vs improve- value = 0.846 vs (0.554- CYTOPLASMICFOLLICULAR vs 57.2% 346d ment) 0.1781 (0.663- NAd 1.27) SIGNAL 196 1.08)B_D PSMB5/ C/C Protein P65% >90% Selected 300 137 238 N: % in 422d 88(26.3% P- HR = NAd 0.6127 0.887 NA R24C POSITIVE 141 ITT: vs improve-value = 0.713 vs (0.558- CYTOPLASMIC vs 44.4% 334d ment) 0.017 (0.54-NAd 1.411) SIGNAL 159 0.943) B_D PSMB5/ C/C Protein P65% >90% Excluded300 137 238 N: % in 352d 5 (1.4% P- HR = NAd 0.9886 1.005 NA R24CPOSITIVE 72 ITT: vs improve- value = 0.953 vs (0.513- CYTOPLASMIC vs20.3% 347d ment) 0.819 (0.633- NAd 1.972) SIGNAL 65 1.435) B_D PSMB5/C/C Protein P65% >90% Total 300 137 238 N: % in 414d 76 (22.5% P- HR =NAd 0.7048 0.929 NA R24C POSITIVE 213 ITT: vs improve- value = 0.782 vs(0.634- CYTOPLASMIC vs 64.7% 338d ment) 0.0354 (0.622- NAd 1.36) SIGNAL224 0.984) Protein P27 >=2+ Protein P65% >90% Selected 348 114 213 N: %in 414d 88 (27% P- HR = NAd 0.2119 0.76 SIGNAL POSITIVE 168 ITT: vsimprove- value = 0.755 vs (0.493- INTENSITY CYTOPLASMIC vs 51.6% 326dment) 0.033 (0.583- NAd 1.171) SIGNAL 180 0.979) Protein P27 >=2+Protein P65% >90% Excluded 348 114 213 N: % in 347d 0 (0% P- HR = NAd0.3256 1.455 SIGNAL POSITIVE 58 ITT: vs improve- value = 1.04 vs (0.686-INTENSITY CYTOPLASMIC vs 16.9% 347d ment) 0.8643 (0.669- NAd 3.086)SIGNAL 56 1.617) Protein P27 >=2+ Protein P65% >90% Total 348 114 213 N:% in 366d 21 (6.1% P- HR = NAd 0.5839 0.902 SIGNAL POSITIVE 226 ITT: vsimprove- value = 0.817 vs (0.623- INTENSITY CYTOPLASMIC vs 68.4% 345dment) 0.0753 (0.654- NAd 1.305) SIGNAL 236 1.021) Clinical HITUBD YESProtein P27% 0-70 Selected 148 315 212 N: % in 324d 85 (35.6% P- HR =1343d 0.7672 0.918 NUCLEI 75 ITT: vs improve- value = 0.677 vs (0.524-POSITIVE vs 21.9% 239d ment) 0.0384 (0.466- NAd 1.61) 73 0.982) ClinicalHITUBD YES Protein P27% 0-70 Excluded 148 315 212 N: % in 426d 69 (19.3%P- HR = NAd 0.4225 0.817 NUCLEI 151 ITT: vs improve- value = 0.852 vs(0.498- posrrrvE vs 46.7% 357d ment) 0.2588 (0.645- NAd 1.34) 163 1.126)Clinical HITUBD YES Protein P27% 0-70 Total 148 315 212 N: % in 366d 21(6.1% P- HR = NAd 0.5615 0.896 NUCLEI 227 ITT: vs improve- value = 0.822vs (0.62- POSITIVE vs 68.6% 345d ment) 0.0844 (0.659- NAd 1.297) 2361.027) Clinical RACEGRP WHITE Protein P65% >90% Selected 341 129 205 N:% in 417d 83 (24.9% P- HR = NAd 0.2846 0.783 POSITIVE 162 ITT: vsimprove- value = 0.725 vs (0.501- CYTOPLASMIC vs 50.5% 334d ment) 0.0163(0.558- NAd 1.226) SIGNAL 179 0.943) Clinical RACEGRP WHITE ProteinP65% >90% Excluded 341 129 205 N: % in 346d −32 (−8.5% P- HR = NAd0.5035 1.257 POSITIVE 67 ITT: vs improve- value = 1.159 vs (0.643-CYTOPLASMIC vs 19.1% 378d ment) 0.4834 (0.767- NAd 2.455) SIGNAL 621.752) Clinical RACEGRP WHITE Protein P65% >90% Total 341 129 205 N: %in 367d 22 (6.4% P- HR = NAd 0.6612 0.921 POSITIVE 229 ITT: vs improve-value = 0.826 vs (0.636- CYTOPLASMIC vs 69.6% 345d ment) 0.0902 (0.663-NAd 1.332) SIGNAL 241 1.03) Clinical ANNARBOR >=III Protein P65% >90%Selected 321 149 205 N: % in 360d 82 (29.5% P- HR = NAd 0.5983 0.891POSITIVE 152 ITT: vs improve- value = 0.75 vs (0.58- CYTOPLASMIC vs47.6% 278d ment) 0.0306 (0.578- NAd 1.369) SIGNAL 169 0.974) ClinicalANNARBOR >=III Protein P65% >90% Excluded 321 149 205 N: % in 435d 3(0.6999- P- HR = NAd 0.8428 1.077 POSITIVE 77 ITT: vs 999999- value =1.063 vs (0.518- CYTOPLASMIC vs 22.1% 432d 9999% 0.78 (0.696- NAd 2.242)SIGNAL 72 improve- 1.622) ment) Clinical ANNARBOR >=III ProteinP65% >90% Total 321 149 205 N: % in 367d 22 (6.4% P- HR = NAd 0.66120.921 POSITIVE 229 ITT: vs improve- value = 0.826 vs (0.636- CYTOPLASMICvs 69.6% 345d ment) 0.0902 (0.663- NAd 1.332) SIGNAL 241 1.03) ClinicalREGION REST Protein CD68 0-50 Selected 137 304 234 N: % in 358d 81(29.2% P- HR = NAd 0.2957 0.716 OF OVERALL 67 ITT: vs improve- value =0.668 vs (0.382- WORLD POSITIVE vs 20.3% 277d ment) 0.0407 (0.452- NAd1.341) 70 0.987) Clinical REGION REST Protein CD68 0-50 Excluded 137 304234 N: % in 380d 29 (8.3% P- HR = NAd 0.9650 1.011 OF OVERALL 150 ITT:vs improve- value = 0.917 vs (0.621- WORLD POSITIVE vs 45% 351d ment)0.552 (0.691- NAd 1.645) 154 1.217) Clinical REGION REST Protein CD680-50 Total 137 304 234 N: % in 360d 15 (4.2999- P- HR = NAd 0.5387 0.887OF OVERALL 217 ITT: vs 999999- value = 0.819 vs (0.604- WORLD POSITIVEvs 65.3% 345d 9999% 0.0864 (0.652- NAd 1.301) 224 improve- 1.029) ment)Clinical RACEGRP WHITE Protein CD68 0-50 Selected 260 181 234 N: % in414d 80 (24% P- HR = NAd 0.1697 0.701 OVERALL 132 ITT: vs improve- value= 0.71 vs (0.421- POSITIVE vs 38.5% 334d ment) 0.0248 (0.526- NAd 1.167)128 0.959) Clinical RACEGRP WHITE Protein CD68 0-50 Excluded 260 181 234N: % in 351d 3 (0.8999- P- HR = NAd 0.4069 1.28 OVERALL 85 ITT: vs999999- value = 0.991 vs (0.713- POSITIVE vs 26.8% 348d 9999% 0.9662(0.696- NAd 2.299) 96 improve- 1.411) ment) Clinical RACEGRP WHITEProtein CD68 0-50 Total 260 181 234 N: % in 360d 15 (4.2999- P- HR = NAd0.5387 0.887 OVERALL 217 ITT: vs 999999- value = 0.819 vs (0.604-POSITIVE vs 65.3% 345d 9999% 0.0864 (0.652- NAd 1.301) 224 improve-1.029) ment) Clinical FLIPI High Protein CD68 0-50 Selected 135 306 234N: % in 352d 79 (28.9% P- HR = 1343d 0.2526 0.727 OVERALL 67 ITT: vsimprove- value = 0.658 vs (0.421- POSITIVE vs 20% 273d ment) 0.0339(0.446- NAd 1.257) 68 0.971) Clinical FLIPI High Protein CD68 0-50Excluded 135 306 234 N: % in 414d 57 (16% P- HR = NAd 0.9548 0.984OVERALL 150 ITT: vs improve- value = 0.898 vs (0.574- POSITIVE vs 45.3%357d ment) 0.4519 (0.677- NAd 1.687) 156 1.191) Clinical FLIPI HighProtein CD68 0-50 Total 135 306 234 N: % in 360d 15 (4.2999- P- HR = NAd0.5387 0.887 OVERALL 217 ITT: vs 999999- value = 0.819 vs (0.604-POSITIVE vs 65.3% 345d 9999% 0.0864 (0.652- NAd 1.301) 224 improve-1.029) ment) B_D PSMB5/ C/C Clinical ANNARBOR >=III Selected 375 167 133N: % in 360d 79 (28.1% P- HR = NAd 0.5509 1.127 NA R24C 182 ITT: vsimprove- value = 0.776 vs (0.761- vs 55.6% 231d ment) 0.0395 (0.61- NAd1.668) 193 0.989) B_D PSMB5/ C/C Clinical ANNARBOR >=III Excluded 375167 133 N: % in 512d 90 (21.3% P- HR = NAd 0.5602 0.814 NA R24C 84 ITT:vs improve- value = 0.996 vs (0.406- vs 24.7% 422d ment) 0.9843 (0.662-NAd 1.631) 83 1.499) B_D PSMB5/ C/C Clinical ANNARBOR >=III Total 375167 133 N: % in 414d 69 (20% P- HR = NAd 0.8540 1.033 NA R24C 266 ITT:vs improve- value = 0.828 vs (0.734- vs 80.3% 345d ment) 0.0744 (0.673-NAd 1.453) 276 1.019) B_D PSMB5/ C/T Clinical HITUBD YES Selected 45 497133 N: % in 352d 77 (28% P- HR = NAd 0.1763 0.496 NA R24C 24 ITT: vsimprove- value = 0.383 vs (0.176- vs 6.7% 275d ment) 0.0054 (0.191- NAd1.399) 21 0.769) B_D PSMB5/ C/T Clinical HITUBD YES Excluded 45 497 133N: % in 414d 67 (19.3% P- HR = NAd 0.5518 1.116 NA R24C 242 ITT: vsimprove- value = 0.856 vs (0.777- vs 73.6% 347d ment) 0.1634 (0.688- NAd1.605) 255 1.065) B_D PSMB5/ C/T Clinical HITUBD YES Total 45 497 133 N:% in 414d 69 (20% P- HR = NAd 0.8540 1.033 NA R24C 266 ITT: vs improve-value = 0.828 vs (0.734- vs 80.3% 345d ment) 0.0744 (0.673- NAd 1.453)276 1.019) Protein CD68 0-50 Protein P27% 0-70 Selected 181 260 234 N: %in 358d 76 (27% P- HR = NAd 0.5757 0.851 OVERALL NUCLEI 85 ITT: vsimprove- value = 0.699 vs (0.485- POSITIVE POSITIVE vs 26.8% 282d ment)0.0484 (0.488- NAd 1.496) 96 1) Protein CD68 0-50 Protein P27% 0-70Excluded 181 260 234 N: % in 367d 18 (5.2% P- HR = NAd 0.7267 0.911OVERALL NUCLEI 132 ITT: vs improve- value = 0.901 vs (0.539- POSITIVEPOSITIVE vs 38.5% 349d ment) 0.4931 (0.669- NAd 1.538) 128 1.213)Protein CD68 0-50 Protein P27% 0-70 Total 181 260 234 N: % in 360d 15(4.2999- P- HR = NAd 0.5387 0.887 OVERALL NUCLEI 217 ITT: vs 999999-value = 0.819 vs (0.604- POSITIVE POSITIVE vs 65.3 345d 9999% 0.0864(0.652- NAd 1.301) 224 improve- 1.029) ment) B_D PSMB9/ A/G Clinical SEXMALE Selected 76 466 133 N: % in 348d 75 (27.5% P- HR = NAd 0.7868 0.879NA R60H 48 ITT: vs improve- value = 0.583 vs (0.345- vs 11.3% 273d ment)0.0491 (0.337- NAd 2.242) 28 1.008) B_D PSMB9/ A/G Clinical SEX MALEExcluded 76 466 133 N: % in 422d 74 (21.3% P- HR = NAd 0.7578 1.06 NAR60H 218 ITT: vs improve- value = 0.835 vs (0.733- vs 69% 348d ment)0.1201 (0.666- NAd 1.533) 248 1.048) B_D PSMB9/ A/G Clinical SEX MALETotal 76 466 133 N: % in 414d 69 (20% P- HR = NAd 0.8540 1.033 NA R60H266 ITT: vs improve- value = 0.828 vs (0.734- vs 80.3% 345d ment) 0.0744(0.673- NAd 1.453) 276 1.019) Protein CD68 0-50 Protein P27 >=2+Selected 252 189 234 N: % in 396d 74 (23% P- HR = NAd 0.1214 0.676OVERALL SIGNAL 129 ITT: vs improve- value = 0.734 vs (0.411- POSITIVEINTENSITY vs 37.3% 322d ment) 0.04 4 (0.543- NAd 1.113) 231 0.992)Protein CD68 0-50 Protein P27 >=2+ Excluded 252 189 234 N: % in 352d 4(1.0999 P- HR = NAd 0.3802 1.31 OVERALL SIGNAL 88 ITT: vs 999999 value =0.944 vs (0.715- POSITIVE INTENSITY vs 28% 34Sd 9999% 0.7527 (0.665- NAd2.402) 101 improve- 1.34) ment) Protein CD68 0-50 Protein P27 >=2+ Total252 189 234 N: % in 360d 15 (4.2999- P- HR = NAd 0.5387 0.887 OVERALLSIGNAL 217 ITT: vs 999999- value = 0.819 vs (0.604- POSITIVE INTENSITYvs 65.3% 345d 9999% 0.0864 (0.652- NAd 1.301) 224 improve- 1.029) ment)Clinical ANNARBOR >=III Protein CD68 0-50 Selected 239 147 289 N: % in351d 73 (26.3% P- HR = NAd 0.2011 0.71 POSITIVE 110 ITT: vs improve-value = 0.693 vs (0.419- FOLLICULAR vs 35.4% 278d ment) 0.0172 (0.512-NAd 1.203) 129 0.939) Clinical ANNARBOR >=III Protein CD68 0-50 Excluded239 147 289 N: % in 435d −57 (−11.6% P- HR = NAd 0.6331 1.187 POSITIVE80 ITT: vs improve- value = 1.29 vs (0.586- FOLLICULAR vs 21.8% 492dment) 0.248 (0.837- NAd 2.406) 67 1.989) Clinical ANNARBOR >=III ProteinCD68 0-50 Total 239 147 289 N: % in 396d 50 (14.5% P- HR = NAd 0.40680.839 POSITIVE 190 ITT: vs improve- value = 0.846 vs (0.554- FOLLICULARvs 57.2% 346d ment) 0.1781 (0.663- NAd 1.27) 196 1.08) Clinical FLIPIInter- Protein P65% <=90% Selected 35 435 205 N: % in 351d −216 (−38.1%P- HR = NAd 0.6255 1.524 mediate POSITIVE 19 ITT: vs improve- value =2.941 vs (0.277- CYTOPLASMIC vs 5.2% 567d ment) 0.0277 (1.075- NAd8.379) SIGNAL 16 8.05) Clinical FLIPI Inter- Protein P65% <=90% Excluded35 435 205 N: % in 396d 70 (21.5% P- HR = NAd 0.5888 0.9 mediatePOSITIVE 210 ITT: vs improve- value = 0.761 vs (0.616- CYTOPLASMIC vs64.4% 326d ment) 0.0193 (0.605- NAd 1.317) SIGNAL 225 0.957) ClinicalFLIPI Inter- Protein P65% <=90% Total 35 435 205 N: % in 367d 22 (6.4%P- HR = NAd 0.6612 0.921 mediate POSITIVE 229 ITT: vs improve- value =0.826 vs (0.636- CYTOPLASMIC vs 69.6% 345d ment) 0.0902 (0.663- NAd1.332) SIGNAL 241 1.03) B_D PSMB9/ A/A Clinical ANNARBOR <=II Selected10 532 133 N: % in 87d −260 (−74.9% P- HR = 140d 0.0009 83427575 NA R60H2 ITT: vs improve- value = 12.341 vs 2.139 vs 1.5% 347d ment) 0.01(1.094- NAd (0-Inf) 8 139.179) B_D PSMB9/ A/A Clinical ANNARBOR <=IIExcluded 10 532 133 N: % in 414d 80 (24% P- HR = NAd 0.9481 0.989 NAR60H 264 ITT: vs improve- value = 0.814 vs (0.7- vs 78.8% 334d ment)0.0538 (0.66- NAd 1.396) 268 1.004) B_D PSMB9/ A/A Clinical ANNARBOR<=II Total 10 532 133 N: % in 414d 69 (20% P- HR = NAd 0.8540 1.033 NAR60H 266 ITT: vs improve- value = 0.828 vs (0.734- vs 80.3% 345d ment)0.0744 (0.673- NAd 1.453) 276 1.019) Clinical AGEGRP >65 ProteinCD68 >50 Selected 25 361 239 N: % in 324d −384 (−54.2% P- HR = NAd0.8613 0.895 POSITIVE 13 ITT: vs improve- value = 2.999 vs (0.257-FOLLICULAR vs 3.7% 708d ment) 0.0252 (1.095- 971d 3.112) 12 8.21)Clinical AGEGRP >65 Protein CD68 >50 Excluded 25 361 289 N: % in 414d 76(22.5% P- HR = NAd 0.4138 0.833 POSITIVE 177 ITT: vs improve- value =0.784 vs (0.536- FOLLICULAR vs 53.5% 338d ment) 0.0595 (0.608- NAd1.293) 184 1.011) Clinical AGEGRP >65 Protein CD68 >50 Total 25 361 289N: % in 396d 50 (14.5% P- HR = NAd 0.4068 0.839 POSITIVE 190 ITT: vsimprove- value = 0.846 vs (0.554- FOLLICULAR vs 57.2% 346d ment) 0.1781(0.663- NAd 1.27) 196 1.08) Clinical RACEGRP OTHER Protein 20S% 0-20Selected 7 456 212 N: % in 351d −412 (−54% P- HR = 371d 0.1573 281008NUCLEAR 2 ITT: vs improve- value = 1861675 vs 16.562 STAINING vs 1% 763dment) 0.0455 64.897 NAd (0-Inf) 5 (0-Inf) Clinical RACEGRP OTHER Protein20S% 0-20 Excluded 7 456 212 N: % in 367d 29 (8.6% P- HR = NAd 0.55430.893 NUCLEAR 223 ITT: vs improve- value = 0.815 vs (0.614- STAINING vs67.6% 338d ment) 0.072 (0.652- NAd 1.299) 233 1.019) Clinical RACEGRPOTHER Protein 20S% 0-20 Total 7 456 212 N: % in 367d 22 (6.4% P- HR =NAd 0.6640 0.921 NUCLEAR 225 ITT: vs improve- value = 0.83 vs (0.634-STAINING vs 68.6% 343d ment) 0.1 (0.665- NAd 1.336) 238 1.037) Protein20S >=3+ Protein P65% <=90% Selected 18 445 212 N: % in 191d −517 (−73%P- HR = NAd 0.3995 0.525 INTENSITY POSITIVE 12 ITT: vs improve- value =9.726 vs (0.114- CYTOPLASMIC CYTOPLASMIC vs 2.7% 708d ment) 0.0111(1.204- 717d 2.411) SIGNAL SIGNAL 6 78.546) Protein 20S >=3+ ProteinP65% <=90% Excluded 18 445 212 N: % in 396d 58 (17.2% P- HR = NAd 0.72120.932 INTENSITY POSITIVE 213 ITT: vs improve- value = 0.781 vs (0.634-CYTOPLASMIC CYTOPLASMIC vs 65.9% 338d ment) 0.033 (0.622- NAd 1.37)SIGNAL SIGNAL 232 0.981) Protein 20S >=3+ Protein P65% <=90% Total 18445 212 N: % in 367d 22 (6.4% P- HR = NAd 0.6640 0.921 INTENSITYPOSITIVE 225 ITT: vs improve- value = 0.83 vs (0.634- CYTOPLASMICCYTOPLASMIC vs 68.6% 345d ment) 0.1 (0.665- NAd 1.336) SIGNAL SIGNAL 2381.037) Clinical SEX FEMALE Protein CD68 >50 Selected 54 332 289 N: % in344d −545 (−61.3% P- HR = 1078d 0.0178 3.398 POSITIVE 22 ITT: vsimprove- value = 2.293 vs (1.16- FOLLICULAR vs 8% 889d ment) 0.0156(1.149- NAd 9.958) 32 4.575) Clinical SEX FEMALE Protein CD68 >50Excluded 54 332 289 N: % in 414d 131 (46.3% P- HR = NAd 0.0624 0.649POSITIVE 168 ITT: vs improve- value = 0.698 vs (0.41- FOLLICULAR vs49.2% 283d ment) 0.007 (0.537- NAd 1.026) 164 0.908) Clinical SEX FEMALEProtein CD68 >50 Total 54 332 289 N: % in 396d 50 (14.5% P- HR = NAd0.4068 0.839 POSITIVE 190 ITT: vs improve- value = 0.846 vs (0.554-FOLLICULAR vs 57.2% 346d ment) 0.1781 (0.663- NAd 1.27) 196 1.08)Protein CD68 >50 Protein P65% <=90% Selected 8 378 289 N: % in 487d −596(−55% P- HR = NAd 0.1967 0 POSITIVE POSITIVE 5 ITT: vs improve- value =15582766 vs (0-Inf) FOLLICULAR CYTOPLASMIC vs 1.2% 1083d ment) 0.0136.206 NAd SIGNAL 3 (0-Inf) Protein CD68 >50 Protein P65% <=90% Excluded 8378 289 N: % in 396d 51 (14.8% P- HR = NAd 0.5254 0.874 POSITIVEPOSITIVE 185 ITT: vs improve- value = 0.821 vs (0.576- FOLLICULARCYTOPLASMIC vs 56% 345d ment) 0.1162 (0.641- NAd 1.325) SIGNAL 1931.051) Protein CD68 >50 Protein P65% <=90% Total 8 378 289 N: % in 396d50 (14.5% P- HR = NAd 0.4068 0.839 POSITIVE POSITIVE 190 ITT: vsimprove- value = 0.846 vs (0.554- FOLLICULAR CYTOPLASMIC vs 57.2% 346dment) 0.1781 (0.663- NAd 1.27) SIGNAL 196 1.08) Protein CD68 >50 ProteinP65% <=90% Selected 8 432 235 N: % in 144d −607 (−80.8% P- HR = 887d0.1970 7048571 OVERALL POSITIVE 5 ITT: vs improve- value = 12170471 vs.582 POSITIVE CYTOPLASMIC vs 1.2% 751d ment) 0.0434 .716 NAd (0-Inf)SIGNAL 3 (0-Inf) Protein CD68 >50 Protein P65% <=90% Excluded 8 432 235N: % in 380d 35 (10.1% P- HR = NAd 0.3832 0.841 OVERALL POSITIVE 211ITT: vs improve- value = 0.793 vs (0.57- POSITIVE CYTOPLASMIC vs 64%345d ment) 0.0487 (0.63- NAd 1.242) SIGNAL 221 0.999) Protein CD68 >50Protein P65% <90% Total 8 432 235 N: % in 366d 21 (6.1% P- HR = NAd0.5608 0.892 OVERALL POSITIVE 216 ITT: vs improve- value = 0.814 vs(0.608- POSITIVE CYTOPLASMIC vs 65.2% 345d ment) 0.0769 (0.648- NAd1.309) SIGNAL 224 1.023) Protein CD68 >50 Protein CD68 0-50 Selected 45339 291 N: % in 344d −739 (−68.2% P- HR = NAd 0.3295 1.784 POSITIVEPOSITIVE 26 ITT: vs improve- value = 2.642 vs (0.548- FOLLICULAR PERI-vs 6.7% 1083d ment) 0.0143 (1.182- NAd 5.8) FOLLICULAR 19 5.908) ProteinCD68 >50 Protein CD68 0-50 Excluded 45 339 291 N: % in 414d 88 (27% P-HR = NAd 0.1951 0.743 POSITIVE POSITIVE 163 ITT: vs improve- value =0.739 vs (0.473- FOLLICULAR PERI- vs 50.2% 326d ment) 0.0227 (0.569- NAd1.167) FOLLICULAR 176 0.96) Protein CD68 >50 Protein CD68 0-50 Total 45339 291 N: % in 406d 60 (17.3% P- HR = NAd 0.4116 0.841 POSITIVEPOSITIVE 189 ITT: vs improve- value = 0.845 vs (0.555- FOLLICULAR PERI-vs 56.9% 346d ment) 0.1772 (0.662- NAd 1.273) FOLLICULAR 195 1.08)Protein CD68 0-50 Protein CD68 >50 Selected 32 354 289 N: % in 307d NA(NA% P- HR = NAd 0.4981 1.592 OVERALL POSITIVE 19 ITT: vs improve- value= 3.155 vs (0.41- POSITIVE FOLLICULAR vs 4.7% NAd ment) 0.0127 (1.22-NAd 6.178) 13 8.164) Protein CD68 0-50 Protein CD68 >50 Excluded 32 354289 N: % in 406d 80 (24.5% P- HR = NAd 0.2670 0.779 OVERALL POSITIVE 171ITT: vs improve- value = 0.755 vs (0.501- POSITIVE FOLLICULAR vs 52.4%326d ment) 0.0309 (0.585- NAd 1.212) 183 0.976) Protein CD68 0-50Protein CD68 >50 Total 32 354 289 N: % in 396d 50 (14.5% P- HR = NAd0.4068 0.839 OVERALL POSITIVE 190 ITT: vs improve- value = 0.846 vs(0.554- POSITIVE FOLLICULAR vs 57.2% 346d ment) 0.1781 (0.663- NAd 1.27)196 1.08) B_D PSMB9/ A/A Clinical REGION UNITED Selected 6 536 133 N: %in 75d −271 (−78.3% P- HR = 211d 0.0177 62252190 NA R60H STATES/ 2 ITT:vs improve- value = 432481 vs .678 CANADA vs 0.9% 346d ment) 0.026990.876 NAd (0-Inf) 4 (0-Inf) B_D PSMB9/ A/A Clinical REGION UNITEDExcluded 6 536 133 N: % in 414d 76 (22.5% P- HR = NAd 0.9831 1.004 NAR60H STATES/ 264 ITT: vs improve- value = 0.814 vs (0.711- CANADA vs79.4% 338d ment) 0.052 (0.661- NAd 1.418) 272 1.002) B_D PSMB9/ A/AClinical REGION UNITED Total 6 536 133 N: % in 414d 69 (20% P- HR = NAd0.8540 1.033 NA R60H STATES/ 266 ITT: vs improve- value = 0.828 vs(0.734- CANADA vs 80.3% 345d ment) 0.0744 (0.673- NAd 1.453) 276 1.019)

1. A method for predicting response to a cancer treatment in a cancerpatient, comprising: determining the level or quantity of a firstpredictor in a biological sample from said patient, wherein said firstpredictor is CD68 or PSMB1 (P11A) polymorphism; and determining thepresence or quantity of a second predictor in said patient; wherein lowCD68 or presence of PSMB1 (P11A) polymorphism is correlated with atleast one positive outcome, and presence, absence, or quantity of saidsecond predictor is correlated with at least one positive outcome. 2.The method of claim 1, wherein the first predictor is low CD68.
 3. Themethod of claim 2, wherein low CD68 is 50% or less CD68-positive cells,as determined by immunohistochemistry.
 4. The method of claim 1, whereinthe first predictor is PSMB1 (P11A) polymorphism.
 5. The method of claim1, wherein the second predictor is selected from the group consistingof: low CD68, PSMB1 (P11A) polymorphism, PSMB5 (R24C) polymorphism, ageof under 65, one prior treatment, low Follicular Lymphoma InternationalPrognostic Index (FLIPI) score, and low tumor burden.
 6. The method ofclaim 1, wherein the cancer is a hematological cancer.
 7. The method ofclaim 6, wherein the hematological cancer is follicular B-cellnon-Hodgkin lymphoma or multiple myeloma.
 8. The method of claim 1,wherein said treatment comprises treatment with a proteasome inhibitor.9. The method of claim 9, wherein said proteasome inhibitor isbortezomib.
 10. The method of claim 1, wherein said treatment is acombination treatment.
 11. The method of claim 10, wherein thecombination treatment comprises a proteasome inhibitor.
 12. The methodof claim 11, wherein said proteasome inhibitor is bortezomib.
 13. Themethod of claim 11, wherein said combination treatment further comprisesrituximab.
 14. A diagnostic kit or equivalent for identifying patientswho are candidates for a particular cancer treatment comprising: areagent for detecting quantity or presence of a first predictor in abiological sample; a reagent for detecting quantity or presence of asecond predictor in a biological sample; and instructions for employingsaid predictors to identify patients who are candidates for saidtreatment; wherein said first predictor is selected from the groupconsisting of CD68 and PSMB1 (P11A) polymorphism.
 15. The kit of claim14, wherein the second predictor is selected from the group consistingof CD68, PSMB1 (P11A) polymorphism and PSMB5 (R24C) polymorphism.
 16. Amethod for treating a patient for cancer comprising: determining thequantity or presence of a first predictor in a biological sample fromsaid patient, wherein said first biomarker is selected from the groupconsisting of CD68 and PSMB 1 (P11A); determining the presence orquantity of a second predictor in said patient; and selecting a methodof treatment dependent on whether said patient is likely to respond tosaid treatment.
 17. Use of a proteasome inhibitor for the treatment ofcancer in a patient, wherein the patient is characterized by low CD68quantity or presence of PSMB1 (P11A) polymorphism.
 18. The use accordingto claim 17, wherein the patient is characterized by 0-50% CD68-positivefollicular cells, as measured by immunohistochemistry.
 19. The useaccording to claim 17, wherein the patient is further characterized byone or more predictors selected from the group consisting of: low CD68,PSMB1 (P11A) polymorphism; PSMB5 (R24C) polymorphism; one priortreatment; low Follicular Lymphoma International Prognostic Index(FLIPI) score; age under 65; and low tumor burden.
 20. The use accordingto claim 17, wherein the cancer is a hematological cancer.
 21. The useaccording to claim 20, wherein the hematological cancer is follicularB-cell non-Hodgkin lymphoma or multiple myeloma.
 22. The use accordingto claim 17, wherein the proteasome inhibitor is bortezomib.
 23. The useaccording to claim 17, wherein the proteasome inhibitor is used incombination with a second therapeutic agent.
 24. The use according toclaim 23, wherein the second therapeutic agent is rituximab, melphalanor prednisone.
 25. A method for treating cancer in a patientcharacterized by low CD68 or PSMB1 polymorphism, comprisingadministering to the patient a proteasome inhibitor.
 26. The methodaccording to claim 26, wherein the patient is characterized by 0-50%CD68-positive follicular cells, as measured by immunohistochemistry. 27.The method according to claim 25, wherein the patient is furthercharacterized by one or more predictors selected from the groupconsisting of: low CD68; PSMB1 (P11A) polymorphism; PSMB5 (R24C)polymorphism; one prior treatment; low Follicular Lymphoma InternationalPrognostic Index (FLIPI) score; age under 65; and low tumor burden. 28.The method according to claim 25, wherein the cancer is a hematologicalcancer.
 29. The method according to claim 28, wherein the hematologicalcancer is follicular B-cell non-Hodgkin lymphoma.
 30. The methodaccording to claim 25, wherein the proteasome inhibitor is bortezomib.31. The method according to claim 25, wherein the proteasome inhibitoris used in combination with a second therapeutic agent.
 32. The methodaccording to claim 31, wherein the second therapeutic agent isrituximab, melphalan or prednisone.